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Resumo 
A isquemia cerebral induz neurodegeneração de populações específicas de 
neurónios, nomeadamente na área CA1 do hipocampo. Apesar da sua elevada 
prevalência e dos esforços na investigação, não existem actualmente tratamentos 
eficazes para prevenir a neurodegeneração associada à isquemia global. Esta 
patologia pode ser estudada in vitro submetendo os neurónios a privação de oxigénio 
e glicose (OGD, do inglês “oxygen and glucose deprivation”). O principal objectivo 
deste trabalho foi o de estudar os mecanismos moleculares associados à morte 
neuronal iniciada pela OGD em culturas primárias de neurónios de hipocampo. Para 
este propósito pesquisámos diferentes aspectos da morte celular. Assim, estudámos o 
fenómeno de excitotoxicidade mediada por receptores de glutamato do tipo NMDA 
(NMDARs), analisámos a activação de um novo mecanismo de morte celular, 
necroptose, e verificámos a activação de vias efectoras da morte celular, em particular, 
as vias das MAPKs. 
Começámos por estudar a influência da subunidade GluN2B dos NMDARs na 
morte neuronal induzida por OGD. Os NMDARs têm um papel de relevo no excesso 
de Ca2+ intracelular característico da excitotoxicidade; contudo, o papel das 
subunidades GluN2 tem permanecido controverso. Há evidências que mostram o 
envolvimento das subunidades GluN2A e GluN2B no processo de morte celular 
enquanto outras mostram o papel tóxico do GluN2B e uma função neuroprotectora do 
GluN2A. Para clarificar esta questão recorremos a um sistema de cultura neuronal de 
murganhos GluN2B-/- e observámos um papel determinante da subunidade GluN2B na 
indução de morte após OGD em neurónios de córtex. Verificámos que a ausência do 
GluN2B eliminou a toxicidade induzida por OGD, que foi recuperada com a 
reintrodução da subunidade nos neurónios GluN2B-/-. Demonstrámos ainda o papel 
preponderante do domínio C-terminal (CTD) da subunidade na toxicidade mediada por 
GluN2B e mapeámos alguns locais de interacção no CTD de GluN2B responsáveis 
por esta função tóxica. O domínio PDZ é responsável pela interacção com a PSD95, 
que faz o acoplamento à nNOS. A interferência com esta interacção teve um efeito 
neuroprotector. Identificámos também dois determinantes moleculares no CTD de 
GluN2B relevantes para este processo, o local de ligação às proteínas AP2 e CaMKII. 
A mutação destes locais eliminou a toxicidade induzida pela subunidade GluN2B. 
Estas evidências apoiam o papel determinante dos NMDARs contendo GluN2B num 
contexto de isquemia cerebral in vitro. O nosso estudo é particularmente relevante na 
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medida em que os trabalhos anteriores utilizavam, na sua maioria, estímulos 
excitotóxicos.  
De seguida, investigámos a indução de morte neuronal por necroptose, um 
novo mecanismo de necrose programada, em neurónios de hipocampo submetidos a 
OGD. Este tipo de morte celular ocorre na sequência da activação de “death 
receptors” (DRs). Em determinadas condições, ocorre a formação de um complexo 
que medeia a apoptose e inibe a necroptose através da clivagem das proteínas 
RIP1/3. Contudo, se ocorrer inibição da caspase8, a RIP3 é recrutada para a RIP1 e 
juntas formam um complexo chamado necrosoma, que activa a necroptose. A OGD 
induziu um componente de morte celular que foi revertido pelo inibidor de necroptose 
Nec-1, mas não pelo inibidor da apoptose zVAD.fmk. A especificidade do efeito 
protector da Nec-1 sobre a necroptose foi comprovada pela ausência de efeito da Nec-
1 no componente apoptótico. Além disso, a OGD induziu a expressão das proteínas 
RIP1 e RIP3. Confirmámos o papel tóxico da RIP3 através de ensaios de 
sobreexpressão e silenciamento. A sobreexpressão das proteínas RIP1 e RIP3 
aumentou a morte neuronal, enquanto o silenciamento da RIP3 reduziu a toxicidade 
induzida por OGD. O efeito tóxico da OGD foi recuperado com a reintrodução da 
proteína RIP3 em neurónios sem RIP3 endógena. Por fim, relacionámos os 
mecanismos observados in vitro com o modelo in vivo, ao observarmos que a 
isquemia global induz o aumento da expressão da RIP3 na área CA1 do hipocampo. 
Estudámos por fim a activação de MAPKs em neurónios de hipocampo 
submetidos a OGD. Estas cinases são responsáveis pela resposta ao stress celular e 
estão envolvidas em diversos paradigmas de morte neuronal. Verificámos a activação 
das cinases p38 e JNK após OGD, às 2h e 6h de recuperação, respectivamente. 
Verificámos ainda que a inibição destas cinases teve um efeito protector, o que sugere 
um papel citotóxico. Curiosamente, a cinase JNK parece ter um duplo papel, já que a 
sua inibição só foi protectora quando efectuada às 4h após o estímulo de OGD. 
Concluindo, os nossos resultados demonstram que a OGD afecta os neurónios 
a vários níveis, incluindo na indução de mecanismos que contribuem para a 
neurodegeneração. Este modelo in vitro apresenta-se assim como uma ferramenta 
importante para a dissecção de mecanismos moleculares subjacentes à isquemia 
cerebral, o que poderá contribuir para o desenvolvimento de estratégias terapêuticas 
para esta patologia. 
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Abstract 
 Cerebral global ischemia induces selective neurodegeneration of specific 
subsets of neurons throughout the brain, namely in the CA1 region of the 
hippocampus. Despite its high prevalence and intensive research, there is still need of 
effective treatments to reduce the neurodegeneration associated with global ischemia. 
This pathology can be studied in vitro by depriving neurons of oxygen and glucose 
(OGD). Our main goal was to study the molecular mechanisms of neuronal death 
activated by OGD in primary cultures of hippocampal neurons. For this purpose we 
targeted distinct aspects of cell death. We studied the excitotoxic component of cell 
death mediated by NMDARs, we addressed the activation of a novel mechanism of 
programmed cell death, necroptosis, and we analyzed the activation of effector 
signaling cascades, in particular MAPKs.  
We started by studying the influence of the GluN2B subunit of NMDARs to 
OGD-induced neuronal demise. NMDARs are major contributors to the overload of 
intracellular Ca2+ characteristic of excitotoxicity and the role of GluN2 subunits has 
remained controversial. This is due to a variety of conflicting evidence showing that 
either both GluN2A and GluN2B contribute to neuronal death or that GluN2B is mostly 
pro-death and GluN2A pro-survival. To clarify this question we used cultured cortical 
neurons from GluN2B-/- mice and wild-type littermates, and observed that GluN2B is 
determinant for induction of excitotoxic neuronal death following OGD. We observed 
that the absence of this subunit blocked neuronal death induced by OGD and that the 
toxicity was rescued when we reintroduced the subunit in the KO neurons. Moreover, 
we demonstrated that the C-terminal domain (CTD) had a preponderant role in 
GluN2B-induced toxicity, and we identified molecular determinants in the CTD of 
GluN2B responsible for this function. We confirmed that the PDZ-binding domain was 
partly responsible for NMDAR toxicity. This domain is responsible for the interaction 
with PSD95 that couples to nNOS, and interfering with this interaction was 
neuroprotective. Additionally, we identified two other regions on the GluN2B CTD that 
are required for OGD-induced cell death, the AP2- and the CaMKII-binding domains. 
Mutations in either of these sites blocked GluN2B-mediated toxicity. These findings 
confirmed the crucial role of GluN2B-containing NMDARs in a context of in vitro 
ischemia, and our study is particularly relevant since most previous work was 
performed under excitotoxic conditions.  
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Next, we investigated whether OGD induced necroptosis, a novel type of 
programmed necrosis, in hippocampal neurons. This type of cell death has been 
recently described to occur following death receptor (DR) signaling. In certain 
conditions a complex called DISC is formed. DISC induces apoptosis and 
downregulates necroptosis via caspase8-mediated cleavage of the proteins RIP1/RIP3. 
However, when caspase8 is inhibited, RIP3 is recruited to RIP1 and together they form 
a complex called the necrosome, and activate necroptosis. We observed that OGD 
induced a component of cell death that was reversed by the necroptotic inhibitor Nec-1 
but not by zVAD.fmk, an apoptotic inhibitor. Notably, we observed that Nec-1 had no 
effect on the apoptotic component of neuronal death. Additionally, OGD induced the 
expression of RIP1 and RIP3. We confirmed the toxic role of RIP3 by performing 
overexpression and knock-down experiments. We observed that overexpression of 
both RIP1 and RIP3 exacerbated neuronal death induced by OGD whereas knockdown 
of RIP3 significantly reduced OGD-mediated toxicity. The damaging effect of the OGD 
challenge was rescued by reintroducing RIP3 in neurons where endogenous RIP3 was 
knocked-down, confirming the specificity of the requirement for RIP3. Finally, we 
correlated these in vitro events with the in vivo challenge, by confirming that global 
cerebral ischemia in the rat also induces RIP3 expression in the CA1 area of the 
hippocampus.  
Lastly, we studied the activation of MAPKs in hippocampal neurons submitted 
to OGD. These kinases are responsible for the majority of the cellular response to 
stress and are involved in several paradigms of cell death, including in neurons. We 
determined that both p38 and JNK are activated following OGD, at 2h and 6h of 
reoxygenation, respectively. Furthermore, inhibition of the activity of these MAPKs has 
a neuroprotective effect, suggesting a cytotoxic function. Interestingly, JNK seems to 
have biphasic function since neuroprotection was only achieved when we inhibited JNK 
at 4h reoxygenation. 
Overall, our results demonstrate that OGD induces a variety of changes in 
neurons, including several mechanisms that contribute to neurodegeneration. This in 
vitro model is thus a powerful tool to address the molecular mechanisms underlying 
cerebral ischemia, which may provide useful insights into the development of 
therapeutic strategies to this pathology. 
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Cerebral Ischemia 
Cerebral ischemia is a leading cause of disability and death in the western 
world (Flynn et al., 2008). This pathology lacks effective treatments, a direct 
consequence of a limited time window for intervention before major neurodegeneration 
ensues as well as of the lack of specificity of some of the treatments developed so far. 
Additionally, the inhibition of some molecular targets proves inefficient due to 
secondary effects. To date, the only treatment administered to cerebral ischemic 
patients is tissue plasminogen activator (tPA) (Fonarow et al., 2011; Iadecola and 
Anrather, 2011b). Cerebral ischemia is broadly divided in two types: global cerebral 
ischemia and focal ischemia (commonly referred to as stroke) (Flynn et al., 2008).  
Transient global ischemia results from a transient interruption of blood supply to 
the entire brain, due to a cardiac arrest or to a near-drowning situation. This type of 
pathology causes selective degeneration of specific subsets of neurons throughout the 
brain, namely the neurons of the Cornu Ammonis 1 (CA1) region of the hippocampus, 
the cortical neurons of layers II, V and VI, the Purkinje cells of the cerebellum and the 
dorsolateral striatal neurons (Lo et al., 2003; Zukin et al., 2004). 
Focal ischemia arises from the occlusion of a blood vessel in the brain 
(ischemic stroke) or from the rupture of a brain vessel (hemorrhagic stroke) leading to 
the deprivation of blood flow on the region of the brain supplied by that vessel. The 
area most severely affected by hypoperfusion constitutes the infarct core, in which 
most neurons degenerate due to an overwhelming stress, and the surrounding area, 
the penumbra, has a gradient of perfusion and mixed neuronal phenotypes, with some 
cells dying whilst others are able to survive (Kunz and Iadecola, 2009). 
The interruption in the blood supply to the brain causes a deprivation of oxygen 
and glucose, leading to a failure in ATP production, which is pernicious due to the brain 
high metabolic demand (Moskowitz et al., 2010). This results in neuronal depolarization 
and excessive glutamate release, accompanied by dysfunction of the glutamate 
reuptake mechanisms in glia cells and neurons, as a result of the dissipation of the Na+ 
gradient, due to the depletion of ATP. Thus, an excessive glutamate accumulation at 
the synapse causes the overactivation of glutamate receptors leading to an intracellular 
Ca2+ overload that may trigger cytotoxicity, a phenomenon called excitotoxicity. 
Notably, depending on the duration and intensity of the insult, other non-excitotoxic 
mechanisms are activated, contributing to Ca2+ overload (Besancon et al., 2008; 
Szydlowska and Tymianski, 2010). Deregulation of Ca2+ homeostasis activates 
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deleterious intracellular mechanisms, including mitochondrial dysfunction and oxidative 
and nitrosative stress, that induce inflammation and ultimately neuronal death (Figure 
1.1) (Moskowitz et al., 2010; Iadecola and Anrather, 2011a). In global ischemia and in 
the penumbra area, neuronal degeneration ensues within 24-72h after the ischemic 
insult, a process called delayed neuronal death. This delay in neuronal demise onset 
suggests the reliance on transcriptional changes, leading to programmed cell death 
mechanisms. 
 
Figure 1.1. Cerebral ischemia induces neuronal demise via activation of deleterious 
mechanisms. Upon interruption of blood flow, distinct damaging mechanisms are 
activated that contribute to the injury. In an early phase, energy imbalance and 
excitotoxicity are activated contributing to mounting oxidative and nitrosative stress. 
These contribute to inflammatory signaling and ultimately programmed cell death 
mechanisms are activated. Concomitantly, several neuroprotective mechanisms are 
activated, to counteract the effect of these damaging signals. (Iadecola and Anrather, 
2011b) 
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Cerebral ischemia can be addressed experimentally, using several research 
models, both in vitro and in vivo. The most common in vivo models to study transient 
global ischemia are the four vessel occlusion (4-VO) and the 2-VO combined with 
hypotension, both in the rat. As for focal ischemia, the middle cerebral artery occlusion 
(MCAO) model is generally used. Regarding the in vitro models, the closest to in vivo 
ischemia is the oxygen and glucose deprivation (OGD) challenge, which is most 
commonly used either in primary cultures of hippocampal or cortical neurons or in 
forebrain or organotypic hippocampal slices. Due to its characteristics, the OGD 
challenge of hippocampal neurons is a good model for global ischemia and allows for 
the dissection of molecular pathways underlying cerebral ischemia. This challenge 
consists of placing the neurons or slices in a glucose-free medium inside an anaerobic 
chamber, thereby combining the deprivation of these two factors which mimics what 
happens in the brain during the interruption of the blood flow, but in a simplified system 
(Zukin et al., 2004). This model also has advantage over other in vitro models [for 
example, application of high concentrations of glutamate receptor (GluR) agonists] 
since it accounts for most changes observed during blood supply deprivation, like 
activation of non-excitotoxic mechanisms, such as Ca2+ entry via acid-sensing ion 
channels (ASICs), transient receptor potential (TRP) channels or Na+/Ca2+ exchangers 
(NCXs) (Szydlowska and Tymianski, 2010), instead of accounting only for excitotoxic 
mechanisms. 
 
EXCITOTOXICITY 
The term excitotoxicity was first used by Olney (1969) to describe 
neurodegeneration associated with the activation of excitatory amino acid receptors 
(Olney, 1969). This phenomenon is a hallmark of several neurodegenerative disorders, 
such as Alzheimer’s disease (AD), Huntington’s disease (HD) and cerebral ischemia, 
and it results from excessive glutamate release from the presynaptic terminal, due to 
the specific disease-associated insult (Figure 1.2). This abnormal glutamate release 
combined with the dysfunction of the mechanisms responsible for removing this 
neurotransmitter from the synapse result in the accumulation of glutamate in the 
synaptic cleft, for longer periods of time. The immediate consequence of this 
accumulation is the overactivation of GluRs, present at the postsynaptic membrane, 
leading to a massive influx of ions, namely Ca2+ (Choi, 1987; Choi et al., 1987; Mehta 
et al., 2013). 
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 Calcium acts physiologically as a second messenger in neurons, which possess 
highly specialized mechanisms of Ca2+ buffering to maintain this ion at low 
concentrations. Thus, localized increases in Ca2+ concentration lead to the activation of 
specific intracellular signaling pathways. Upon an excitotoxic insult, the Ca2+ overload 
induces the deregulation of Ca2+ buffering mechanisms, for exceeding their capacity, 
contributing to the activation of damaging Ca2+-dependent processes that may 
ultimately lead to neuronal death (Choi, 1988; Tymianski and Tator, 1996; Arundine 
and Tymianski, 2003; Mehta et al., 2013). Evidence linking excessive Ca2+ influx to 
neuronal damage lead to the formulation of the “Calcium Hypothesis” which states that 
“neuronal calcium overload contributes to neurodegeneration” (Arundine and 
Tymianski, 2003). 
  
 
Figure 1.2. Mechanisms of excitotoxicity. The excessive glutamate release from the 
presynaptic terminal combined with the dysfunction of the glial mechanisms of glutamate 
clearance result in excessive concentrations of glutamate in the synapse. This leads to 
overactivation of GluRs located postsynaptically and activation of pro-death signaling 
pathways that promote neuronal demise. (Popoli et al., 2012) 
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The understanding of the paramount role exerted by Ca2+ to the mechanisms of 
excitotoxicity lead to initial efforts aiming at the blockade of this Ca2+ overload, to 
prevent neurodegeneration. This strategy, however, proved ineffective since GluR 
antagonists also blocked their physiological functions, which had adverse side effects 
(Lees, 1998). Thus, researchers started focusing on the intracellular pathways that are 
activated as a consequence of Ca2+ overload. Notably, the route of Ca2+ entry seems to 
be determinant for the activation of specific downstream signaling pathways that have 
distinct contributions to neuronal fate (“Source-specificity Hypothesis”) (Bading et al., 
1993; Ghosh and Greenberg, 1995; Sattler and Tymianski, 2001). Due to their role as 
primary gateways for Ca2+ entry in neurons, ionotropic GluRs (iGluRs) are one of the 
main sources of neuronal Ca2+, in particular N-methyl-D-aspartate receptors 
(NMDARs), which are highly permeable to this ion (Mehta et al., 2013). 
 
 
Glutamatergic Neurotransmission 
Glutamate is the major excitatory neurotransmitter in the mammalian central 
nervous system (CNS). Glutamate is released from the presynaptic terminal, during 
excitatory neurotransmission, leading to its diffusion across the synaptic cleft and 
consequent activation of GluRs present at the postsynaptic membrane (Catarzi et al., 
2007; Greger et al., 2007; Hansen et al., 2007). Glutamatergic synapses undergo 
activity-dependent long-lasting changes in synaptic strength, such as long-term 
potentiation (LTP) and long-term depression (LTD), mechanisms that are necessary for 
learning and memory (Malenka and Nicoll, 1999; Catarzi et al., 2007; Greger et al., 
2007). 
Glutamate activates two major classes of receptors: metabotropic GluRs 
(mGluRs) and ionotropic GluRs. The mGluRs mediate slow synaptic responses, due to 
their coupling to intracellular G proteins. To date, eight subtypes of mGluR family 
members have been identified, mGluR1-8, and classified into three groups (groups I–
III), based on sequence similarity, pharmacology and transduction mechanism 
(Friedman, 2006; Catarzi et al., 2007). The iGluRs are responsible for the majority of 
fast excitatory neurotransmission in the mammalian brain. These are heterotetrameric 
cation channels, comprising three functionally distinct subtypes: α-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA), kainate (KA) and NMDA receptors. These 
receptors are mainly concentrated at postsynaptic sites, where they fulfill a variety of 
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different functions (Cull-Candy et al., 2006; Greger et al., 2007). The NMDARs mediate 
the slow component of excitatory postsynaptic currents. NMDARs are highly permeable 
to Ca2+, Na+ and K+ and can be fully activated under membrane depolarization, which 
is necessary to abolish the inhibition of the receptor by Mg2+. The membrane 
depolarization is mainly afforded by AMPAR activation, which mediates the fast 
component of excitatory neurotransmission. Most AMPARs, as well as the KARs, are 
permeable to Na+ and K+, but impermeable to Ca2+. The permeability of AMPARs to 
Ca2+ is dependent on their subunit comsition and is regulated by the GluA2 subunit 
(Won et al., 2002; Hazell, 2007). 
Eukaryotic iGluR subunits are each composed of an extracellular amino-
terminal domain, a ligand binding domain (LBD), a transmembrane domain, and an 
intracellular carboxy-terminal domain (Figure 1.3). The transmembrane domain 
contains three membrane-spanning segments (M1, M3 and M4) and a ‘‘re-entrant 
loop’’, termed M2, which is located at the pore-lining region of the receptor, as 
determined by crystallography (Sobolevsky et al., 2009). Two extracellular segments, 
S1 and S2, have been shown to constitute the LBD which is responsible for the binding 
of both the neurotransmitter and the competitive agonists/antagonists. Glutamate 
binding to the extracellular LBD segment of the receptor triggers a series of 
conformational changes that lead to activation of the receptor (Catarzi et al., 2007). 
One of the goals of this work consisted of studying the contribution of NMDAR 
subunits for OGD-induced death. For that reason, this introductory section will be 
mainly focused on NMDARs. 
 
NMDA RECEPTORS 
The NMDARs are heterotetrameric structures composed of different 
combinations of three types of subunits: GluN1, GluN2 and GluN3 (Hollmann and 
Heinemann, 1994; Wenthold et al., 2003). These receptors are most commonly 
assembled from two GluN1 subunits and two GluN2 subunits. NMDARs containing 
GluN1 and GluN2 subunits are ion channels with high permeability to Ca2+ 
(MacDermott et al., 1986; Mayer and Westbrook, 1987), which contributes to their chief 
role in the mechanisms of excitotoxicity. In order to be activated, NMDARs require 
binding of glutamate and also glycine (or D-serine), which are mandatory cofactors 
(Johnson and Ascher, 1987; Labrie and Roder, 2010). Agonist binding combined with 
membrane depolarization contributes to relief of the Mg2+ block and channel opening 
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(Mayer et al., 1984; Nowak et al., 1984). The activity of NMDARs is modulated by 
polyamines (for example, spermine) (Benveniste and Mayer, 1993; Rock and 
Macdonald, 1995), among other factors. The NMDARs have paramount roles in 
physiological processes, such as synaptic plasticity, learning and memory but also in 
diverse neuropathologies, including AD, schizophrenia and cerebral ischemia (Lau and 
Zukin, 2007). 
 
Figure 1.3. iGluR subunit structure. (A) iGluR subunits possess four functional 
domains: the extracellular amino-terminal domain (ATD) and LBD, the transmembrane 
domains comprising three membrane-spanning helices (M1, M3 and M4) and the re-
entrant P-loop region of M2 and the large intracellular C-terminal domain (CTD). (B) 
Ribbon structure representation of the rat GluA2 homomeric AMPAR with each of the four 
subunits coloured coded and indicating the two conformationally distinct pairs of subunits, 
A/C and B/D. (C) Model NMDAR structure based on the GluA2 crystal structures of the 
ATD and transmembrane domains and the GluN1-GluN2A LBD heterodimer crystal 
structure. (Adapted from Sobolevsky et al., 2009; Wyllie et al., 2013) 
 
NMDAR Subunits 
The GluN1 is an obligatory subunit that binds glycine or D-serine instead of 
glutamate (Fukaya et al., 2003; Furukawa and Gouaux, 2003). This subunit has 8 
splice variants that may modulate synaptic targeting of the receptors (Ferreira et al., 
2011). Changes in ambient pH can modulate NMDAR function as protons can exert an 
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inhibitory effect on NMDARs via direct interaction with a Lys residue on GluN1 subunits 
(Traynelis and Cull-Candy, 1990). GluN1 subunits and the level of neuronal activity are 
two contributing factors that regulate the exit of NMDARs from the endoplasmic 
reticulum (ER). These subunits are produced in large excess relatively to GluN2 
subunits (Huh and Wenthold, 1999; Mu et al., 2003) and are retained in the ER until 
they are assembled with other subunits (Wenthold et al., 2003). Upon assembly of 
functional receptors, vesicles containing NMDARs are transported to dendrites. This is 
a type of active transport process, relying on motor proteins that carry the vesicles 
along microtubules (Hirokawa and Takemura, 2004). 
The GluN2 subunits can be divided in four subtypes, GluN2A-D. These four 
subunits have distinct expression in neurons: GluN2A is widely distributed throughout 
the brain, while GluN2B is predominantly expressed in the forebrain, GluN2C in the 
cerebellum and GluN2D is mostly found in the thalamus (Buller et al., 1994). Thus, the 
most common assemblies of NMDARs consist of GluN1-GluN2A receptors or GluN1-
GluN2B (Al-Hallaq et al., 2007), but triheteromeric receptors also exist (Sheng et al., 
1994; Cull-Candy and Leszkiewicz, 2004; Brothwell et al., 2008). Different subunit 
compositions fine-tune the receptors, namely in terms of intracellular interactions, 
localization in the membrane, and also channel properties (Figure 1.4). Indeed, 
relatively to GluN2B, the GluN2A subunit confers the receptor faster kinetics, lower 
glutamate affinity, greater channel open probability and more prominent Ca2+-
dependent desensitization. Moreover, the GluN2C/D subunits confer reduced 
sensitivity to the Mg2+ block and lower conductance opening (Cull-Candy and 
Leszkiewicz, 2004; Wyllie et al., 2013). 
There are two subtypes of GluN3 subunits, GluN3A and GluN3B. The former 
are expressed throughout the CNS, while the latter are found mostly in motor neurons. 
Like GluN1, these subunits bind glycine (Yao et al., 2008). When present in the final 
receptor assembly, GluN3 subunits confer lower Ca2+ permeability and reduced surface 
expression (Cull-Candy and Leszkiewicz, 2004). 
 The GluN2 subunits share high degree of similarity in their extracellular and 
transmembrane domains, suggesting a common function for these domains in all 
subunits. Notably, the C-terminal domain of NMDARs is the most divergent region 
among the subunits. In fact, the GluN2A and GluN2B subunits share only 29% identity 
in their C-terminal domains. This region enables the NMDARs to interact with diverse 
intracellular proteins and links the receptor to downstream signaling pathways. The 
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divergent C-terminus among the different subunits suggests functional adaptations in 
intracellular signaling, specific for each GluN2 subunit (Ryan et al., 2008). 
 
Figure 1.4. The subunit composition of NMDARs influences channel properties. The 
four di-heteromeric NMDARs (GluN1 subunits indicated in grey) display different features, 
such as agonist and co-agonist potency (lowest – GluN1/GluN2A NMDARs, highest – 
GluN1/GluN2D NMDARs); deactivation rates (fastest – GluN2A-containing NMDARs, 
slowest – GluN2D-containing NMDARs); voltage-dependent block by Mg2+; permeability 
to Ca2+ and unitary conductance. (Wyllie et al., 2013) 
 
NMDAR Regulation by Phosphorylation 
 One of the key mechanisms that regulate iGluR function and localization is 
phosphorylation (Lee, 2006). Accordingly, the C-terminal domain of NMDARs, 
particularly of the GluN2A and GluN2B subunits, has diverse sites of phosphorylation 
(Chen and Roche, 2007). Several kinases, including Ca2+-calmodulin kinase II 
(CaMKII), cyclin-dependent kinase 5 (Cdk5), Src, protein kinase A (Tararuk et al.), PKC 
and casein kinase 2 (CK2) have the ability to phosphorylate NMDAR subunits, with 
different impact on channel properties and trafficking of the receptors (Chen and 
Roche, 2007). The protein CaMKII is a Ca2+-dependent kinase that autophosphorylates 
at Thr286 as a consequence of NMDAR activation, promoting its translocation to the 
spines where it interacts with GluN2B subunits (Shen and Meyer, 1999; Bayer et al., 
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2006). This kinase shows higher affinity for GluN2B subunits than GluN2A (Strack and 
Colbran, 1998). CaMKII activity regulates synaptic plasticity phenomena via 
phosphorylation of AMPARs (Lisman et al., 2002) and modulation of NMDAR function 
(Gardoni et al., 2001; Gardoni et al., 2003; Chung et al., 2004). 
 
Influence of GluN2 Subunits on Neuronal Fate 
GluN2A and GluN2B are believed to have differential contributions to excitotoxic 
neuronal death (Wyllie et al., 2013). Indeed, while GluN2A is considered to have a 
prosurvival role (Liu et al., 2007; Terasaki et al., 2010), GluN2B overactivation is 
thought to exert a detrimental effect (Aarts et al., 2002; Soriano et al., 2008; Martel et 
al., 2012). However, there are also some reports that both subunits may contribute to 
neuronal death (Graham et al., 1992; Stanika et al., 2009; Zhou et al., 2013), 
suggesting that the regulation of these mechanisms implies an interplay of factors, 
such as subunit composition and receptor localization (Lai et al., 2011). Indeed, 
although both GluN2A and GluN2B are located at synaptic and extrasynaptic sites 
(Thomas et al., 2006; Harris and Pettit, 2007; Zhou et al., 2013), GluN2A is thought to 
preferentially locate in the synapse and GluN2B is believed to concentrate 
extrasynaptically (Kew et al., 1998; Li et al., 1998b; Scimemi et al., 2004; Groc et al., 
2006; Zhang and Diamond, 2009). 
The C-terminal domain of GluN2 subunits seems to be determinant for NMDAR-
mediated toxicity (Martel et al., 2012). This report elegantly demonstrates that the 
influence of chimeric GluN2 subunits to neuronal death relies on the identity of the C-
terminal domain. Swapping the C-terminal domain of GluN2A for that of GluN2B 
promotes neuronal demise in an excitotoxic context (Figure 1.5). The complementary 
experiment, swapping the C-terminal domain of GluN2B for that of GluN2A does the 
opposite, promoting neuronal survival (Cepeda and Levine, 2012; Martel et al., 2012). 
Additional support of the concept of a detrimental role of the GluN2B subunit is 
advanced by several reports demonstrating a neuroprotective effect of interfering with 
activation of downstream signaling pathways, specifically neuronal nitric oxide 
synthase (nNOS) (Aarts et al., 2002; Cui et al., 2007a; Cook et al., 2012). 
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Figure 1.5. Differential contribution of GluN2A and GluN2B subunits to excitotoxic 
neuronal death. The C-terminal domain of GluN2B subunits is more lethal than that of 
GluN2A. The extent of cell death upon excitotoxic stimulation depends in part on the C-
terminal domain of NMDAR subunits. Swapping the C-terminal domain of GluN2A for 
GluN2B produces more cell death. Conversely, swapping the C-terminal from GluN2B for 
GluN2A reduces cell death, due in part to increased phosphorylation of CREB. The C-
terminal domain of GluN2B displays stronger coupling to the PSD95/nNOS pathway, 
which suppresses CREB activation. This indicates that the GluN2B subunit, regardless of 
location at synaptic or extrasynaptic sites, is more lethal than the GluN2A subunit. 
(Cepeda and Levine, 2012)  
 
NMDAR Membrane Localization 
The majority of NMDARs localizes to highly specialized structures called 
postsynaptic densities (PSDs). However, they can also be targeted to extrasynaptic 
sites (Brickley et al., 2003; Thomas et al., 2006; Petralia et al., 2010), and also 
perisynaptic (Zhang and Diamond, 2009) and presynaptic (Bidoret et al., 2009) sites. 
The PSDs possess a complex web of scaffold, adaptor and downstream signaling 
proteins. Two scaffold proteins, PSD95 and synapse-associated protein 102 (SAP102), 
are abundant at the PSD strucutures, and contain PSD95/Dlg/ZO-1 (PDZ) domains 
that have the ability to interact with the NMDARs and control their trafficking and 
synaptic delivery (Kim and Sheng, 2004). Receptors enter and exit the synapse via 
lateral diffusion mechanisms. In fact, NMDARs have been shown to undergo rapid 
synaptic exchange (Tovar and Westbrook, 2002) and to diffuse between synaptic and 
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extrasynaptic sites (Groc et al., 2004). Extrasynaptic NMDARs may function as a highly 
mobile pool of receptors that can rapidly diffuse to synaptic sites upon mechanisms of 
activity-induced plasticity. Interestingly, PKC activation seems to regulate both lateral 
mobility and synapse dispersal of NMDARs (Fong et al., 2002; Groc et al., 2004), 
which may imply the existence of membrane microdomains that could also be 
associated with endocytic zones (Blanpied et al., 2002). Furthermore, subunit 
composition may also contribute to the control of NMDAR surface targeting. 
 
Role of NMDAR Localization in Excitotoxic Mechanisms 
 Localization of NMDARs at the membrane is thought to have distinct impact on 
neuronal fate, upon excitotoxic stimulation. Indeed, synaptic NMDARs are considered 
to induce neuroprotection, whilst NMDARs located extrasynaptically are thought to 
promote pro-death signaling (Figure 1.6) (reviewed in Hardingham and Bading, 2010). 
 
Figure 1.6. Differential contribution of synaptic and extrasynaptic NMDAR 
activation to excitotoxic neuronal death. Synaptic NMDARs activate CREB-dependent 
transcription. CREB is phosphorylated at Ser133 by CaMK (A) or ERK1/2 (B), in order to 
recruit its coactivator CREB binding protein (CBP). CBP is phosphorylated at Ser301 by 
the nuclear Ca2+-dependent CaMKIV (C). Synaptic NMDAR-induced Ca2+ signals 
promote transducer of regulated CREB activity (TORC) import into the nucleus via 
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calcineurin-dependent dephosphorylation (D). In contrast to these CREB-activating 
signals of synaptic NMDARs, extrasynaptic NMDARs suppress CREB activity through 
inactivation of the Ras-ERK1/2 pathway (E) and the nuclear translocation of Jacob, which 
promotes CREB dephosphorylation (F). (Adapted from Hardingham and Bading, 2010)  
 
Synaptic NMDAR signaling is thought to induce neuronal survival via several 
mechanisms. One of the most prominent pathways of neuroprotection occurs through 
nuclear Ca2+ signaling, which induces gene expression (Zhang et al., 2007; Zhang et 
al., 2009b; Hardingham and Bading, 2010). Among these is the protein CaMKIV, which 
regulates the activity of the prosurvival transcription factor cAMP response element-
binding protein (CREB) (Chrivia et al., 1993; Enslen et al., 1994; Matthews et al., 1994; 
Hardingham et al., 1997; Mayr and Montminy, 2001; Lonze et al., 2002). Also, the 
activity of the mitogen-activated protein kinase (MAPK) extracellular-signal regulating 
kinase 1/2 (ERK1/2), which leads to the activation of CREB, is stimulated by synaptic 
NMDAR signaling (Chandler et al., 2001; Papadia et al., 2005; Hetman and Kharebava, 
2006). Increased CREB transcriptional activity induces the expression of pro-survival 
genes (for example Atf3, Gadd45b, Serpinb2) (Zhang et al., 2007; Zhang et al., 2009b; 
Zhang et al., 2011). CREB also stimulates Bdnf expression, a known prosurvival 
neurotrophin (Thoenen et al., 1987; Hansen et al., 2004; Almeida et al., 2005). 
Concomitantly with induction of prosurvival signaling, synaptic NMDARs also promote 
neuroprotection by suppressing prodeath signaling. These receptors trigger signaling 
that suppresses the expression of pro-apoptotic proteins, like Puma (Lau and Bading, 
2009; Leveille et al., 2010) and inhibit the activity of pro-death transcription factors such 
as forkhead O (FOXO) proteins (Lehtinen et al., 2006; Salih and Brunet, 2008; Dick 
and Bading, 2010). Additionally, synaptic NMDAR activity also seems to improve the 
anti-oxidant defenses, thereby further contributing to neuronal survival (Papadia et al., 
2008). 
Activation of extrasynaptic NMDARs antagonizes the effect of synaptic 
receptors by inducing CREB shut-off. This occurs via coupling the extrasynaptic 
NMDARs with a dominant CREB-dephosphorylating pathway, performed by the protein 
Jacob (Hardingham and Bading, 2002; Hardingham et al., 2002; Dieterich et al., 2008; 
Karpova et al., 2013). Additionally, upon activation of extrasynaptic NMDARs, ERK1/2 
activity is rapidly decreased (Bading and Greenberg, 1991; Chandler et al., 2001; Kim 
et al., 2005; Ivanov et al., 2006; Leveille et al., 2008). Also, extrasynaptic NMDAR 
signaling leads to FOXO transcription factor activation, contrary to the effect of synaptic 
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NMDARs (Dick and Bading, 2010). Extrasynaptic NMDARs also induce the activation 
of other deleterious proteins, such as calpains, as confirmed by cleavage of calpain-
specific substrates (Xu et al., 2009). For example, NCX3, which is responsible for 
removal of Ca2+ from the cytoplasm, upon cleavage by calpains accelerates the 
disruption of Ca2+ homeostasis which is highly damaging to neurons (Bano et al., 2005; 
Araujo et al., 2007). Calpains also promote cleavage of striatal-enriched tyrosine 
phosphatase (STEP), which leads to disinhibition of the pro-death p38 MAPK, allowing 
this kinase to be activated and phosphorylate its substrates (Kawasaki et al., 1997; Xu 
et al., 2009). Overall, extrasynaptic NMDARs contribute to neuronal death by 
concomitantly suppressing pro-survival pathways and activating deleterious signaling 
cascades. Despite the plethora of evidence showing a pro-survival role of synaptic 
NMDARs, these have also been shown to be capable of inducing excitotoxic neuronal 
death (Papouin et al., 2012). 
 
NMDAR Interactors 
 Some of the best studied interactors of NMDAR subunits are proteins of the 
membrane associated guanylate kinase (MAGUK) family (Gardoni et al., 2009). These 
proteins function as NMDAR scaffolds and as organizers of the PSD, coupling 
signaling complexes to receptor activity. The members of the MAGUK family, which 
comprises PSD93, PSD95, SAP97 and SAP102, interact with GluN1 and GluN2 
subunits (Zheng et al., 2011). Interestingly, GluN2A was shown to have higher affinity 
for PSD95 while GluN2B interacts preferentially with SAP102, which may impact on 
receptor localization. Additionally, the complex between NMDARs and the scaffolds 
may occur early in the secretory pathway, for example in the ER (Sans et al., 2005). 
Notably, the interaction of GluN2B-containing NMDARs with PDZ-containing proteins 
seems to be essential for synaptic localization (Prybylowski et al., 2005; Yi et al., 2007) 
but not for their targeting to extrasynaptic sites (Sans et al., 2005). This protein family is 
responsible for coupling NMDARs to downstream signaling pathways. One of the most 
remarkable examples is the coupling to nNOS (Sattler et al., 1999), which has been 
shown to have detrimental effects upon excitotoxic injury (Aarts et al., 2002; Cao et al., 
2005; Zhou et al., 2010; Cook et al., 2012). 
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NMDAR Internalization 
Contrary to AMPARs, which are rapidly internalized in a synaptic activity-
regulated manner (Ehlers, 2000; Lin et al., 2000), NMDARs are considered to be 
relatively stable in the synapse, even during synaptic plasticity phenomena, in mature 
neurons (Roche et al., 2001). There are, however, certain stimuli that lead to NMDAR 
internalization (Snyder et al., 2001; Nong et al., 2003). The GluN2B subunit has two C-
terminal domains that regulate the synaptic localization of NMDARs: the PDZ-binding 
domain and the clathrin adaptor protein 2 (AP2)-binding motif, corresponding to the 
amino acid sequence YEKL. This is a consensus internalization motif, through which 
GluN2B interacts with the µ2 subunit of AP2, thus linking the receptor to clathrin-coated 
pits. GluN2A subunits also possess an AP2 binding motif (LL) on its C-terminus 
(Lavezzari et al., 2004). Interestingly, there is preferential interaction of GluN2B 
subunits with AP2, relatively to GluN2A. This fact may justify the decrease in the 
internalization rate of NMDARs in mature neurons, since GluN2A subunit expression 
increases with development (Groc and Choquet, 2006). Notably, subunit composition 
influences the sorting of the endosomes: GluN2B-containing receptors are associated 
with recycling endosomes and are probably later reinserted to the plasma membrane, 
while GluN2A-containing receptors are sorted to late endosomes and degraded 
(Lavezzari et al., 2004; Scott et al., 2004). Both subunits possess a membrane-
proximal endocytic motif that targets the receptors for late endosomes (Scott et al., 
2004). 
 
 Cerebral ischemia induces a plethora of mechanisms that contribute to neuronal 
demise, beyond excitotoxicity. Thus, we proposed to study an additional mechanism 
related to induction of a novel programmed cell death process, necroptosis, that is 
mediated by death receptor (DR) signaling. 
 
 
Death Receptor Signaling and Cell Fate 
 Tumor necrosis factor α (TNFα) is a pleiotropic cytokine involved in the initiation 
and regulation of proinflammatory and immune responses (Gruen and Weissman, 
1997; Makhatadze, 1998). It induces the expression of adhesion molecules on the 
vascular endothelium allowing the recruitment of leukocytes and immune cells to areas 
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of tissue damage and infection (Gamble et al., 1985; Barbara et al., 1996). This 
cytokine is produced as a membrane-bound precursor molecule of 26 kDa that is 
processed by the TNFα converting enzyme (TACE) to produce a 17 kDa active 
cytokine and binds TNF receptors (TNFRs), which are constitutively expressed in 
neurons and glia (Benveniste and Benos, 1995). The TNFα receptors include TNFR1 
and TNFR2. The latter does not possess a death domain (DD), thus TNFR1 is thought 
to play a major role in TNFα-induced intracellular signaling. 
 In the brain, TNFα is produced in its majority by activated microglia and 
astrocytes, along with other proinflammatory mediators such as the cytokines 
interleukin-1 (IL-1) and IL-6 and the chemokine interferon gamma (IFNγ), to promote 
neuroinflammation. Secretion of these cytokines by glial cells induces their autocrine 
production, further enhancing the expression of TNFα and astrogliosis (Rao et al., 
2012). To a lesser extent, TNFα has also been shown to be secreted by neurons 
(Breder et al., 1993). Increased levels of TNFα have been shown to occur in several 
neurological disorders, such as AD (Rubio-Perez and Morillas-Ruiz, 2012), multiple 
sclerosis (MS) (Rieckmann et al., 1995) and brain ischemia (Tuttolomondo et al., 
2012). 
In a context of in vitro global cerebral ischemia, the neurotoxic effect of TNFα 
has been demonstrated. Indeed, cortical cultures of TNF-/- animals display enhanced 
protection against the OGD challenge. Additionally, treating wild-type (WT) cultures 
with neutralizing antibodies against TNF has similar prosurvival effects. This 
neuroprotection has also been shown in the mouse model of focal ischemia, MCAO 
(Martin-Villalba et al., 2001). Also, if TNFα is exogenously added after the insult, it 
exacerbates OGD-mediated injury (Wilde et al., 2000). OGD induces increased TACE 
activity and expression, leading to increased TNFα secretion, which seems to 
contribute to the observed inducible NOS (iNOS) activity following OGD (Hurtado et al., 
2001). The increased TACE expression seems to occur in microglia and astrocytes, 
both following OGD and glutamate exposure (Hurtado et al., 2001; Hurtado et al., 
2002). Additionally, OGD induces mRNA and protein expression of TNFα and TNFR1 
in cortical neurons and microglia, but not in astrocytes (Badiola et al., 2009). 
Interestingly, OGD has been shown to down-regulate miR-181c, which controls 
microglia-induced neuronal apoptosis by reducing TNFα expression (Zhang et al., 
2012). Notably, if TNFα is present prior to the OGD challenge, it exerts a pro-survival 
effect, via nuclear factor kappa B (NF-κB) transcriptional activity (Wilde et al., 2000; 
Romera et al., 2004).  
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DEATH RECEPTORS 
Death receptor signaling is rather complex because it may induce a variety of 
outcomes, concerning cellular fate. Indeed, upon activation due to ligand binding (for 
example, TNFα – Table I), it may lead to increased NF-κB-mediated gene transcription, 
which contributes to cell survival and inflammation but, depending on the molecular 
context of the cell, DRs may also activate mechanisms of programmed cell death. 
Specifically, DR signaling may activate either the extrinsic pathway of apoptosis, upon 
assembly of the death inducing signaling complex (DISC), or a recently described type 
of programmed necrosis, called necroptosis, which is mediated by a signaling complex 
called necrosome (Weinlich et al., 2011). 
The decision between life and death starts upon TNFα stimulation (Figure 1.7), 
with the recruitment of DD-containing proteins to the vicinity of the TNFR1 – complex I 
– which includes, among others, the proteins receptor-interacting protein kinase 1 
(RIP1), TNFR-associated factor 2 (TRAF2) and TNFR-associated via death domain 
(TRADD) (Micheau and Tschopp, 2003). Also, cellular inhibitor of apoptosis protein 1 
(cIAP1) may be found in this complex, which leads to survival signaling mediated by 
NF-κB transcriptional activity, since cIAP1 acts as an inhibitor of death ligand (DL)-
induced apoptosis (Wang et al., 1998; Yang and Du, 2004; Gaither et al., 2007; 
Geserick et al., 2009). When NF-κB signaling is impaired, a second complex with high 
molecular weight is formed – complex II. This complex comprises RIP1, TRADD, 
TRAF2, Fas-associated protein with death domain (FADD) and procaspase-8 and is 
dissociated from TNFR1, which is internalized. In these conditions, cells are able to 
undergo apoptosis, through processing of caspases-8, -2 and -3 (Micheau and 
Tschopp, 2003). Inhibition of caspases sensitizes some cells, such as L929 cells, to 
TNF-mediated necrosis, which involves the formation of a third complex, complex IIB or 
necrosome (Declercq et al., 2009) and reactive oxygen species (ROS) production 
(Vercammen et al., 1998; Cho et al., 2009). 
Table I. Death Receptor Superfamily members 
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The ubiquitination state of RIP1 seems to be determinant for induction of 
complex II assembly. This post-translational modification of RIP1 is highly regulated by 
both ubiquitinases and deubiquitinases (DUBs). Indeed, cIAP1 and cIAP2 are able to 
ubiquitinate RIP1 and upon inhibition of these enzymes the recruitment of RIP1 to 
complex II is increased (Geserick et al., 2009). The DUB Cezanne leads to 
suppression of NF-κB signaling in response to TNFα activation by removing Lys63 
polyubiquitin chains from RIP1, in complex I. This contributes to increased stability of 
the inhibitor of kappa B (IκB) complex, which retains NF-κB on the cytoplasmatic 
compartment (Enesa et al., 2008). Inhibition of both cIAP1 and transforming growth 
factor-β activated kinase-1 (TAK1) induces the formation of the necrosome and 
subsequent ROS production, via increased recruitment of RIP3 and RIP1 kinase 
activity (Vanlangenakker et al., 2011b). Interestingly, TAK1 seems to have a function 
as an adaptor molecule, independently of its kinase activity, preventing premature 
dissociation of RIP1 from complex I and induction of necroptosis (Arslan and 
Scheidereit, 2011). Although RIP1 is generally thought to be necessary for canonical 
NF-κB activation (Ting et al., 1996; Kelliher et al., 1998; Ea et al., 2006; Li et al., 2006), 
there evidence shows that it may not be essential. Indeed, in RIP1-/- mouse embryonic 
fibroblasts (MEFs), the cells are still able to induce NF-κB transcriptional activity, 
through increased degradation of IκBα (Wong et al., 2010). Interestingly, HeLa cells 
treated with etoposide to induce DNA damage were shown to induce biphasic NF-κB 
activation, with differential regulation. RIP1 kinase activity was shown to be exclusively 
necessary for the second phase of NF-κB activity. Furthermore, this type of insult was 
shown to induce the recruitment of FADD and caspase-8 to a RIP1-NF-κB essential 
modulator (NEMO) complex, thereby initiating apoptotic signaling, which is prevented 
by knock-down (Tia et al.) of either RIP1 or caspase-8 (Biton and Ashkenazi, 2011). 
The association between RIP1 and caspase-8 in complex II seems to be highly 
dependent on FADD availability, since treatment of cells with a dominant negative form 
of FADD (FADD-DN) renders cells resistant to TNF-induced apoptosis and impairs this 
interaction. This effect can be rescued by expression of WT FADD (Micheau and 
Tschopp, 2003). The protein FADD can, in fact, have a deep impact on the phenotype 
of cell death being activated following TNFR1 signaling. Different domains of this 
protein have the ability to induce caspase-dependent apoptosis (death effector domain 
– DED) or necrosis (DD), in a caspase-independent manner. This seems to be 
regulated by their ability to selectively interact with caspase-8 or RIP-1, respectively 
(Vanden Berghe et al., 2004). 
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Figure 1.7. DR signaling complexes. Upon DL binding, the DR recruits a complex of 
DD-containing proteins to its vicinity (complex I). In this complex, RIP1 is ubiquitinated by 
cIAPs, initiating signaling to NF-κB activation. This contributes to cell survival via 
transcription of survival genes. Upon deubiquitination of RIP1, the complex dissociates 
from the receptor and recruits FADD and procaspase-8, forming a complex called DISC. 
Caspase-8 auto-activates, cleaves RIP1 inhibiting necroptosis, and initiates apoptosis. In 
conditions of low caspase-8 activity, RIP3 is recruited to interact with RIP1, assembling 
the necrosome, and together they activate necroptosis. 
 
Apoptosis and necroptosis are complementary cell death pathways, as 
demonstrated by occlusion of the lethality observed in caspase-8-/- mice when RIP3 is 
concomitantly depleted, in caspase8-/-/RIP3-/- double knock-out (KO) mice (Kaiser et 
al., 2011; Oberst et al., 2011), which emphasizes the role of caspase-8 as a negative 
regulator of necroptosis. This regulation is achieved by the formation of catalytically 
active dimers of caspase-8 and FLICE-like inhibitory protein long (FLIPL), which inhibit 
the assembly of the necrosome, without inducing apoptosis (Micheau et al., 2002; 
Oberst et al., 2011). Interestingly, RIP3 overexpression is not lethal per se, but 
sensitizes MEFs to TNFα treatment, in a RIP1 and caspase-8 independent manner 
(Moujalled et al., 2013). 
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Although TNFα and its receptor TNFR1 are the most commonly studied in 
necroptosis research, other DLs and their respective DRs might have a role in 
induction of cell death signaling (reviewed in Han et al., 2011). Indeed, TNF-related 
weak inducer of apoptosis (TWEAK), which binds DR3, has been shown to induce the 
formation of a DISC comprising RIP1, FADD and caspase-8, but lacking TRADD, and 
to induce apoptosis. Interestingly, this DL does not seem to induce activation of 
necroptosis (Ikner and Ashkenazi, 2011). Also, Fas ligand (FasL) and TNF-related 
apoptosis-inducing ligand (TRAIL) were shown to induce a form of caspase-
independent necrotic cell death that is dependent on RIP1 kinase activity (Holler et al., 
2000). The receptor cluster of differentiation 95 (CD95) is also known to induce 
apoptotic cell death in T cells. Upon caspase inhibition, however, the type of cell death 
is shifted to necrosis and proinflammatory signaling via ERK and p38. This receptor 
was also shown to induce NF-κB activity, which lead to increased cytokine production 
(Scheller et al., 2002). Toll-like receptor 3 (TLR3) signaling has also been shown to 
activate necroptotic mechanisms of cell death (Kalai et al., 2002). 
 
Survival Signaling 
Upon TNFα binding to TNFR1, complex I is recruited to the receptor (Figure 
1.8) and RIP1 is ubiquitinated by cIAPs (Bertrand et al., 2008; Varfolomeev et al., 
2008; Bianchi and Meier, 2009). The Lys63 chains linked to RIP1 then recruit TAK1 
binding protein 2 (TAB2) and NEMO, with the associated kinases (TAK1 and IκB 
kinase – IKK, respectively) (Kanayama et al., 2004; Ea et al., 2006; Li et al., 2006; Wu 
et al., 2006a). Linear Ub chain assembly complex (LUBAC) is also recruited to complex 
I, in an Ub-dependent manner, and was shown to stabilize this complex (Haas et al., 
2009). LUBAC is responsible for ubiquitinating NEMO. Linear ubiquitination of this 
protein was shown to be necessary for TNFR1-induced NF-κB activity (Tokunaga et 
al., 2009; Tokunaga et al., 2012; Verhelst et al., 2012). Once in this complex, TAK1 
phosphorylates IKKβ. Upon activation, IKKβ phosphorylates IκB, targeting it for 
degradation. This results in the relief of NF-κB inhibition, which is then able to 
translocate to the nucleus and initiate gene transcription (Karin and Ben-Neriah, 2000). 
Activation of NF-κB signaling has been shown to be counteracted by the action 
DUBs on RIP1, such as A20 (He and Ting, 2002; Wertz et al., 2004) and 
cylindromatosis (CYLD) (Wright et al., 2007). The A20 ubiquitin-editing enzyme 
removes Lys63 polyubiquitin chains from RIP1 and concurrently links Lys48 
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polyubiquitin chains to this protein, thus targeting it for degradation by the proteasome 
system. This results in concomitant inhibition of NF-κB survival signaling and inhibition 
of TNF-induced cell death by either apoptosis or necrosis (He and Ting, 2002; Wertz et 
al., 2004; Vanlangenakker et al., 2011a). On the other hand, CYLD removes Lys63 
chains from RIP1, promoting necroptosis (Welz et al., 2011). This DUB is rapidly 
cleaved by active caspase-8 (O'Donnell et al., 2011) thus, it is only stabilized and 
capable of deubiquitinating RIP1 upon insufficient activity of caspase-8, which may 
sensitize the cells to necroptotic death. Contrary to its ubiquitination state, the kinase 
activity of RIP1 does not regulate NF-κB activation (Lee et al., 2004; Wong et al., 
2010). 
Besides the known NF-κB signaling regulation, activation of TNFRs also leads 
to activation of MAPKs. The kinase RIP1 was shown to be necessary for TNFα-induced 
MAPK activation (ERK, p38 and c-Jun N-terminal kinase – JNK), as observed by 
reduction of MAPK phosphorylation in RIP1-/- MEFs. The kinase activity of RIP1, 
however, seems to be only required for ERK activation (Devin et al., 2003; Lee et al., 
2003). JNK is thought to contribute to the build-up of oxidative stress, promoting 
mitochondrial dysfunction, downstream of RIP1 and TRAF2, and leading to necrotic 
cell death (Davis, 2000; Shen et al., 2004; Xu et al., 2006). 
 
Apoptosis 
Apoptosis is generally described as a type of programmed cell death, due to its 
reliance on specific and sequential cellular mechanisms, in order to be activated. This 
type of cell death induces several cytoarquitectural alterations, including membrane 
blebbing, with formation of apoptotic bodies, chromatin condensation, DNA laddering 
and fragmentation of the nucleus, organelle fragmentation and release of protein 
content from the mitochondria to the cytoplasm. After cellular deconstruction, the debris 
are removed by phagocytes, avoiding activation of inflammatory responses and 
damage to the neighboring cells (Taylor et al., 2008). 
There are two major pathways of apoptosis: the extrinsic (or DR pathway) and 
the intrinsic (or mitochondrial pathway). These pathways are thought to cross-talk and 
influence one another (Igney and Krammer, 2002) (Figure 1.9). 
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Figure 1.8. Assembly of DR-associated complex I. Upon activation, TRADD, TRAF2 
and RIP1 are recruited to interact with the TNFR1, through their DDs. cIAPs ubiquitinate 
RIP1 and TRADD and RIP1-bound polyubiquitin chains recruit TAB2/3 and NEMO. TAK1 
becomes active and phosphorylates IKKβ, which becomes active. This kinase then 
phosphorylates IκB, which relieves the inhibition exerted on NF-κB dimmers. LUBAC is 
also recruited to this complex in an Ub-dependent manner and it stabilizes the complex 
by ubiquitinating NEMO. Upon relief of the inhibition, NF-κB dimmers translocate to the 
nucleus and initiate gene transcription, promoting cell survival and inflammation. 
 
The extrinsic pathway of apoptosis is initiated by DR signaling. Under 
appropriate conditions, complex II or DISC is assembled and auto-catalytic activation of 
caspase-8 occurs (Kischkel et al., 1995). The activation of caspase-8 can be inhibited 
by cFLIP isoforms (FLIPL, FLIPS and FLIPR) that bind procaspase-8 keeping it in an 
inactive state (Kataoka et al., 1998; Scaffidi et al., 1999). This process is regulated by 
the activity of complex I. Upon NF-κB activation via complex I, the transcription factor 
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induces, among other antiapoptotic genes, the expression of FLIPL, which then exerts 
a negative regulatory effect on complex II, through inhibition of caspase-8. However, if 
complex I displays limited activity, then the expression of FLIPL will be lower and 
complex II will have the ability to initiate apoptotic signaling (Micheau and Tschopp, 
2003). The FLIPL protein possesses caspase-like domains, but has no catalytic activity 
(Tschopp et al., 1998), thus it interacts with procaspase-8, allowing its allosteric 
activation and partial processing. This event inhibits induction of apoptosis due to 
caspase-8 limited activity, but allows this enzyme to process local substrates, like RIP1 
(Krueger et al., 2001; Micheau et al., 2002; Kavuri et al., 2011). Therefore it facilitates 
concomitant inhibition of apoptosis and necroptosis (Oberst et al., 2011). The FLIPS 
isoform, on the other hand, inhibits caspase-8 auto-activation (Krueger et al., 2001; 
Golks et al., 2005), thereby limiting the cleavage of RIP1, which is then capable of 
initiating necroptosis signaling. In conditions where caspase-8 is able to auto-activate, 
it triggers the execution phase of apoptosis. The extrinsic pathway of apoptosis cross-
talks with the intrinsic pathway via caspase-8 mediated truncation of BH3 interacting-
domain death agonist (Bidoret et al.). This proapoptotic protein is then able to 
translocate to the mitochondria, activate the proapoptotic proteins Bax/Bak and 
promote the formation of outer membrane pores and the release of apoptotic 
mitochondrial proteins to the cytoplasm (Li et al., 1998a; Esposti, 2002; Kaufmann et 
al., 2012). 
The intrinsic pathway of apoptosis is characterized by mitochondrial 
dysfunction, resulting in the opening of the mitochondrial pores. This induces loss of 
mitochondrial membrane potential and release of proapoptotic proteins to the 
cytoplasm (Saelens et al., 2004). A first group of proteins to be released includes 
cytochrome c, second mitochondria-derived activator of caspase/direct inhibitor of 
apoptosis-binding protein with low pI (Smac/DIABLO) and high temperature 
requirement protein A2 (HtrA2/Omi) (Du et al., 2000; van Loo et al., 2002; Garrido et 
al., 2006). Once in the cytoplasm, cytochrome c interacts with apoptotic peptidase 
activating factor 1 (Apaf-1) and procaspase-9, forming the so-called apoptosome and 
initiating the caspase-dependent mitochondrial pathway (Chinnaiyan, 1999; Hill et al., 
2004). At a later stage, a second group of proteins is released from the mitochondria, 
after the cell has committed to the death program. This includes apoptosis-inducing 
factor (AIF) and endonuclease G, which translocate to the nucleus to induce DNA 
fragmentation and nuclear condensation (Joza et al., 2001; Li et al., 2001). In the 
cytoplasm, the caspase activated DNase (CAD) is kept in an inactive state by its 
inhibitor, ICAD. Upon caspase-3 cleavage of ICAD, the active endonuclease is 
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released and further exacerbates chromatin condensation (Enari et al., 1998; Sakahira 
et al., 1998).  
The regulation of the mitochondrial pathway of apoptosis is mediated by a 
family of proteins, the B-cell lymphoma-2 (Bcl-2) family, which includes both pro-
apoptotic (for example, Bax, Bak, Bim, BID, Bad) and anti-apoptotic members 
(including Bcl-2, Bcl-XL, Bcl-x, BAG) (Cory and Adams, 2002). Several other pro- and 
anti-apoptotic proteins, as well as additional signaling pathways, like MAPK signaling 
cascades, participate in apoptotic mechanisms, contributing to a very complex program 
to induce cellular demise.  
These two pathways of apoptosis converge to the execution phase, which is 
performed by active caspases. The executioner caspases (caspase-3, -6 and -7) are 
activated by the initiator caspases (caspase-8, -9 and -10) by cleavage of the 
procaspase, and exert their effects via proteolysis of a plethora of substrates. Among 
these are poly-ADP ribose polymerase (PARP), α-fodrin, endonucleases, ICAD and 
gelsolin (Slee et al., 2001). The latter is cleaved by caspase-3 causing disruption of the 
cytoskeleton (Kothakota et al., 1997), which contributes to the cellular demolition 
characteristic of apoptosis (Taylor et al., 2008). 
The final stage of apoptosis is the phagocytic removal of cellular debris. This 
process is preceded by externalization of phosphatidylserine on the cell surface, which 
facilitates the recognition of the cells to be phagocytosed, without activation of 
inflammatory mechanisms (Fadok et al., 2001). This feature, however, is not exclusive 
of apoptosis (Krysko et al., 2004). 
Global ischemic insults have been shown to induce apoptotic neuronal death in 
the CA1 region of the hippocampus, where the cells display shrunk and condensed 
nuclei, along with other features related to this type of cell demise (Ozawa et al., 1999). 
Global ischemia also induces translocation of the pro-apoptotic protein Bad, to the 
mitochondria, where it assembles with other pro-apoptotic proteins, such as Bcl-XL. 
The latter is cleaved to produce a pro-death fragment that promotes the dissipation of 
mitochondrial membrane potential. This then leads to release of proapoptotic proteins 
from the mitochondria to the cytosol, such as cytochrome c and Smac/DIABLO. These 
proteins promote the formation of the apoptosome, which induces activation of 
caspases, namely the executioner caspase-3. The activity of this caspase is increased 
after global ischemia, in a region-specific manner, since its activity is observed in CA1 
neurons, but not in the CA3/dentate gyrus (DG) area. Caspase-3 then promotes DNA 
fragmentation and subsequent neuronal death in CA1 neurons (Miyawaki et al., 2008). 
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Figure 1.9. Apoptotic Pathways. Apoptosis is elicited in cells via two distinct pathways 
that cross-talk. Extrinsic pathway: Upon deubiquitination of RIP1, complex I dissociates 
from TNFR1 and recruits FADD and procaspase8. In the presence of low levels of cFLIP 
isoforms, caspase8 is able to autoactivate and cleave RIP1, thereby inhibiting 
necroptosis. Caspase8 truncates BID and processes caspase3, which contributes to the 
intrinsic pathway of apoptosis. Intrinsic pathway: Apoptotic stimulation of cells leads to 
mitochondrial dysfunction, with formation of membrane pores. This contributes to the 
release of pro-apoptotic mitochondrial proteins such as cytochrome C and 
Smac/DIABLO. This process is regulated by members of the Bcl-2 family, which includes 
a variety of pro- and anti-apoptotic proteins. In the cytoplasm, cytochrome C interacts with 
Apaf-1 and procaspase9, assembling the apoptosome. Caspase9 becomes catalytically 
active and caspase3, a major executioner caspase, is processed, becoming activated. 
This enzyme exerts its effects by cleaving a variety of intracellular substrates, contributing 
to apoptotic cell death. 
 
Accordingly, the OGD challenge also induces apoptosis, as demonstrated by 
typical morphological alterations, as well as activation of specific molecular pathways. 
Morphologically, there are evidences of DNA laddering and chromatin condensation 
(Kalda and Zharkovsky, 1999). The OGD challenge also induces depolarization of the 
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mitochondria, as measured by dissipation of mitochondrial membrane potential (He et 
al., 2009; Liu et al., 2011), which occurs during apoptotic cell death. Upon induction of 
OGD in cerebrocortical cultures, both caspases and calpains become activated. This 
has been shown through the increased formation of spectrin cleavage products of 120 
kDa and 145 kDa, which are specific for caspases and calpains, respectively, and also 
by neuroprotection afforded by caspase (Nath et al., 1998) and calpain inhibitors 
against OGD-induced death (Newcomb-Fernandez et al., 2001). 
The OGD challenge appears to also activate the extrinsic apoptotic pathway. 
Treatment with an anti-TNFα antibody reduced the number of apoptotic neurons, in 
cortical cultures submitted to OGD. Additionally, OGD enhances caspase-8 activation 
mediated by TNFR1 and subsequent caspase-3 activation (Badiola et al., 2009). The 
OGD challenge also induces cleavage of the pro-apoptotic protein BID, a caspase-8 
substrate, before the onset of neuronal death. Furthermore, the cell death elicited by 
OGD is reduced when BID is inhibited (Culmsee et al., 2005) and in BID-/- cortical 
neurons, compared to WT neurons. These effects are also observed in vivo, using the 
focal ischemia model MCAO, where BID-/- animals display reduced infarct volumes as 
well as reduced cytochrome c release from the mitochondria (Plesnila et al., 2001).  
On the other hand, members of the anti-apoptotic Bcl-2 family have been shown 
to have neuroprotective effects against ischemic stimuli. Indeed, cells overexpressing 
Bcl-2 display increased resistance to the OGD challenge and reduced activation of 
caspase-3 and cytochrome c release from the mitochondria, as well as diminished loss 
of mitochondrial membrane potential (Koubi et al., 2005). Moreover, the Bcl-XL family 
member was shown to reduce nuclear translocation of AIF as well as the extent of cell 
death induced by OGD (Cao et al., 2003).  
Futhermore, the anti-apoptotic protein Apaf-1 interacting protein (AIP), which 
acts by preventing apoptosome formation, has been demonstrated to be up-regulated 
in the regions of the hippocampus that are resistant to OGD-induced damage, but not 
in the CA1 area. Furthermore, overexpressing AIP in CA1 neurons significantly 
reduces OGD- or global ischemia-induced neuronal death and caspase-3 activation 
(Cao et al., 2004a). 
 
Necroptosis 
Caspase-independent cell death that occurs as a consequence of DR-mediated 
signaling is considered to be a type of regulated necrotic cell death because it displays 
necrotic features, such as plasma membrane damage, swollen mitochondria and slow 
mitochondrial membrane depolarization, subsequent to nuclear and cytoplasmatic 
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morphological changes. Also, mitochondrial apoptotic markers like cytochrome C 
release or caspase-3-dependent cleavage of PARP, as well as chromatin condensation 
or oligonucleosomal DNA degradation, typical features of apoptosis, are not observed 
in this type of cell death (Holler et al., 2000; He et al., 2009; Vandenabeele et al., 
2010), hence its classification as programmed necrosis (necroptosis). 
Necroptotic stimulation, such as a combination of Smac mimetics (which 
contribute to cIAP1/2 degradation) and caspase inhibitors, such as N-
Benzyloxycarbonyl-Val-Ala-Asp(O-Me)-fluoromethyl ketone (zVAD.fmk), leads to a 
necrotic phenotype, in a DR-dependent manner, as demonstrated by KD of TNFR1 or 
treatment with a TNFα neutralizing antibody (He et al., 2009). RIP1 was shown to 
regulate autocrine TNFα production, in a NF-κB-independent manner. In certain 
contexts, such as caspase inhibition (with zVAD.fmk), cIAP1/2 depletion (with Smac 
mimetics) or absence of TRAF2, RIP1 associates with the protein E3 ubiquitin-protein 
ligase UBR5 (EDD) and together they activate the JNK signaling pathway. JNK then 
phosphorylates its substrates activator protein-1 (AP-1) and specificity protein 1 (Sp-1), 
which become transcriptionally active, inducing TNFα expression and subsequent 
inflammation and cell death by necrosis (Christofferson et al., 2012). 
In an effort to elucidate the mechanism of necroptosis that is activated in 
response to DR signaling, three independent groups identified RIP3 as a protein that is 
specifically associated with necroptotic signaling, using different approaches (Cho et 
al., 2009; He et al., 2009; Zhang et al., 2009a). The failure of a RIP3-DN to prevent 
FADD-induced apoptosis (Feng et al., 2006) is in accordance with these reports that 
relate RIP3 specifically to necroptosis. 
Cho and colleagues (2009) performed a siRNA screen in FADD-deficient Jurkat 
cells, which are known to die by necroptosis in response to TNFα. They identified both 
RIP1 and RIP3 as crucial mediators of this type of cell death. Interestingly, they also 
found that RIP3 KD had no effect on TNF- and FasL-induced apoptosis or NF-κB 
activation. This emphasizes the specific role of RIP3 on the necroptotic mechanism. 
This protein was shown to be specifically recruited to complex II but, unlike RIP1, was 
not present in complex I (Cho et al., 2009). 
He et al. (2009) adopted a similar strategy. They performed a genome-wide 
siRNA screen and transfected HT-29 cells with different siRNA pools to assess which 
of these were protective against necroptotic stimulation. Besides RIP1, which had been 
previously identified, they found RIP3 to be important for this process. Importantly, this 
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protein was specifically correlated with necroptosis since it did not interfere with 
induction of apoptosis. In fact, the ability of different cell lines to undergo necroptosis 
seems to be correlated with RIP3 expression. Accordingly, cells that express RIP3 
have the ability to induce necroptosis (for example Jurkat, U937, L929 and MEFs) 
while cells with no observable expression of RIP3, are resistant to necroptotic 
stimulation, including HEK293T, MCF-7 and U2OS. Interestingly, when they expressed 
RIP3 in “resistant” cells, like T98G cells, they rendered the cells susceptible to 
necroptosis (He et al., 2009). 
Zhang et al. (2009) studied the mechanism of necroptosis in two lines of 
NIH3T3 cells, N and A cells, which are, respectively, susceptible and resistant to 
necroptosis. They performed a microarray analysis to detect changes in genes that 
might be responsible for this differential vulnerability and found that RIP3 was 
responsible for induction of necroptosis in N cells, while A cells lack expression of this 
protein. Specifically, they demonstrated that KD of RIP3 abolishes the component of 
necroptotic death in N cells, whereas expression of RIP3 in A cells renders them 
susceptible to TNF-induced necroptosis (Zhang et al., 2009a). 
The human RIP3 gene has been shown to produce a full length (FL-RIP3) 
protein and two splice variants – RIP3β and RIP3γ. The FL-RIP3 is widely expressed 
throughout the organism, including the heart, brain, lung and spleen. While the RIP3γ 
variant displays comparable mRNA expression to that of the FL-RIP3, in most tissues, 
the RIP3β variant is expressed at very low levels (Yang et al., 2005). Unlike FL-RIP3 
(Yang et al., 2004), both RIP3γ and RIP3β seem to be unable to shuttle between the 
cytoplasm and the nucleus, which may be related to their inability to induce cell death 
(Yang et al., 2005). The RIP3 kinase activity is required for nuclear localization of the 
protein and to the induction of caspase-independent cell death. In fact, RIP3 seems to 
translocate to the nucleus upon induction of cell death (Feng et al., 2007). 
RIP1 and RIP3 where demonstrated to associate through their RIP homotypic 
interaction motif (RHIM) domains (Sun et al., 2002), forming an amyloid complex upon 
induction of necroptosis (Li et al., 2012) (Figure 1.10). Additionally, RIP3 was shown to 
autophosphorylate and phosphorylate RIP1. Phosphorylation of RIP1 seems to act as 
a cue to shut-off NF-κB signaling, which contributes to cell death (Sun et al., 2002) and 
it may contribute to the stabilization of the association of RIP1 within complex II (Cho et 
al., 2009). Also, the kinase activity and the RHIM domains of RIP1/3 are crucial for 
induction of necroptosis (Cho et al., 2009; He et al., 2009; Zhang et al., 2009a; Li et al., 
2012). Mutations in the RHIM domain of RIP3 abolished its ability to induce necroptosis 
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(He et al., 2009). Necrostatin-1 (Nec-1) a pharmacological inhibitor of necroptosis, was 
found to inhibit RIP1 kinase activity, by inhibiting, for example, RIP1 
autophosphorylation. In fact, four putative autophosphorylation sites were identified 
(Ser14/15, Ser20, Ser161 and Ser166), all in the N-terminal domain, which is also the 
kinase domain of RIP1 (Degterev et al., 2008). The pronecrotic complex II, called 
necrosome, seems to be distinct from the apoptotic one (DISC) since the interaction 
between RIP1 and RIP3 appears to occur specifically under necrotic-inducing 
conditions (Cho et al., 2009) (Figure 1.11). Interestingly, RIP1-independent (but RIP3-
dependent) necroptosis has been shown to occur upon KD of both RIP1 and caspase-
8, evidencing once again the negative regulation exerted by caspase-8 and suggesting 
that RIP3 may be sufficient to induce necroptosis in certain cellular contexts 
(Vanlangenakker et al., 2011a). The intermediate domain (ID) of RIP1 seems to be 
important for induction of necroptosis, as deletion of this domain in the protein shifts the 
type of cell death from necroptosis to apoptosis, due to increased recruitment of RIP1 
and caspase-8 to FADD (Duprez et al., 2012). 
 
Figure 1.10. Struture of the human RIP1/3 proteins. RIP1 and RIP3 share partial 
homology in their structure. They both contain a N-terminal kinase domain and a RHIM 
domain, through which they interact upon necroptosis induction. RIP1 also possesses a 
C-terminal DD, which allows this protein to interact with other DD-containing proteins (for 
example, TNFR1) in complex I and II. 
 
This pronecrotic interaction between RIP1 and RIP3 was recently shown to be 
regulated by the acetylation state of RIP1. Under basal conditions, RIP3 interacts with 
the deacetylase sirtuin2 (SIRT2). Upon induction of necrosis, the RIP3-SIRT2 complex 
is recruited to RIP1, thereby facilitating SIRT2-dependent deacetylation of RIP1 on 
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Lys530. Due to the close proximity of this residue to the RHIM domain of RIP1, which 
comprises residues 531-547 of RIP1, acetylation on Lys530 possibly disrupts the 
interaction with RIP3. Upon deacetylation of this residue, RIP1 and RIP3 are able to 
interact and necroptosis ensues. This evidence is further supported by the fact that 
SIRT2-/- MEFs are protected from necrosis-inducing insults (Narayan et al., 2012). 
Mixed lineage kinase domain-like (MLKL) was shown to be a molecular target of 
the necrosome (Sun et al., 2012; Zhao et al., 2012). Its role in necroptosis is 
emphasized by complete abrogation of necroptosis upon MLKL KD or in the presence 
of necrosulfonamide, a MLKL inhibitor. The mitochondrial protein Ser/Thr-protein 
phosphatase (PGAM5) is also phosphorylated by RIP3 and associates with the RIP1/3-
MLKL complex. The short isoform of PGAM5 (PGAM5S) is proposed to be an effector 
downstream of the necrosome since its RIP3-mediated phosphorylation is abrogated 
by necrosulfonamide. PGAM5S then dephosphorylates the mitochondrial protein 
dynamin related protein 1 (Drp-1), resulting in its activation, which contributes to 
mitochondrial fragmentation (Wang et al., 2012). 
The cellular signaling network involved in the necroptotic process was shown to 
be regulated by several genes (Hitomi et al., 2008) and requires de novo protein 
synthesis (Yu et al., 2004). Mitochondrial dysfunction, ROS accumulation and ATP 
depletion have been shown to contribute to the detrimental effect of necroptosis, which 
is prevented in RIP1-/- cells (Cho et al., 2009; He et al., 2009; Irrinki et al., 2011). The 
RIP3 kinase promotes mitochondrial ROS generation via a group of metabolism-related 
enzymes, known to associate with RIP3: phosphorylase-glycogen-liver (PYGL), 
glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1). These 
enzymes are involved in mitochondrial metabolism. The protein PYLG is the rate-
limiting enzyme in glycogen degradation, while GLUL and GLUD1 are determinant 
enzymes for oxidative phosphorylation (Zhang et al., 2009a). This seems to contribute 
to the insertion of the proapoptotic protein BCL2/adenovirus E1B 19 kDa interacting 
protein 3 (BNip3) in the mitochondria, contributing to mitochondrial damage. 
Interestingly, BNip3 is induced following TNFα stimulation in alveolar lung cells, but it is 
not involved in the extrinsic pathway of apoptosis but instead in induction of 
necroptosis (Kim et al., 2011). Another Bcl-2 family member, Bmf, was also shown to 
be important for necroptosis induction as KD of this protein inhibits necroptotic cell 
death (Hitomi et al., 2008). These reports emphasize the complex interplay and 
common players found between these two distinct programs of cell death: apoptosis 
and necroptosis. 
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Figure 1.11. Assembly of the necrosome. When caspase8 is downregulated, RIP1 is 
capable of recruiting RIP3. This process is regulated by the acetylation state of RIP1. 
Upon deacetylation of RIP1 by SIRT2, RIP1 and RIP3 interact through their RHIM 
domains and autoactivate. The necrosome then phosphorylates its substrates, including 
PGAM5 and MLKL. PGAM5S then dephosphorylates Drp-1, which becomes active and 
promotes mitochondrial fragmentation.  
 
On the other hand, spontaneous formation of a protein module similar to 
complex II has been described (Feoktistova et al., 2011; Tenev et al., 2011). Due to its 
independence from DR signaling, this high molecular weight complex comprising RIP1, 
FADD and caspase-8, among other proteins, was called ripoptosome. The formation of 
this complex occurs following genotoxic stress (Tenev et al., 2011) or TLR3 stimulation 
(Feoktistova et al., 2011), both in conditions of cIAP depletion, suggesting that these 
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proteins inhibit the assembly of the ripoptosome. The FLIPL isoform is also recruited to 
the complex, exerting an inhibitory regulation of the ripoptosome. Accordingly, KD of 
FLIPL enhanced the formation of the ripoptosome. This complex seems to have the 
ability to induce both apoptosis and necroptosis, depending on the cellular context 
(Tenev et al., 2011). Interestingly, cFLIPS seems to specifically inhibit ripoptosome-
induced apoptosis and to promote necroptosis (Feoktistova et al., 2011). 
 
Necroptosis in Disease Context 
 Necroptosis might be a relevant mechanism in several paradigms of cell death, 
namely, to fight virus infections. Viruses such as the Vaccinia virus express apoptotic 
inhibitors, delaying the activation of cell death programs in infected T cells, which 
contributes to disseminate the infection. Thus, if cells are able to activate alternative 
death programs, the organism may more efficiently fight the infection. Accordingly, 
Vaccinia virus infected T cells are sensitized to TNF-induced necroptotic cell death 
(Cho et al., 2009). Mouse cytomegaloviruses (MCMV) express cell death suppressors 
that specifically inhibit RIP3 activity, in a RHIM-dependent manner (Upton et al., 2010). 
This aspect emphasizes the relevance of necroptosis as a physiological programmed 
cell death mechanism. 
In another disease context, an animal model of cerulean-induced pancreatitis, 
much of the cell death in the pancreas seems to be attributable to RIP3-dependent 
necroptosis. This protein is significantly induced specifically in these cells and RIP3-/- 
animals have a much lesser extent of pancreatic cell death (He et al., 2009). 
 Necroptosis is also involved in Crohn’s disease pathogenesis. Indeed, RIP3 
seems to be specifically expressed in the cells that are most affected by the disease, 
the Paneth cells of the terminal ileum, which might confer increased susceptibility to 
necroptotic insults. Additionally, intestinal epithelial cells lacking caspase-8 are 
sensitized to necroptotic cell death, as observed by rescue of this effect with Nec-1. 
This provides further evidence for a role of caspase-8 in the inhibition of necrosome 
formation and subsequent activation of necroptosis (Gunther et al., 2011). 
 Moreover, in a mouse model of cardiac ischemia, Nec-1 provided significant 
neuroprotection, reducing the infarct size, the phosphorylation of RIP1/3 and the 
inflammation, while having no impact on the extent of apoptotic cell death (Oerlemans 
et al., 2012). Likewise, necroptosis was shown to occur in retinal neurons following 
ischemic damage. Necrostatin-1 was effective in reducing specifically this component 
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of cell death, without affecting apoptotic neuronal death and in improving the functional 
outcome in the ischemia challenged retina (Rosenbaum et al., 2010). Also, in a mouse 
model of retinal detachment, both inhibition of RIP1 as well as RIP3 ablation were 
shown to be neuroprotective, demonstrating the activation of necroptotic mechanisms 
upon apoptosis inhibition (Trichonas et al., 2010). 
In vitro cerebral ischemia has also been shown to induce a component of 
necroptotic neuronal death (Xu et al., 2010; Meloni et al., 2011) which was also 
observed to occur in vivo, following neonatal hypoxia/ischemia (Northington et al., 
2011) and MCAO (Degterev et al., 2005; Xu et al., 2010). These reports showing a role 
for necroptosis following ischemic insults, either in vitro or in vivo, used a specific 
inhibitor of necroptosis, Nec-1, to support this finding. This inhibitor acts on the kinase 
activity of RIP1 (Degterev et al., 2008), however, this protein has also been correlated 
to the apoptotic signaling, mainly as a scaffold for complex II formation. Thus, the 
specificity of Nec-1 may be argued against, which emphasizes the need to develop 
novel strategies to clearly dissect the contribution of necroptosis, in order to better 
clarify the role of this mechanism on neuronal death, following ischemic insults. 
Additional neuronal death paradigms have been shown to induce necroptosis. 
Indeed, following treatment with 24(S)-hydroxycholesterol (24S-OHC), which is 
cytotoxic, both human neuroblastoma SH-SY5Y cells and cortical neurons were shown 
to die by necroptosis (Yamanaka et al., 2011). Additionally, menadione, a compound 
that induces superoxide production, with concomitant mitochondrial dysfunction and 
ATP depletion, was shown to induce caspase-independent necroptotic like death in 
HT-22 cells, a cell line of immortalized mouse hippocampal neurons (Fukui et al., 
2012). In a mouse model of traumatic brain injury (TBI), Nec-1 was shown to be 
effective in reducing the damage associated with the injury, suggesting the occurrence 
of necroptosis (You et al., 2008). Interestingly, necroptosis was also proposed to have 
a neuroprotective effect by being activated in inflamed microglia, which results in less 
damage to neurons. Upon inflammatory stimulation, inhibition of caspase-8 activity is 
beneficial to neurons by promoting necroptosis in microglia, whereas Nec-1 rescues 
neurodegeneration. This implies that caspase inhibitors could promote neuronal 
survival against certain insults by promoting microglial demise (Fricker et al., 2013). 
 
Beyond the study of the NMDARs and of the necroptotic neuronal death, we 
also addressed the activation of effector signaling pathways, such as the MAPKs, 
which are known to be involved in several neuronal death paradigms. 
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MAP Kinase Pathways 
 The MAPKs are a family of stress-responsive proteins that regulate an array of 
functions in the cell. They exert their effects by phosphorylating a plethora of 
substrates, including transcription factors, enzymes and cytoskeletal proteins impacting 
on cell division, proliferation, metabolism and cell fate (Davis, 2000; Qi and Elion, 2005; 
Burke, 2007). 
 These proteins have a typical three-tiered activation cascade. Following an 
appropriate stimulus a MAPK kinase kinase (MAPKKK) autophosphorylates, leading to 
relief of autoinhibition and oligomerization. The MAPKKK then activates a MAPK 
kinase (MAPKK), by dual phosphorylation of Ser and Thr residues within the activation 
loop of the catalytic domain (Songyang et al., 1996; Chen et al., 2001). Finally, the 
activated MAPKK phosphorylates the MAPK, on conserved Thr and Tyr residues within 
a conserved Thr-X-Tyr motif on the activation loop (Silva et al., 2005; Burke, 2007). 
The MAPKKs are highly specific and typically phosphorylate only one MAPK, but are 
regulated by many, less specific, MAPKKKs. The MAPKs phosphorylate a wide range 
of substrates on Ser and Thr residues on a consensus PXT/SP motif. The pathway 
specificity may be increased by the organization of different signaling complexes by 
distinct scaffold proteins, which have been shown to have many functions, beyond 
bringing the elements of the pathway together. Scaffold proteins have the ability of 
binding, sequestering, and fostering the specific components of the pathway. This 
organization in a multiprotein complex allows for specific types of stimuli to produce 
unique and coordinated MAPK signaling responses (Burack and Shaw, 2000; 
Yoshioka, 2004; Xu et al., 2007). The inactivation of the MAPKs is performed by dual-
specificity MAPK phosphatases (MKPs) (Keyse, 2000), among other phosphatases. 
MAPKs may be found in many subcellular locations, namely in the ER, endosomes, 
microtubules and may translocate to the nucleus to phosphorylate nuclear substrates. 
 In mammals, three major groups of MAPKs have been defined: ERK, p38 and 
JNK (Figure 1.12) (Davis, 2000; Johnson and Lapadat, 2002). 
 
EXTRACELLULAR SIGNAL-REGULATED KINASE 
The ERK subfamily of MAPKs comprises two members, ERK1 and ERK2, with 
44 and 42 kDa that are activated by mitogenic stimuli like growth factors and cytokines. 
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These kinases regulate cell motility, proliferation, differentiation, meiosis and cell 
survival and, in neurons, they impact as well on learning and memory processes. 
 
 
Figure 1.12. MAPK cascades. Diverse stimuli contribute to activation of the typical three-
tiered MAPK cascades, consisting of a MAPKKK that activates a MAPKK which then is 
able to phosphorylate a MAPK. These proteins are involved in an array of cellular 
functions, in particular the response to stress. (Adapted from Pierce and Lefkowitz, 2001)  
 
The ERK1/2 kinases are phosphorylated in their activation loops by MAPK/ERK 
kinase 1 (MEK1) and MEK2. Upstream of these MAPKKs are a variety of MAPKKKs, 
depending on the cellular context and on the stimulus. Raf kinases are the primary 
MAPKKKs for ERK1/2, but this pathway may also be activated by Mos and Tumor 
progression locus 2 (TPL2) (Raman et al., 2007). Upon binding of ligands to receptor 
Tyr kinases or G-protein coupled receptors, Ras becomes activated and triggers the 
activation of Raf isoforms and their recruitment to the plasma membrane (Wellbrock et 
al., 2004). 
When active, ERK1/2 may phosphorylate a variety of substrates, which include 
the protein kinases p90 ribosomal S6 kinase (RSK), mitogen and stress activated 
kinase (MSK) and MAPK interacting kinase (MNK) that have roles in cell attachment 
and migration. The ERK1/2 proteins also phosphorylate transcription factors, including 
Elk1, c-Fos, c-Myc and Ets domain factors, among others and the anti-apoptotic protein 
Bcl-2, which regulates cell survival mechanisms (Johnson and Lapadat, 2002; Yoon 
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and Seger, 2006). Additionally, ERK phosphorylates the proapoptotic protein Bim, 
leading to its proteasomal degradation (Luciano et al., 2003; Ley et al., 2004). 
The ERK1/2 kinases are distributed throughout the cell, and are associated with 
plasma membrane receptors and transporters. Association with scaffold proteins is 
thought to direct ERK1/2 to specific cell compartments, such as the Golgi apparatus 
and endosomes (Raman et al., 2007). 
 
ERK Activation in the Context of Global Ischemia 
Global ischemic insults lead to a reduction in phospho-ERK levels that increase 
again in the hippocampus, neocortex and striatum, after a short period of reperfusion. 
The same pattern of phosphorylation is observed for JNK however, after reperfusion, 
phospho-JNK levels only increase in the hippocampus and striatum (Shackelford and 
Yeh, 2006). Phospho-ERK1/2 levels appear to be upregulated in the resistant areas of 
the hippocampus, but not the CA1, which is particularly vulnerable to ischemic insults 
(Sugino et al., 2000; Zablocka et al., 2003). In vitro ischemia also seems to induce ERK 
phosphorylation in the hippocampus (Bernardi et al., 2010). Additionally, ERK 
activation seems to be relevant for induction of LTP by in vitro ischemia in 
corticostriatal synapses, in a PKC and mGluR1 dependent manner (Calabresi et al., 
2001). The activation of ERK mediated by PKC is thought to mediate neuroprotection 
in preconditioning models (Jia et al., 2007). 
Although ERK signaling is most commonly associated with neuronal survival, 
some reports describe a role of this signaling pathway in the induction of cell death 
following OGD. In fact, the ERK1/2-RSK pathway was shown to be activated following 
OGD and to promote Na+/H+ exchanger 1 (NHE1) phosphorylation, which increased its 
activity and contributed to neuronal death. The toxic role of this cascade was further 
demonstrated by the neuroprotection afforded by the MEK inhibitor U0126, which is an 
ERK upstream kinase (Luo et al., 2007). 
 
P38 MAP KINASE 
Along with JNK, p38 MAPKs are described as stress-activated protein kinases 
(SAPKs) because they are frequently activated by a wide range of physical and 
chemical stresses, namely UV radiation, hormones and cytokines (Figure 1.13). These 
kinases are involved in diverse cellular processes, such as regulation of the cell cycle, 
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induction of cell death, differentiation and senescence (Coulthard et al., 2009). This 
group comprises four isoforms: p38α, β, γ and δ, with significant differences in tissue 
expression and signaling cascade elements. While p38α and p38β have a ubiquitous 
expression, the γ and δ isoforms have a more restricted distribution (Raman et al., 
2007). The specific function of each p38 isoform is still not completely understood. 
 
Figure 1.13. p38 MAPK signaling pathway. p38 MAPKs are activated by environmental 
stress, inflammatory cytokines and virus infection and are dually phosphorylated at the 
Thr-Gly-Tyr motif by MKK3/6.These are in turn activated by MEKKs, MLKs and ASK1. 
P38 phosphorylates transcription factors, including Stat1, Elk-1 ATF-2 and CHOP. 
(Aurelian, 2005) 
 
The p38 MAPKs are regulated by a vast group of MAPKKKs, including MEK 
kinase (MEKK)1-4, apoptosis signal regulating kinase 1 (ASK1), mixed-lineage kinase 
(MLK)2/3, TAK1 and TAO kinase (Kataoka et al.)1/2. These MAPKKKs phosphorylate 
MKK3 and MKK6 and these two MAPKKs are then responsible for dual-
phosphorylation of p38 protein on Thr-Gly-Tyr motifs located within the regulatory loop 
between subdomains VII and VIII (Raman et al., 2007). The kinetics of p38 
phosphorylation may be determinant for its functions and sustained p38 activation has 
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been correlated with induction of apoptosis (Tobiume et al., 2001; Murphy and Blenis, 
2006). A role of MKK4 (a JNK pathway MAPKK) in activating p38 was demonstrated in 
vitro and in conditions in which MKK3 and MKK6 are absent (Brancho et al., 2003). 
Similar to what happens with the other MAPKs, the phosphorylation of p38 is canceled 
out by phosphatases, including MKPs, protein phosphatase (PP)1 or PP2A in a 
negative feedback loop that allows tight regulation of p38 activity (Salojin et al., 2006; 
Hu et al., 2007; Owens and Keyse, 2007). 
In line with its diverse functions in cellular function and response to a variety of 
stress insults, p38 has a wide range of substrates for phosphorylation. These include 
transcription factors, other kinases and cytoskeletal proteins. Interestingly, the 
substrate specificities of p38α/β differ from that of p38γ/δ. For example, MAPK-
activated protein kinase 2 (MAPKAPK2) is specifically phosphorylated by the α/β 
isoforms, but not by p38γ/δ (Raman et al., 2007) and stathmin, a cytoplasmic protein 
involved in microtubule dynamics, is specifically phosphorylated by the p38δ isoform 
(Parker et al., 1998). 
This pathway may also be regulated by scaffold proteins, such as JIP2/4 
(Buchsbaum et al., 2002; Kelkar et al., 2005), TAB1 (in a MAPKK-independent 
manner) (Ge et al., 2002) and the osmosensing scaffold for MEKK3 (OSM) (Uhlik et al., 
2003), although the impact of scaffold proteins on p38 signaling is much less studied 
than their role on the JNK pathway.  
 
The Role of p38 in Disease 
 The p38 MAPK has prominent roles in diverse cell death paradigms and is 
important in the etiology of several human disorders (Coulthard et al., 2009), including 
those with an inflammatory content (Kumar et al., 2003). These include rheumatoid 
arthritis (Korb et al., 2006; Diarra et al., 2007), Crohn’s disease (Bantel et al., 2002; 
Waetzig et al., 2003) and psoriasis (Johansen et al., 2005; Yu et al., 2007), all of which 
display increased p38 activity in the affected cells. The p38 MAPK has also been 
implicated in a plethora of neurological disorders, including AD, HD, Parkinson’s 
disease (PD), amyotrophic lateral sclerosis (Ivanov et al.) and MS (Harper and Wilkie, 
2003; Johnson and Bailey, 2003). Additionally, some p38 substrates, like MAPKAPK2 
(Culbert et al., 2006; Thomas et al., 2008b) and activator transcription factor 2 (ATF2) 
(Johnson and Bailey, 2003), have been associated with the development of 
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neurodegenerative disorders. Inhibition of p38 MAPK is thought of as a promising 
avenue towards treatment to some of these disorders (Bendotti et al., 2006). 
 
p38 MAPK Activation in Cerebral Ischemia 
Activation of p38 MAPK has been reported to correlate with induction of cell 
death following global ischemia since administration of SB203580, a specific p38 
inhibitor, had a neuroprotective effect, while inhibiting phosphorylation of known p38 
substrates, such as the transcription factor ATF2 (Sugino et al., 2000). This suggests 
that sustained p38 activation can have a pro-death role, thereby contributing to the 
selective vulnerability of the CA1 area of the hippocampus. 
The OGD challenge also activates the p38 signaling pathway (Guo and Bhat, 
2007; Shinozaki et al., 2007; Xu et al., 2009; Lu et al., 2011), which has death 
promoting effects in organotypic hippocampal slices (Barone et al., 2001; Strassburger 
et al., 2008; Lu et al., 2011) and in forebrain cultures (Legos et al., 2002), since 
neuronal death is reversed in the presence of the p38 inhibitors, SB239063 or 
SB203580. Pharmacological inhibition of this kinase also reduces the extent of 
neuronal death following in vivo focal ischemia (Barone et al., 2001). Knock-down of 
p38 also has a neuroprotective effect, both in organotypic hippocampal slices, reducing 
the formation of superoxide induced by OGD (Lu et al., 2011), as well as in a motor 
neuron cell line (Guo and Bhat, 2007). The p38 MAPK mediates the inflammatory 
response, as SB239063 reduces the extent of activated microglia following OGD, but 
also the IL-1β mRNA levels (Strassburger et al., 2008). The p38 MAPK was also found 
to lead to activation of NADPH oxidase, thereby contributing to oxidative stress and 
subsequent neuronal death induced by OGD and by an in vivo model of neonatal 
hypoxia-ischemia (Lu et al., 2012). Additionally, inhibition of the interaction between 
nNOS and NOS1 associated protein (NOS1AP), which leads to p38 activation, confers 
neuroprotection against neonatal hypoxia-ischemia (Li et al., 2013). 
The p38 signaling pathway can be regulated by calpains, which are Ca2+-
dependent proteases with a determinant role in ischemic conditions, as previously 
mentioned. Calpains cleave a plethora of substrates, as is the case of the phosphatase 
STEP. The FL STEP61 is cleaved to a smaller isoform, STEP33, in a NMDAR-
dependent manner. Upon extrasynaptic NMDAR activation, p-p38 levels are increased 
with concomitant cleavage of STEP61 by calpain, in a process that is facilitated by 
Cdk5. Thus, STEP seems to counteract the toxic effects of NMDAR overactivation by 
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dephosphorylating key kinases such as p38, thereby improving neuronal survival. 
Accordingly, a TAT peptide with the ability to inhibit STEP cleavage had 
neuroprotective effects against the OGD challenge in corticostriatal slices. This 
neuroprotective effect is mediated by a decrease in p38 phosphorylation induced by 
OGD (Xu et al., 2009). Global ischemic insults induce strong expression of p25 in CA1 
neurons, which is sufficient to activate Cdk5 in this area and induce subsequent 
neuronal death. The Cdk5-mediated induction of neuronal death seems to derive from 
phosphorylation of GluN2A subunits of NMDARs (Ser1232), which increases NMDAR 
electrophysiological properties. Additionally, AMPARs seem to be the route of Ca2+ 
entry, leading to calpain activation which, in turn, cleaves p35 to produce p25 that then 
activates Cdk5. This effect is specific to the CA1, as the CA3 and the DG do not 
display such induction (Wang et al., 2003; Liu et al., 2004). 
 
C-JUN N-TERMINAL KINASE 
The JNK MAPKs, also known as SAPKs, are activated by a wide range of 
environmental stresses (Kyriakis and Avruch, 1990; Kyriakis et al., 1994; Davis, 2000; 
Weston and Davis, 2002), but are also involved in physiological functions (Waetzig et 
al., 2006). Accordingly, JNK is activated in response to cytokines (Shirakabe et al., 
1997; Yao et al., 1999), DNA damage and oxidative stress (Finkel and Holbrook, 2000; 
Kamata et al., 2005), UV radiation (Derijard et al., 1994) and excitotoxicity (Yang et al., 
1997; Maroney et al., 1999; Vieira et al., 2010), but is also important during embryonic 
development (Boylan and Gruppuso, 1996; Sun et al., 2013) and for neurite outgrowth 
(Yao et al., 1997; Tararuk et al., 2006; Feltrin et al., 2012; Tezuka et al., 2013). 
Three genes encode mammalian JNK isoforms, Jnk1, Jnk2 and Jnk3. These 
genes are alternatively spliced to produce ten different isoforms of 46 and 54 kDa 
(Gupta et al., 1996) and while JNK1 and JNK2 are ubiquitously expressed, JNK3 
expression is restricted to the brain, heart and testis (Mohit et al., 1995; Martin et al., 
1996). Some studies using Jnk gene disruption in mice demonstrated that there is an 
extensive complementation between Jnk genes and that individual tissues may 
express specific isoforms of JNK (Tournier et al., 2000). 
The signaling through the JNK group is highly complex, due to a variety of 
MAPKKKs that regulate JNK activity, including MLKs, ASK and MEKK1-4. These 
MAPKKKs activate two MAPKKs, MKK4 and MKK7, which are then responsible for 
phosphorylating JNK isoforms (Figure 1.14) (Davis, 2000; Weston and Davis, 2002; 
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Weston and Davis, 2007). In general, MKK7 is primarily activated by cytokines (such 
as TNFα and IL-1) and MKK4 by environmental stress. Although both MAPKKs can act 
alone to phosphorylate JNK on Tyr and Thr, and therefore activate it, they can act 
synergistically to activate JNK in response to certain stimuli (Davis, 2000; Burke, 2007). 
In general, MKK4 preferentially targets JNK Tyr-185, whereas MKK7 usually 
phosphorylates Thr-183 (Silva et al., 2005). 
 
Figure 1.14. JNK signaling pathway. JNK is activated by stress signals, namely heat 
shock, osmotic stress and pro-inflammatory cytokines. MKK4 and MKK7 phosphorylate 
JNK (at Thr-Pro-Tyr motif). MEKKs 1-4, MLK3 and ASK-1, in turn, phosphorylate 
MKK4/7. Activated JNKs dimerize and translocate to the nucleus where they 
phosphorylate transcription factors including c-Jun, ATF-2, Elk-1 and p53. Activation of 
the JNK signaling cascade generally results in apoptosis and is involved in inflammation. 
(Aurelian, 2005) 
 
The existence of a large number of MAPKKKs that activate the JNK pathway 
suggests that different MAPKKKs respond to distinct stimuli, thereby conferring 
specificity to JNK signaling (Weston and Davis, 2007). Accordingly, whilst TAK1 was 
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shown to activate JNK in response to inflammatory cytokines and TLR activity (Sato et 
al., 2005; Shim et al., 2005; Wan et al., 2006), MEKK3 is determinant for TLR-8-
induced JNK activation (Qin et al., 2006) and MLK3 and TPL2 were demonstrated to 
contribute to TNF-mediated JNK signaling in embryonic fibroblasts (Brancho et al., 
2005; Das et al., 2005). The kinase MLK3 is also important for the response to 
metabolic stress induced by free fatty acids (Jaeschke and Davis, 2007) and, in 
neurons, for nerve growth factor (NGF) withdrawal-induced cell death (Xu et al., 2001). 
The JNK cascade may be regulated by a variety of scaffold proteins (Morrison 
and Davis, 2003), including members of the JNK-interacting protein (JIP) family 
(Whitmarsh et al., 1998; Yasuda et al., 1999; Kennedy et al., 2007), β-arrestin2 
(McDonald et al., 2000) and plenty of SH3s (POSH) (Xu et al., 2003; Xu et al., 2005; 
Wilhelm et al., 2007). These scaffolds may transport the signaling module to specific 
locations in the cell, which may confer a higher specificity to signaling via this pathway. 
The kinase JNK has the ability to phosphorylate a plethora of substrates in a 
stimulus-dependent manner. The archetypal JNK substrate is the transcription factor c-
Jun, which is dual-phosphorylated by JNK in its N-terminal domain (Ser63 and Ser73), 
increasing its transcriptional activity (Pulverer et al., 1991; Derijard et al., 1994; Minden 
et al., 1994; Watson et al., 1998). Besides c-Jun, JNK also phosphorylates other 
transcription factors, namely of the Jun, Fos and ATF families (for example, JunB, 
JunD, c-Fos and ATF2). Members of the Jun and Fos families assemble the AP-1 
complex (Bogoyevitch and Kobe, 2006), which is responsible for the transcription of 
several stress responsive genes. Furthermore, JNK contributes to the mitochondrial 
pathway of apoptosis by inducing the gene expression of mitochondrial proteins like 
Bim (Harris and Johnson, 2001; Putcha et al., 2001; Whitfield et al., 2001; Gilley et al., 
2003). This kinase has been shown to phosphorylate H2A histone family, member X 
(H2AX), which is determinant for DNA fragmentation induced by apoptotic stimulation. 
Phosphorylation mutants for Ser139 resulted in an absence of DNA fragmentation 
upon UV radiation (Lu et al., 2006; Sluss and Davis, 2006). Despite its major role in 
gene transcription regulation, JNK can also mediate apoptotic mechanisms via non-
transcriptional effects (Tournier et al., 2000; Bogoyevitch and Kobe, 2006). 
Accordingly, several anti- and pro-apoptotic proteins of the Bcl-2 family are JNK 
substrates and their phosphorylation by this kinase regulates their activity in the 
apoptotic signaling (Maundrell et al., 1997; Yamamoto et al., 1999; Kharbanda et al., 
2000; Donovan et al., 2002; Lei and Davis, 2003; Liu and Lin, 2005). JNK also has 
some neuron-specific substrates, namely two AMPAR subunits – GluA4 and GluA2L. 
Phosphorylation by JNK contributes to the regulation of AMPARs containing these 
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subunits, which are constitutively phosphorylated by JNK at GluA4-Thr855 and 
GluR2L-Thr912. This phosphorylation is proposed to play a role in controlling activity-
dependent GluR2L trafficking (Thomas et al., 2008a). JNK mediated phosphorylation of 
GluA4 on Thr855 is increased upon excitotoxic stimulation however, the role of this 
phosphorylation in this context is not fully understood (Vieira et al., 2010). 
The activity of JNK is counteracted by MKPs, as demonstrated by increased 
JNK activity upon ablation of either MKP1 (Chi et al., 2006; Wu et al., 2006b; Zhao et 
al., 2006) or MKP5 (Zhang et al., 2004). Interestingly, the association of the MKPs may 
occur directly with JNK or via interaction with the JNK scaffold proteins JIP1 and β-
arrestin2 (Willoughby et al., 2003; Willoughby and Collins, 2005). The phosphatase 
MKP1 is part of a negative feedback loop in a NGF withdrawal paradigm of cell death 
in sympathetic neurons. Activation of JNK signaling promotes MKP1 expression via c-
Jun/ATF2 transcriptional activity (Kristiansen et al., 2010). 
The role of JNK in apoptosis is well established (Eilers et al., 1998; Tournier et 
al., 2000; Tournier et al., 2001), however it seems to be highly dependent on the type 
of cell and on the specific stimulus (Davis, 2000; Weston and Davis, 2002). Notably, 
the requirement for JNK and p38, in neuronal death paradigms, seems to be highly 
stimulus-specific. For example, whilst caspase-independent glutamate-induced 
neuronal demise relies on p38 activity, trophic factor withdrawal is solely dependent on 
JNK signaling (Cao et al., 2004b). Additionally, JNK seems to have dual roles in the 
decision between life and death. In fact, JNK has been reported to have two phases of 
activity (Hirt et al., 2004; Ventura et al., 2006; Vieira et al., 2010), which may have 
differential impact on the cellular fate. An initial, transient increase in JNK activity was 
shown to contribute to cell survival whereas a later, sustained phase of JNK activity 
reportedly contributed to cell death (Ventura et al., 2006). Interestingly, neurons were 
shown to have distinct pools of JNK, performing individual functions. A pool located 
close to the neurites was proposed to be responsible for physiological functions while a 
nuclear pool of JNK, more readily available to phosphorylate c-Jun, was responsible for 
the cell death mechanisms (Coffey et al., 2000; Bjorkblom et al., 2008). Furthermore, 
neurons have a high constitutive JNK activity, attributed in its majority to JNK1 and, 
upon stressful insults, JNK2/3 is activated and is responsible for the damaging effects 
of c-Jun (Coffey et al., 2002). Furthermore, although JNK clearly contributes to 
apoptotic cell death, it has also been shown to be involved in other cell death 
mechanisms, namely necrosis (Ventura et al., 2004). 
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JNK Signaling and Disease 
As a hallmark signaling pathway in stress responses, JNK activity has been 
associated with a variety of pathologies, especially those with a strong apoptotic 
component (Cui et al., 2007b). Indeed, the JNK signaling pathway is involved in the 
etiology of Type 2 diabetes (Hirosumi et al., 2002; Jaeschke et al., 2005; Kaneto et al., 
2006), cancer and inflammatory diseases. Furthermore, JNK activity is critically 
involved in several neurological disorders, including PD (Saporito et al., 2000; Hunot et 
al., 2004; Silva et al., 2005), polyglutamine diseases (Liu, 1998; Taylor et al., 2013), AD 
(Savage et al., 2002; Ferrer et al., 2005) and cerebral ischemia (Herdegen et al., 1998; 
Kuan et al., 2003; White et al., 2012). 
In order to counteract the toxic effects of JNK, several compounds have been 
developed, with different specificities. One of the most promising is a peptide inhibitor, 
which consists of a small peptide corresponding to the JNK binding domain (JBD) of 
the JNK scaffold JIP-1, attached to the cell permeable TAT sequence (D-JNKI-1). This 
peptide acts as a competitive inhibitor, preventing the binding of JNK to its substrates 
that possess a similar JBD. This peptide has been shown to have protective effects 
against IL-1β-induced apoptosis in pancreatic β-cells (Bonny et al., 2001) and in 
several models of focal ischemia (Borsello et al., 2003). Notably, inhibition of JNK, and 
also p38, is a promising avenue for treatment against a wide range of neurological 
disorders (Bendotti et al., 2006). 
 
JNK and Global Ischemia 
Global ischemic insults lead to the activation of MAPK signaling pathways: JNK, 
p38 and ERK (Ozawa et al., 1999; Sugino et al., 2000). The pattern of MAPK activation 
seems to be dependent on the intensity and duration of the stimulus and also on the 
animal model used. Hence, the timing of MAPK activation varies in different reports. 
Indeed, while Sugino and coworkers observed activation of JNK and p38 both in the 
CA1 and CA3 areas of the hippocampus, although with differences in terms of kinetics 
(Sugino et al., 2000), other authors have reported a specific activation of JNK in the 
CA1 area. These authors describe a biphasic activation of the JNK pathway in CA1, 
accompanied by c-Jun phosphorylation (Zablocka et al., 2003), involving the upstream 
kinases ASK1 and MKK4, whereas the CA3 and DG do not display JNK activation. 
Interestingly, only the second phase of JNK pathway activation seems to be specifically 
mediated by the signaling complex formed by ASK1-MKK4-JNK, which may influence 
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the role of JNK on the neuronal outcome. Also, this second phase seems to be 
mediated by Ca2+-permeable AMPARs (CP-AMPARs) and oxidative stress (Zhang et 
al., 2003). The AS601245 compound, a specific JNK inhibitor, was shown to be 
neuroprotective against neuronal death in the hippocampus after global ischemia in 
gerbils and focal ischemia in rats. Moreover, this inhibitor reverses the increased c-Jun 
phosphorylation observed in the CA1 area after the insult (Carboni et al., 2004). In view 
with the involvement of CP-AMPARs in the activation of JNK, we have shown that 
overactivation of homomeric GluA4-containing AMPARs induced JNK activation, in a 
biphasic and Ca2+-dependent manner (Vieira et al., 2010). Moreover endogenous 
GluA4 of the rat brain hippocampus associates with JIP1 upon excitotoxic stimulation in 
vivo, suggesting that the JIP1 scaffold couples CP-AMPARs to JNK activation (Vieira et 
al., 2010) and to increased AP-1 binding activity (Santos et al., 2006) propagating the 
excitotoxic signal from the cell surface to the nucleus. The OGD-induced death has 
also been shown to be mediated by JNK signaling. In fact, there are reports of 
increased c-Jun phosphorylation, following OGD stimulation (Thevenet et al., 2009) as 
well as of JNK itself, which corresponds to increased activation of this kinase 
(Shinozaki et al., 2007). This increase in c-Jun phosphorylation seems to be related 
with induction of CA1 hippocampal neuron death. Additionally, some reports show 
significant neuroprotection afforded by the JNK inhibitor D-JNKI-1, against the OGD 
challenge (Hirt et al., 2004; Benakis et al., 2010). In fact, D-JNKI-1 has elicited 
promising results, since administration 6h after OGD had a neuroprotective effect and 
improved neuronal functional recovery. Interestingly, administration at 3h after OGD 
had no significant effect, which points to dual functions performed by JNK: a pro-
survival, and a pro-death role. In vivo, D-JNKI-1 also proved neuroprotective. When 
administered 3h after permanent MCAO, it reduced the infarct volumes and improved 
neurological scores (Hirt et al., 2004) and reduced c-Jun phosphorylation (Repici et al., 
2007). This peptide was also effective in preventing NMDA-induced excitotoxicity 
(Centeno et al., 2007). Another JNK inhibitor peptide, TAT-TIJIP, was also found to be 
protective against OGD and to prevent caspase-3 activation in this paradigm of 
neuronal death (Arthur et al., 2007). In JNK3-/- hippocampal neurons, there is increased 
resistance to OGD-induced death and they display reduced cytoplasmic staining for 
cytochrome c. JNK3-/- animals also display reduced vulnerability to excitotoxicity (Yang 
et al., 1997) and hypoxia-ishemia accompanied by decreased levels of apoptotic 
markers, such as Bim and Fas (Kuan et al., 2003). 
Some JNK upstream kinases, such as TAK1, have been shown to be activated 
in neurons, in response to OGD. This MAPKKK is related to neuronal death as its 
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acute inhibition protects cortical neurons from OGD-induced apoptosis, reduces the 
infarct volume and improves the sensorimotor outcome following MCAO. Activation of 
TAK1 results in phosphorylation and activation of the MAPKs JNK and p38 following 
OGD, which then induce neuronal death, through the transcriptional activity of AP-1 
and NF-κB, which contributes to oxidative stress generation. Interestingly, prolonged 
TAK1 inhibition/deletion is not neuroprotective as other MAPKKKs, such as ASK1, 
compensate for TAK1 absence (Neubert et al., 2011). 
JNK also seems to be correlated to the toxic effects of KAR activation during in 
vitro or in vivo ischemia. Indeed, the signaling module GluK2-PSD95-MLK3 seems to 
induce toxicity in rat hippocampal neurons following OGD and 4-VO (Hu et al., 2009) or 
MCAO (Yu et al., 2009). This signaling module leads to downstream JNK3 activation, 
with subsequent c-Jun phosphorylation and activation of the apoptotic machinery. By 
interfering with the formation of this module, increased neuroprotection is observed 
following in vitro and in vivo ischemia (Pei et al., 2006; Hu et al., 2009; Yu et al., 2009). 
Although many reports demonstrate the importance of MAPKs to the death 
promoting effects following OGD or in vivo ischemia, some reports challenge this view 
by showing no significant protection afforded by MAPK inhibitors. Zhou et al. describe a 
reduction in ERK1/2, p38 and JNK phosphorylation following OGD, and no significant 
effect of the MEK inhibitor U0126 or SB203580, a p38 inhibitor, both in young (P10) 
and adult (2 month old) rat hippocampal slices (Zhou et al., 2007). These discrepancies 
in the reports may be justified by the timing of application of the inhibitors, which varies 
in the different reports, as well as the intensity of the stimuli. 
The transcription factor AP-1 is composed of dimers of proteins of the Jun and 
Fos families, among others, that are regulated by phosphorylation mediated by MAPK 
protein members. The c-Jun transcription factor has a role in the induction of neuronal 
death following OGD. In fact, KD of this protein significantly protects neurons in this 
model of neuronal death (Cardoso et al., 2010). Excitotoxic stimulation of CP-AMPARs 
leads to increased DNA binding activity of AP-1, and the inhibition of c-Jun 
transcriptional activity was cytoprotective (Santos et al., 2006). Similar to the JNK 
inhibitory peptides, AP-1 inhibition using TAT peptides significantly protects cortical 
neurons against an excitotoxic paradigm (Meade et al., 2010). 
Overall, both JNK and p38 MAPKs have an established role in the induction of 
neuronal death following cerebral ischemic insults and targeting these pathways is a 
promising avenue for the development of novel strategic therapies for this type of 
pathology. 
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Objectives 
 In this work, we aimed to study the mechanisms of toxicity underlying the 
neuronal death induced by OGD in rat primary cultures of hippocampal neurons, an in 
vitro global ischemia model, in order to advance the knowledge of the molecular 
mechanisms of cerebral ischemia, thus contributing to identify new molecular targets 
that may be useful for the development of effective therapeutic strategies to this 
pathology. 
 To achieve our main goal, we targeted different steps in the mechanisms that 
lead to neuronal death. Hence, we investigated the activation of NMDARs and the 
specific contribution of the GluN2B subunit to the toxicity induced by the OGD 
challenge. For this purpose, we used a GluN2B-/- culture system and addressed the 
contribution of the C-terminal domain of this subunit by introducing different mutant 
GluN2B subunits in these neurons. With this, we intended to clarify the domains in the 
C-terminus of GluN2B responsible for the toxicity of this subunit upon OGD (Chapter 
II). We also investigated the activation of a novel type of programmed cell death called 
necroptosis upon OGD stimulation, in order to establish the underlying mechanisms 
that lead to the activation of this cell death program under ischemic stimulation. For this 
we analysed the neuroprotective effect of Nec-1 on the OGD-induced death, using a 
few cell death assays (LDH, PI uptake and analysis of the nuclear morphology with 
Hoechst 33342). We also studied the contribution of the necrosome proteins RIP1 and 
RIP3 to the neuronal death process following OGD (Chapter III). Additionally, we 
addressed the study of signaling pathways commonly associated with ischemic 
neuronal death, specifically the MAPK signaling pathways JNK and p38. We analysed 
the activation of both pathways and observed the effect of the inhibition of either p38 or 
JNK to the hippocampal neuronal death elicited by OGD: Additionally, we assessed the 
mRNA levels of some MAPK substrates and upstream kinases using qPCR (Chapter 
IV). 
 Our approach aimed to clarify the events associated with different players of the 
neuronal death process under ischemic stimulation so as to pinpoint molecular targets 
involved in hippocampal neuronal death. Ultimately, this will contribute to a better 
understanding of the molecular mechanisms that contribute to neurodegeneration in 
cerebral ischemia and, hopefully, will be valuable in the development of therapeutics to 
improve patient outcome. 
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Abstract 
Global cerebral ischemia induces selective neurodegeneration of specific 
subsets of neurons throughout the brain, namely in the Cornu Ammonis 1 (CA1) region 
of the hippocampus and in the cortical layers II, V and VI. One of the major hallmarks 
of cerebral ischemia is a phenomenon called excitotoxicity. It consists in the 
overactivation of glutamate receptors (GluRs) at the postsynaptic membrane with 
consequent overload of Ca2+. This leads to deregulation of Ca2+ homeostasis and 
neuronal demise. N-methyl-D-aspartate receptors (NMDARs) are considered to be 
largely responsible for excitotoxic mechanisms due to their high Ca2+ permeability. The 
NMDARs are most prominently composed of combinations of two GluN1 subunits and 
two GluN2A or GluN2B subunits. While GluN2A is commonly believed to be located at 
the synapse and to mediate prosurvival signaling, GluN2B is thought to be most 
abundant at extrasynaptic sites and its activation is believed to mediate neurotoxicity. 
We investigated whether GluN2B is in fact responsible for activation of prodeath 
signaling using an in vitro model of global ischemia by submitting primary cultures of 
hippocampal neurons to oxygen and glucose deprivation (OGD). We observed that 
OGD induces a component of excitotoxic cell death that is prevented upon GluN2B 
antagonism or in the absence of this subunit. We also describe a crucial role of the C-
terminal domain of GluN2B that goes beyond the PSD95/Dlg/ZO-1 (PDZ) domain, 
which has been previously established. Indeed, expression of YFP-GluN2B in GluN2B-
/- mouse cortical neurons rescued neuronal death upon OGD, whereas expression of 
the YFP-GluN2B C-terminus mutants for the binding sites to postsynaptic density 95 
(PSD95), Ca2+-calmodulin kinase II (CaMKII) or clathrin adaptor protein 2 (AP2) failed 
to induce neuronal death in OGD conditions. Taken together, our results show a crucial 
role of the C-terminal domain of the GluN2B subunits in promoting neuronal death in 
ischemic conditions, which seems to be responsible for the divergent roles of the 
GluN2A and GluN2B subunits to neuronal fate. 
 
 
Introduction 
Transient cerebral global ischemia is one of the most common causes of 
disability and mortality in the western world. It results from a lack of blood supply to the 
entire brain that may arise due to cardiac arrest, leading to the delayed death of 
specific subpopulations of neurons. The hippocampus and some cerebral cortical 
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layers are prominently affected following global cerebral ischemia in patients (Petito et 
al., 1987) and also in animal models (Kirino, 1982; Zukin et al., 2004). Global cerebral 
ischemic insults can be reproduced in vitro by performing oxygen and glucose 
deprivation (OGD) on primary neuronal cultures or brain slices, typically from the 
hippocampus or the cerebral cortex (Goldberg and Choi, 1993; Martin et al., 1994; 
Calderone et al., 2003). 
Excitotoxicity is a major hallmark of several neurological disorders, including 
cerebral ischemia, and is characterized by the accumulation of glutamate in the 
extracellular space, leading to overactivation of glutamate receptors (GluRs) and the 
consequent induction of neuronal death. One key factor in excitotoxic cell death is the 
Ca2+ overload (Arundine and Tymianski, 2003; Forder and Tymianski, 2009). Among 
GluRs, the N-methyl-D-aspartate receptors (NMDARs) have long been implicated in 
excitotoxic phenomena, due to their high Ca2+ permeability (Goldberg and Choi, 1993; 
Gwag et al., 1995; Wang and Qin, 2010). The NMDARs are ionotropic GluRs (iGluRs) 
that form tetrameric structures assembled from two obligatory GluN1 subunits and two 
GluN2 (A-D) or GluN3 (A, B) subunits (Traynelis et al., 2010). Most NMDAR complexes 
are composed by GluN2A or GluN2B in combination with GluN1 subunits. In rodents, 
the GluN2 subunits are differentially regulated throughout development, with GluN2B 
being highly expressed during embryonic development and GluN2A expression 
increasing around the second post-natal week (Watanabe et al., 1992; Monyer et al., 
1994). The role of these two subunits in excitotoxicity has remained controversial, as 
some reports suggest that both subunits contribute to neuronal death (Stanika et al., 
2009; Zhou et al., 2013), while others imply a differential contribution of the two 
subunits (Wyllie et al., 2013). Specifically, GluN2A is thought to be related with 
activation of survival signaling (Liu et al., 2007; Terasaki et al., 2010), while GluN2B 
activates deleterious pathways (Aarts et al., 2002; Soriano et al., 2008; Martel et al., 
2012). 
In this work we investigated the impact of the GluN2B subunit to OGD-induced 
neuronal death. We chose this insult because most reports use excitotoxic treatments 
(usually high NMDA concentrations), which do not correlate as accurately to in vivo 
cerebral ischemia as the OGD challenge. We observed a specific role of this subunit in 
OGD-induced death, in particular of its C-terminal domain. While GluN2B expression in 
GluN2B-/- cortical neurons rescued neuronal death in ischemic conditions, the GluN2B 
subunit with its C-terminal tail swapped with that of GluN2A failed to produce cell death 
upon OGD. We confirmed previous evidence showing a neuroprotective effect of 
interfering with the interaction between GluN2B and postsynaptic density 95 (PSD95) 
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but we went further to observe a determinant role of two additional domains in the C-
terminus of the GluN2B subunit. Indeed, we report the absence of neuronal death in 
the presence of GluN2B mutant subunits for the Ca2+-calmodulin kinase II (CaMKII)- 
and clathrin adaptor protein (AP2)-binding sites. 
 
 
Materials & Methods 
Materials 
 The NMDAR antagonist (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801, #0924) and the GluN2B 
selective antagonist ifenprodil (#2892) were purchased from Tocris Bioscience (Bristol, 
UK). 
 The plasmids pll-synapsin-GluN2B-YFP, encoding the wild-type (WT) GluN2B 
subunit of NMDARs, pll-synapsin-GluN2B swap tail-YFP, encoding the GluN2B subunit 
with the entire tail swapped with that of GluN2A, pll-synapsin-GluN2B PDZ mutant-
YFP, encoding the GluN2B subunit with a mutation on the PDZ domain (ESDV → 
EAAV), pll-synapsin-GluN2B CaMKII mutant-YFP, encoding the GluN2B subunit with a 
mutation on the CaMKII binding domain (RQHS → QQHD) and pll-synapsin-GluN2B 
AP2 mutant-YFP, encoding the GluN2B subunit with a mutation on the AP2 binding 
domain (YEKL → ASKL) (Figure 2.2-B) were generous gifts from Ann Marie Craig, 
University of British Columbia, Vancouver, Canada. 
The TAT cell permeable peptides L-TAT and L-TAT-NR2B9c were generous 
gifts from Michael Courtney, Kuopio University, Kuopio, Finland. 
 
Cell Culture and Transfection 
Two distinct types of neuronal cultures were used in this study. We used 
cultured cortical neurons from GluN2B-/- and WT littermates (due to limiting numbers of 
GluN2B-/- hippocampal neurons), or primary cultures of rat hippocampal neurons (for 
the studies with NMDAR antagonists). 
For the GluN2B-/- and WT littermate cultures, cortical neurons were prepared 
from embryonic day 17-18 (E17-18) mice, as previously described (Ferreira et al., 
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2011). Briefly, cortices were dissected and maintained in Hibernate E (Brain Bits, 
Springfield, IL) supplemented with NeuroCult™ SM1 Neuronal Supplement 
(StemCell™ Technologies, Grenoble, France) at 4°C overnight, while genotyping was 
performed. Tissues from the same genotype were pooled together and dissociated with 
papain (20 units/ml, 10 min, 37°C) and deoxyribonuclease I (0.20 mg/ml). 
Cortical neurons were electroporated on the day of the culture using the 
AMAXA system (Lonza, Basel, Switzerland). Briefly, 0.75 million cells were centrifuged 
and the cell pellet resuspended in 50 µl of Ingenio™ Electroporation Solution 
(MIR50111 – Mirus Bio LLC, Madison, WI) and 2.5 µg of each plasmid was added. 
After electroporation, neurons were transferred to coverslips coated with poly-D-lysine 
(PDL) in 12 multiwell (MW) plates containing pre-warmed minimal essential medium 
(MEM) supplemented with 10% horse serum. Once the neurons attached to the 
substrate, the plating medium was removed and neurons were placed in Neurobasal® 
Medium (Gibco®, Life Technologies™, Paisley, UK) supplemented with 2% 
NeuroCult® SM1, 0.5 mM glutamine, 0.125 μg/ml gentamicin, and insulin (20 μg/ml). 
Neurons were maintained at 37°C in a humidified incubator with 5% CO2/95% air for 15 
days in vitro (DIV). 
For neuroprotection studies with NMDAR antagonists, primary cultures of 
hippocampal neurons were prepared from E18 rats (Santos and Duarte, 2008). Briefly, 
hippocampi were dissected and dissociated with trypsin (1.5 mg/ml Hank’s Balanced 
Salt Solution – HBSS). Neurons were cultured in MW plates with or without glass 
coverslips, coated with PDL, at a density of 85,000 cells/cm2, in Neurobasal® medium 
supplemented with 2% NeuroCult™ SM1 Neuronal Supplement, 0.5 mM glutamine, 
0.125 µg/ml gentamicin and 25 µM glutamate. Neuronal cultures were maintained at 
37ºC in a humidified incubator with 5% CO2/95% air up to 15 DIV. 
 
Oxygen-Glucose Deprivation (OGD) Challenge 
 At DIV 15, hippocampal neurons were challenged with an in vitro ischemic 
insult. For that purpose, neurons were placed in a glucose-free deoxygenated buffer 
medium (OGD medium – 10 mM HEPES, 116 mM NaCl, 5.4 mM KCl, 0.8 mM 
NaH2PO4, 25 mM sodium bicarbonate, 25 mM sucrose, 1.8 mM CaCl2, 0.04% phenol 
red, pH 7.3), inside an anaerobic chamber with a mixture of 5% CO2, 7.5% H2 and 
87.5% N2 (OGD chamber, Thermo Forma 1029, Thermo Fisher Scientific, Waltham, 
MA), at 37ºC for 2h. Control neurons were placed in a similar buffer, containing 25 mM 
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glucose, instead of sucrose (sham medium) and kept for 2h in an oxygenated 
incubator. After the insult, neurons were placed in their conditioned medium and 
returned to the normoxic incubator for an additional period of recovery that lasted up to 
24h. 
When indicated, MK-801 or ifenprodil were added to the medium 15 min prior to 
stimulation and kept during the stimulation and post-stimulation periods, at the 
indicated concentrations. The cell-permeable peptides, L-TAT and L-TAT-NR2B9c were 
pre-incubated 1h prior to stimulation and kept for the remainder of the experiment. 
 
Immunocytochemistry 
Cortical mouse neurons were labeled with an anti-GFP antibody (1:500 - #598, 
MBL International, Woburn, MA), to detect transfected neurons. Briefly, following 
methanol fixation (10 min at -20°C), the coverslips were incubated with 10% bovine 
serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 hour at 37°C to prevent 
nonspecific antibody binding, and incubated overnight with the primary antibody in 3% 
BSA at 4ºC. Secondary antibody anti-rabbit-Alexa 488 (Jackson ImmunoResearch, 
Suffolk, UK) was also prepared in 3% BSA and incubated at 37°C for 1 hour. The 
coverslips were extensively washed with PBS after antibody incubations and were then 
mounted in fluorescence mounting medium from DAKO (Glostrup, Denmark), after the 
staining with Hoechst 33342 in order to visualize cell nuclei. 
 
Nuclear Morphology 
 Neuronal death was assessed 24h following the OGD insult by analysis of the 
nuclear morphology. For that purpose, fixed neurons were stained with the nuclear dye 
Hoechst 33342 (2 µg/ml) for 15 min at RT and then mounted in florescence mounting 
medium. Neurons were analyzed under fluorescence microscopy for chromatin 
condensation, a feature of apoptotic cells. At least 200 cells were counted in each 
coverslip. When using transfected cells, GFP-positive neurons were detected using the 
green fluorescence filter and nuclear morphology was analyzed using the blue 
fluorescence filter. The totality of transfected cells in each coverslip was counted. The 
results were expressed as the percentage of cell death (dead cells/total number of 
cells). 
 
Chapter II 
58 
 
LDH release assay 
 At 24h of recovery after the OGD challenge, the lactate dehydrogenase (LDH) 
release to the extracellular medium was evaluated by a colorimetric assay using the 
CytoTox96 Non-Radioactive assay kit (Promega, Madison, WI), according to the 
manufacturer’s instructions. The percentage of LDH release is a measure of the extent 
of neuronal death and was determined as the ratio between LDH activity in the 
extracellular medium and total LDH activity obtained after complete cell lysis with Triton 
X-100. All experiments were carried out in duplicate or triplicate, for each independent 
experiment, as previously described (Vieira et al., 2010). 
 
Statistical Analysis 
Results are presented as means ± S.E.M. of the indicated number of 
experiments. Statistical significance was assessed by one-way analysis of variance 
(ANOVA) followed by the Dunnett’s or the Bonferroni’s test. These statistical analyses 
were performed using the software package GraphPad Prism 5. 
 
 
Results 
The GluN2B Subunit is Determinant for OGD-induced Neuronal Death 
 Excitotoxicity is one of the major hallmarks of brain ischemic injury, as a 
consequence of excessive glutamate release to the synapse and dysfunction of 
glutamate buffering mechanisms (Olney, 1969; Lipton and Rosenberg, 1994; Wang 
and Qin, 2010), with resultant Ca2+ entry in neurons via GluRs (Arundine and 
Tymianski, 2003; Forder and Tymianski, 2009). Evidence in the literature suggests that 
both NMDAR (Hardingham et al., 2002; Arundine and Tymianski, 2004) and α-amino-3-
hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs), specifically Ca2+-
permeable (CP)-AMPARs (Gorter et al., 1997; Pellegrini-Giampietro et al., 1997) are 
responsible for the excitotoxic component of ischemic insults. In this study we used 
OGD in hippocampal and cortical cultured neurons as an in vitro model of global 
ischemia. To validate this model, we verified whether it induced an excitotoxic 
component of neuronal death in primary cultures of hippocampal neurons. For that 
purpose, we deprived hippocampal neurons from both oxygen and glucose for 2h and 
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then placed them back in glucose-containing and oxygenated conditions for an 
additional period of 24h. To address the role of NMDARs in this system we added 
NMDAR antagonists 15 min prior to OGD stimulation and kept the compounds for the 
remainder of the experiment (Fig 2.1-A). Using the LDH activity assay, we observed 
that the NMDAR antagonist MK-801 (10 µM) was effective in reducing neuronal death 
induced by OGD (from 37.1±4.5% to 19.7±2.9% of LDH release). Interestingly, we also 
observed significant neuroprotection by the selective GluN2B antagonist ifenprodil (3 
µM reduced LDH release to 20.5%±5.3). This suggests that receptors containing this 
subunit in their composition are responsible, at least partially, for the neuronal death 
induced by excitotoxicity in this system. These results demonstrate the occurrence of a 
NMDAR-mediated excitotoxic component in the OGD model. 
The neuroprotective effect of ifenprodil (Fig 2.1-A), along with the evidence in 
the literature of a relevant role of the GluN2B subunit in excitotoxic events (Kapin et al., 
1999; Aarts et al., 2002), prompted us to investigate the actual role of GluN2B under 
OGD conditions. Thus, we took advantage of a GluN2B-/- system to address this issue. 
To confirm that the GluN2B subunit is determinant for the excitotoxic component of 
OGD-induced damage, we compared the neuronal death elicited by OGD in GluN2B-/- 
neurons and in WT neurons (Fig 2.1-B, C). In WT mouse cortical neurons, OGD 
induced cell death (35.12±3.4%), as determined by analyzing the nuclear morphology. 
On the contrary, the extent of cell death in GluN2B-/- neurons was much restricted in 
this assay and OGD-elicited death was not significantly different from basal neuronal 
death (Fig 2.1-B). This result suggests that, in the absence of GluN2B expression, 
neurons become more resistant to ischemic insults, similarly to what has been 
observed for NMDA-induced excitotoxic neuronal damage (Liu et al., 2007). 
To confirm that this increased resistance is a result of the absence of GluN2B 
excitotoxic signaling, and not only an effect of reduced levels of NMDARs at the 
surface, we reintroduced the GluN2B subunit in cortical neuronal cultures and analyzed 
cell death elicited by OGD in transfected cells. We observed that expression of GluN2B 
rescues the toxic effect of the OGD challenge (from 11.1% to 33.0% of cell death) (Fig 
2.2-C). The GluN2B and GluN2A subunits present low homology at the C-terminal 
intracellular domain (Fig. 2.2.-A), and their differential role in cell death mechanisms 
could be a consequence of C-terminal-mediated processes. To test this idea we 
introduced a chimeric construct comprising YFP-GluN2B with the GluN2B C-terminal 
domain swapped by that of the GluN2A subunit (Fig. 2.2-B). In fact, introduction of this 
construct in GluN2B-/- neurons failed to rescue the neuronal death that we observed for 
the WT GluN2B subunit (5.7% of neuronal death) (Fig 2.2-C). Importantly, this chimeric 
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subunit is still targeted to the membrane (Ann Marie Craig personal information, data 
not shown), further supporting the notion that the WT GluN2B subunit expression is 
determinant for NMDAR-dependent toxicity and that the C-terminal domain of this 
subunit is crucial for induction of excitotoxic mechanisms. This is in accordance with a 
previous report where similar chimeric subunits were used, that demonstrated that 
these subunits did not alter NMDA currents and the proportion of extrasynaptic 
receptors, suggesting that these subunits form functional NMDARs that are trafficked to 
the cell membrane.  
 
Figure 2.1. OGD induces excitotoxic neuronal death that is prevented in GluN2B-/- 
neurons. (A) Mature cultures of hippocampal neurons (15 DIV) were submitted to OGD. 
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For that purpose, neurons were placed in a glucose–free saline buffer and deprived of 
oxygen for 2h. Control neurons were placed in a similar saline buffer containing glucose 
and kept in an air/CO2 chamber for the same period of time. The cultures were then 
transferred to the conditioned medium and returned to the air/CO2 incubator for 24h. The 
NMDAR antagonist – MK-801: 10 µM, n=7; and the GluN2B antagonist – ifenprodil: 3 µM, 
n=4 were added 15 min prior to stimulation and kept during the stimulation and post-
stimulation periods. The LDH activity was assayed as indicated in the manufacturer’s 
protocol. Bars represent the mean ± SEM of the indicated number of experiments. 
*Significantly different from control (***p<0.001 (compared to Control); #p<0.05, ##p<0.01 
(compared to OGD), One way ANOVA followed by Bonferroni’s multiple comparison test). 
(B) Mature cultures of WT or GluN2B-/- mouse cortical neurons (15 DIV) were stimulated 
as rat hippocampal neurons, and 24h after the insult nuclear morphology of cortical 
neurons was analyzed. The results were expressed as the percentage of dead cells 
relatively to the total number of cells. Bars represent the mean ± SEM of 4 independent 
experiments. *Significantly different from control (*p<0.05, Student’s t test). (C) 
Representative images from B. Scale bar – 20 µm. 
 
C-terminal-specific Interactions are Determinant for GluN2B-mediated Toxicity 
 Recently, a specific role of the C-terminal domains of GluN2B and GluN2A was 
suggested to determine the activation of pro-death or pro-survival signaling pathways, 
respectively (Martel et al., 2012). This is further supported by the fact that the C-
terminus is the most divergent region between GluN2A and GluN2B subunits (Fig 2.2-
A). Thus, we studied the C-terminal domain of GluN2B, using diverse mutant forms of 
the subunit (Fig 2.2-B), to identify molecular determinants required for cell death. In 
order to identify relevant interactions established between the C-terminal domain of the 
GluN2B subunit and intracellular proteins that are relevant for mediating a toxic 
pathway, we transfected GluN2B-/- cortical neurons with C-terminus mutants of GluN2B 
subunits, for known interaction sites. Of note, all of the mutants used were targeted to 
the cell surface (Ann Marie Craig personal information, unpublished results), thus, the 
effects observed are specific to the mutation and not a consequence of reduced levels 
of NMDARs at the surface. 
The PDZ-binding domain of GluN2B has been shown to be important for activation of 
excitotoxic mechanisms (Sattler et al., 1999; Aarts et al., 2002; Cao et al., 2005). This 
domain was reported to be involved in the interaction with PSD95 which, upon NMDAR 
overactivation, leads to the recruitment of the Ca2+-dependent neuronal nitric oxide 
synthase (nNOS) to the vicinity of NMDARs, thereby contributing to neuronal death 
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through nitric oxide (NO) production (Aarts et al., 2002; Zhou et al., 2010). Accordingly, 
we found that expression of the GluN2B subunit with a mutation in the PDZ-binding 
domain in GluN2B-/- neurons fails to rescue OGD toxicity (Fig 2.3-A). Furthermore, to 
determine whether we could reproduce the neuroprotective effect of disrupting the 
coupling between GluN2B and PSD95, we used a cell permeable peptide (L-TAT-
NR2B9c), which targets this interaction (Aarts et al., 2002). We observed that this 
peptide significantly protected rat hippocampal neurons from the OGD-induced death 
(Fig 2.3-C). 
 
Figure 2.2. The C-terminal domain of the GluN2B subunit determines its toxic effect 
following OGD. (A) Alignment of the C-terminal domains of the mouse GluN2A 
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(NP_032196) and GluN2B (NP_032197) subunits. There is a high level of divergence 
between the C-terminus of GluN2A and GluN2B, which may contribute to their differential 
roles in excitotoxic mechanisms. (B) Diagram of the different mutant GluN2B subunits 
used in this work. A mutant consisting of a substitution of the C-terminal domain for that 
of the GluN2A subunit (swap tail) was developed. Additionally, the C-terminal domain of 
the GluN2B subunit was mutated in different domains, to produce an AP2 binding mutant 
(YEKL → ASKL), a CaMKII binding mutant (RQHS → QQHD) and a PDZ domain mutant 
(ESDV → EAAV). (C) Reintroduction of the GluN2B subunit in GluN2B-/- neurons rescues 
OGD-induced toxicity. Cortical neurons from GluN2B-/- animals were electroporated (5 
µg/1500000 cells) with constructs encoding the YFP tag (n=4), the YFP-GluN2B subunit 
(n=4) or the YFP-GluN2B-swap tail (n=3) using the AMAXA system. After 15 DIV, the 
cultures were submitted to OGD. Twenty-four hours after the insult, cells were fixed with 
methanol. The nuclear morphology of transfected cells was analyzed and expressed as 
the number of dead (apoptotic-like cells) relative to the total number of transfected cells. 
(*p<0.05, relative to OGD-YFP; #p<0.05, relative to OGD-GluN2B, One way ANOVA 
followed by Bonferroni’s multiple comparison test). (D) Representative images from C. 
Scale bar – 20 µm; insert – 10 µm. Inserts show nuclear morphology of a transfected cell. 
 
 The PDZ-binding domain of GluN2B has been shown to be important for 
activation of excitotoxic mechanisms (Sattler et al., 1999; Aarts et al., 2002; Cao et al., 
2005). This domain was reported to be involved in the interaction with PSD95 which, 
upon NMDAR overactivation, leads to the recruitment of the Ca2+-dependent neuronal 
nitric oxide synthase (nNOS) to the vicinity of NMDARs, thereby contributing to 
neuronal death through nitric oxide (NO) production (Aarts et al., 2002; Zhou et al., 
2010). Accordingly, we found that expression of the GluN2B subunit with a mutation in 
the PDZ-binding domain in GluN2B-/- neurons fails to rescue OGD toxicity (Fig 2.3-A). 
Furthermore, to determine whether we could reproduce the neuroprotective effect of 
disrupting the coupling between GluN2B and PSD95, we used a cell permeable 
peptide (L-TAT-NR2B9c), which targets this interaction (Aarts et al., 2002). We 
observed that this peptide significantly protected rat hippocampal neurons from the 
OGD-induced death (Fig 2.3-C). 
To address a putative role of other known domains of the C-terminus of 
GluN2B, we expressed two additional GluN2B mutants in the GluN2B-/- neurons. Both 
mutants – one for the CaMKII binding site and the other for the AP2 interaction domain 
– were unable to rescue OGD-induced toxicity (Fig 2.4-A). These results demonstrate 
that GluN2B subunits induce neuronal death by a variety of mechanisms and 
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pathways, not only through Ca2+ influx, but also by activating diverse intracellular 
signaling pathways that have deleterious effects. 
 
Figure 2.3. The PDZ-binding domain of the C-terminus of the GluN2B subunit is 
determinant for the OGD-induced neuronal death. For the OGD challenge, mature 
cultures of GluN2B-/- mouse cortical neurons (15 DIV) transfected with the indicated 
constructs or untransfected rat hippocampal neurons were placed in a glucose–free 
saline buffer and deprived of oxygen for 2h. Control neurons were placed in a similar 
saline buffer containing glucose and kept in an air/CO2 chamber for the same period of 
time. The cultures were then transferred to the conditioned medium and returned to the 
air/CO2 incubator for 24h. (A) After fixation with methanol, mouse cortical neurons were 
probed with an anti-GFP antibody to identify transfected neurons and with Hoechst 33342 
in order to analyze the nuclear morphology of transfected neurons. The results were 
expressed as the percentage of dead cells relatively to the total number of transfected 
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cells. Bars represent the mean ± SEM of the indicated number of experiments (YFP – 
n=4; YFP-GluN2B – n=3; YFP-GluN2B-PDZ mutant – n=2). *Significantly different from 
OGD-YFP (*p<0.05, One way ANOVA followed by Bonferroni’s multiple comparison test). 
(B) Representative images from A. Scale bar – 20 µm; insert – 10 µm. Inserts show 
nuclear morphology of a transfected cell. (C) One hour prior to the OGD challenge, rat 
hippocampal neurons were treated with the cell-permeating peptides (control TAT and 
TAT-NR2B9c) which were kept throughout the experiment. Twenty four hours after OGD 
the LDH activity of the extracellular medium was assayed. Bars represent the mean ± 
SEM of 5 independent experiments. *Significantly different from control (*p<0.05, relative 
to control, #p<0.05, relative to OGD, §p<0.05, relative to OGD-TAT, One way ANOVA 
followed by Bonferroni’s multiple comparison test). 
 
 
Discussion 
 The determinant contribution of the GluN2B subunit to excitotoxic neuronal 
death has been widely studied. Using a GluN2B-/- system, we intended to clarify the 
role of this subunit and, in particular, of its C-terminal domain, to the neuronal death 
induced by OGD, an in vitro insult more similar to cerebral ischemia than the exposure 
to NMDA or other GluR agonists. We observed that OGD-induced cell death is 
dependent on the expression of the GluN2B subunit, since it is abolished in GluN2B-/- 
neurons. Expression of YFP-GluN2B in these cultures promoted a component of 
excitotoxicity upon the OGD challenge while the expression of a chimera consisting of 
the N-terminus and transmembrane domains of GluN2B attached to the C-terminal 
domain of GluN2A was not capable of restoring cortical neuronal death in the GluN2B-/- 
cultures. Interestingly, we observed that several domains in the C-terminus of GluN2B 
are responsible for its function in excitotoxic phenomena. Indeed, we observed that not 
only is the PDZ-binding domain crucial for OGD-induced death, but also the interaction 
sites for both CaMKII and the clathrin adaptor protein AP2 contribute to the activation 
of cell death mechanisms in these conditions. Thus, this report provides new 
mechanisms of GluN2B-mediated excitotoxicity following in vitro ischemia. 
OGD insults elicit excitotoxic cell death dependent on NMDA and AMPA/kainate 
receptors (KARs) (Goldberg and Choi, 1993; Gwag et al., 1995). This in vitro ischemic 
challenge induces long-lasting potentiation of NMDA responses in the vulnerable CA1 
region of the hippocampus, while transiently depressing these responses in the more 
resistant CA3 area (Gee et al., 2006). In this report we confirm the role of NMDARs to 
Chapter II 
66 
 
the damaging effect of the OGD challenge, by showing the neuroprotective effect of 
NMDAR antagonists. 
 
Figure 2.4. Several domains in the C-terminus of GluN2B are responsible for the 
subunit-specific toxicity. For the OGD challenge, mature cultures of GluN2B-/- mouse 
cortical neurons (15 DIV) transfected with the indicated constructs were placed in a 
glucose–free saline buffer and deprived of oxygen for 2h. Control neurons were placed in 
a similar saline buffer containing glucose and kept in an air/CO2 chamber for the same 
period of time. The cultures were then transferred to the conditioned medium and 
returned to the air/CO2 incubator for 24h. After fixation with methanol, neurons were 
probed with an anti-GFP antibody to identify transfected neurons and with Hoechst 33342 
in order to analyze the nuclear morphology of transfected neurons. (A) The results were 
expressed as the percentage of dead cells relatively to the total number of transfected 
cells. Bars represent the mean ± SEM of the indicated number of experiments (YFP – 
n=4; YFP-GluN2B – n=3; YFP-GluN2B-CaMKII mutant – n=2; YFPGluN2B-AP2 mutant – 
n=2). *Significantly different from control (*p<0.05, One way ANOVA followed Dunnett’s 
multiple comparison test). (B) Representative images from A. Scale bar – 20 µm; insert – 
10 µm. Inserts show nuclear morphology of a transfected cell. 
 
Synaptic and extrasynaptic NMDARs have been shown to be differentially 
regulated (Li et al., 2002) and to have opposing contribution to the neuronal death 
associated with excitotoxic phenomena (Hardingham et al., 2002; Hardingham and 
GluN2B & Neuronal Death 
67 
 
Bading, 2010). Synaptic NMDAR activation leads to increased activity of 
phosphoinositide 3-kinase (PI3K)/Akt, phosphorylation of extracellular-signal regulated 
kinase (ERK) and transcriptional activity of cAMP-response-element-binding protein 
(CREB), which contributes to neuronal survival (Chandler et al., 2001; Hardingham et 
al., 2002; Papadia et al., 2005; Zhang et al., 2011). On the contrary extrasynaptic 
NMDARs are thought to contribute to activation of deleterious signaling pathways, such 
as p38 mitogen-activated protein kinase (MAPK), and to induce CREB shut-off, thereby 
promoting neuronal demise (Hardingham et al., 2002; Ivanov et al., 2006; Leveille et 
al., 2008; Wahl et al., 2009; Xu et al., 2009). 
Interestingly, the GluN2A and GluN2B subunits of NMDARs have also been 
shown to exert opposing effects against excitotoxic insults (Wyllie et al., 2013). Indeed, 
while GluN2B antagonism or knock-down (KD) prevents neuronal death induced by in 
vitro and in vivo insults, GluN2A inhibition does not display any neuroprotective effect. 
In fact, selective activation of GluN2A-containing receptors has a prosurvival effect (Liu 
et al., 2007). The role of GluN2A subunits in survival signaling is further supported by 
reports showing its involvement in ischemic preconditioning phenomena, leading to 
CREB phosphorylation and transcriptional activity (Terasaki et al., 2010). 
This prosurvival role of the GluN2A subunit has been challenged in several 
reports, demonstrating a lack of specificity of GluN2A inhibitors (Weitlauf et al., 2005; 
Frizelle et al., 2006; Neyton and Paoletti, 2006; Stanika et al., 2009), and in some 
reports pointing out a protective effect of interfering with the interaction between 
GluN2A subunits with PSD95 and Src, contributing to decreased GluN2A 
phosphorylation and decreased activation of nNOS (Zhang et al., 2007; Wang et al., 
2010). In these reports, however, the authors did not address a putative effect on the 
GluN2B subunit. Furthermore, recent evidence reported a role for both subunits in 
either the survival as well as the toxic function of NMDARs. Indeed, both subunits are 
shown to contribute to activation of the CREB and brain-derived neurotrophic factor 
(BDNF) survival signaling, as well as for the shut-off of these pathways, supporting the 
hypothesis that synaptic NMDARs activate prosurvival signaling whilst the 
extrasynaptic ones activate prodeath mechanisms. Interestingly, they found that 
inhibition or KD of GluN2B subunits was more effective in rescuing neurons from 
excitotoxicity induced by NMDA or OGD, which was more evident with increasing 
intensity of the insults (Zhou et al., 2013). These findings complicate the interpretation 
of NMDAR function, since both location and subunit composition seem to contribute to 
the opposing effects of NMDARs. Interestingly, although neither GluN2A nor GluN2B 
are exclusively present in either site, they were found to be most abundant in the 
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synapse or in extrasynaptic locations, respectively (Li et al., 1998; Tovar and 
Westbrook, 1999; Groc et al., 2006). 
 In this report we did not address the role of the GluN2A subunit directly. Using a 
KO culture system for the GluN2B subunit we determined that this subunit is crucial for 
the excitotoxic events induced by OGD. Indeed, we observed that antagonism or 
absence of this subunit abrogates neuronal death induced by OGD. Ifenprodil, which is 
considered a highly selective GluN2B antagonist (Williams, 1993; Karakas et al., 2011; 
Ogden and Traynelis, 2011) abrogated OGD-induced toxicity in rat hippocampal 
neurons and the results with this antagonist are further supported by the absence of 
OGD-induced toxicity, relatively to the WT, in GluN2B-/- mouse cerebral cortical 
neurons. We confirmed the specificity of this effect by rescuing the toxicity of OGD 
when we introduced the GluN2B subunit in the GluN2B-/- neurons. 
Whilst sharing high degree of similarity in their extracellular and transmembrane 
domains (69%), the mouse NMDAR subunits GluN2A and GluN2B share only 29% of 
identity in their C-terminal domains [Fig. 2.2-A, (Ryan et al., 2008)]. This suggests that 
the C-terminal domains of these two subunits are the main determinants of their 
specific functions in the cells, and their proposed differential role under excitotoxic 
conditions (Wyllie et al., 2013). Interestingly, a recent report by Martel and colleagues 
supports this notion. They describe that the C-terminal domain of GluN2B is the region 
of the subunit responsible for mediating its toxic effect. Indeed, when they used 
chimeric subunits, comprising the GluN2B subunit attached to the C-terminus of 
GluN2A, they failed to induce neuronal death following excitotoxic treatment with 
NMDA (Martel et al., 2012). It should be noted that the tail swapping does not seem to 
alter the gating properties of the receptors (Maki et al., 2012; Punnakkal et al., 2012), 
nor their targeting to the cell membrane (Ann Marie Craig personal communication, 
unpublished results) conferring specificity to the findings with this type of chimeric 
subunit. In this report we describe a comparable finding. Using a similar chimeric 
subunit, we observed that GluN2B swap tail failed to rescue the toxicity induced by 
OGD, unlike the WT GluN2B subunit. Importantly, not only does this result support a 
prominent role of the GluN2B subunit to the excitotoxic mechanisms, in detriment of the 
GluN2A subunit, specifically of its C-terminal domain, we also demonstrate the 
relevance of this effect by using an insult that more closely models in vivo ischemia. 
One of the suggested mechanisms regulating the specific neurotoxic effect of 
GluN2B is the interaction between this subunit with PSD95, through its PDZ domain. 
The scaffold PSD95 couples to nNOS upon activation of NMDARs, contributing to 
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deleterious production of NO and mounting oxidative and nitrosative stress, as well as 
p38 activation (Sattler et al., 1999; Aarts et al., 2002; Cao et al., 2005; Zhou et al., 
2010). To prevent the toxic effects of GluN2B-containing NMDARs, a peptide targeting 
the interaction between GluN2B and PSD95 (TAT-NR2B9c) has been developed, in 
order to uncouple NMDARs containing the GluN2B subunit from nNOS activation. 
Several reports have shown a significant neuroprotective effect when disrupting this 
interaction (Aarts et al., 2002; Cui et al., 2007; Soriano et al., 2008; Martel et al., 
2009a; Cook et al., 2012), which has the advantage of not interfering with the PSD 
apparatus. Similar strategies using cell permeable peptides targeting specific protein 
interactions have been adopted and were found to be similarly neuroprotective (Tu et 
al., 2010; Li et al., 2013). In this report we also demonstrate a neuroprotective effect of 
the peptide TAT-NR2B9c, which is in accordance with these previous reports. 
Specifically, we demonstrate the relevance of the PDZ-binding domain by introducing a 
PDZ-binding domain mutant subunit, which is unable to bind PSD95 and fails to induce 
toxicity following OGD, as observed for the C-terminal domain chimera, relatively to the 
WT subunit. Again, our results gain functional significance due to the type of insult 
chosen, which correlates better with in vivo cerebral ischemia, while most reports use 
only excitotoxic insults. 
 Although the role of the PDZ-binding domain of the GluN2B subunit, and the 
interaction with PSD95, have been extensively associated with excitotoxic phenomena, 
a role for the remainder of the C-terminal domain of the subunit cannot be excluded in 
the neuronal demise that ensues in these conditions. However, to date, these 
mechanisms are still not completely elucidated. One possible additional mechanism of 
regulation of excitotoxicity is the phosphorylation of the subunit by CaMKII. The 
interaction between GluN2B and CaMKII was shown to be important for neuronal 
development and function (Wang et al., 2011). This kinase phosphorylates GluN2B at 
Ser1303 and this phosphorylation was found to regulate the interaction between 
CaMKII and GluN2B (Raveendran et al., 2009; O'Leary et al., 2011). The OGD 
challenge induces increased CaMKIIα autophosphorylation (Thr286) and CaMKIIα-
dependent phosphorylation of GluN2B subunits. Phosphorylation of this residue causes 
increased Ca2+ influx, thereby contributing to neuronal demise. Moreover, GluN2B 
activation contributes to CREB shut-off, which is prevented by CaMKII inhibition 
(Farinelli et al., 2012). In this report we describe, for the first time, the abrogation of 
neuronal death induced by an ischemic stimulus elicited by a GluN2B mutant for the 
CaMKII binding site. Unlike the WT GluN2B, this mutant subunit failed to elicit neuronal 
death following the OGD challenge. This suggests that the interaction between GluN2B 
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and CaMKII is a determinant event in the extent of toxicity induced by in vitro ischemia. 
This mechanism may account for the differences observed between GluN2A and 
GluN2B subunits, since CaMKII was shown to bind with higher affinity to GluN2B 
subunits (Strack and Colbran, 1998). 
Synaptic NMDAR localization has been shown to be regulated by tyrosine 
phosphorylation of the C-terminus of GluN2 subunits, which inhibits the binding of the 
clathrin adaptor protein AP2 (Roche et al., 2001; Vissel et al., 2001). The endocytosis 
of synaptic NMDARs seems to be differentially regulated from that of extrasynaptic 
NMDARs (Li et al., 2002). Interestingly, the PDZ-binding domain of the GluN2B subunit 
was shown to be also important for this regulation, counteracting the internalization of 
NMDARs (Roche et al., 2001; Prybylowski et al., 2005). Thus, an increase in the 
number of synaptic NMDARs was observed upon mutation of the AP2 binding site 
(Tyr1472) on GluN2B subunits (Prybylowski et al., 2005). We found a curious effect of 
the AP2-binding site mutant (YEKL). We observed that this mutant GluN2B subunit 
failed to rescue the damaging effect of the OGD challenge in GluN2B-/- neurons. This 
result may imply that, in the KO background used in this work, mutations in the AP2 
binding site may target most receptors to synaptic sites, where they will most likely 
participate in prosurvival signaling, as suggested by several reports (Papadia et al., 
2008; Al-Mubarak et al., 2009; Martel et al., 2009b). If this is the case, this evidence 
supports the notion of an intricate interplay between receptor subunit composition and 
localization in the prosurvival versus prodeath function of NMDARs. However, it should 
be noted that the AP2-binding site is in close proximity to the PDZ-binding domain, thus 
we cannot exclude a possible interference of the mutation of the former site with 
binding to the latter. This, however, seems unlikely, as mutants for the two distinct sites 
display differential effects on receptor localization and properties (Prybylowski et al., 
2005). 
The several mechanisms of regulation of NMDAR-dependent toxicity described 
seem to have one common player, Ca2+. Indeed, not only is the activation of nNOS 
(downstream of the interaction between GluN2B and PSD95) dependent on Ca2+ entry, 
but also CaMKII is activated by this cation. Additionally, a mechanism of regulation of 
NMDAR endocytosis during LTD has been demonstrated to be dependent on Ca2+, by 
regulation via a Ca2+ sensor protein – hippocalcin. This protein binds to PSD95 and 
promotes dissociation of this protein from the receptor on sensing Ca2+, thereby 
allowing the interaction of AP2 with NMDAR subunits, which promotes receptor 
internalization (Jo et al., 2010). Thus, upon overactivation of NMDARs, influx of Ca2+ 
may contribute to the internalization of synaptic NMDARs via a mechanism dependent 
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on AP2 and, simultaneously leads to activation of CaMKII and nNOs, favoring neuronal 
demise. 
 
Overall, our results support the notion that the GluN2B subunit of NMDARs has 
a determinant role in the induction of toxicity, in ischemic conditions. Specifically, we 
provide evidence for the crucial role of its C-terminal domain for much of the toxicity of 
GluN2B, distinguishing it from the GluN2A subunit. Additionally, we also identified 
several mechanisms of regulation of this subunit, correlatable with GluN2B subunit 
toxicity. In conclusion, our results suggest that the toxicity mediated by GluN2B-
containing NMDARs is the result of a complex interplay of factors, namely subunit 
phosphorylation, protein interactions and recycling. We identify, for the first time, a 
mechanism of regulation by the clathrin adaptor protein AP2 which may contribute to 
toxicity by promoting endocytosis of synaptic NMDARs. 
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Abstract 
 Global cerebral ischemia induces selective neurodegeneration of the CA1 
region of the hippocampus. The type of cell death that ensues may include different 
programmed cell death mechanisms namely apoptosis and necroptosis, a recently 
described type of programmed necrosis. We investigated whether necroptosis 
contributes to hippocampal neuronal death following oxygen-glucose deprivation 
(OGD), an in vitro model of global ischemia. We observed that OGD induced a death 
receptor (DR)-dependent component of necroptotic cell death in primary cultures of 
hippocampal neurons. Additionally, we found that this ischemic challenge upregulated 
the receptor-interacting protein kinase 3 (RIP3) mRNA and protein levels, with a 
concomitant increase of the RIP1 protein. Together, these two related proteins form the 
necrosome, the complex responsible for induction of necroptotic cell death. 
Interestingly, we found that caspase-8 mRNA, a known negative regulator of 
necroptosis, was transiently decreased following OGD. Importantly, we observed that 
the OGD-induced increase in the RIP3 protein was paralleled in an in vivo model of 
transient global cerebral ischemia, specifically in the CA1 area of the hippocampus. 
Moreover, we show that the induction of endogenous RIP3 protein levels influenced 
neuronal toxicity since we found that RIP3 knock-down (KD) abrogated the component 
of OGD-induced necrotic neuronal death while RIP3 overexpression exacerbated 
neuronal death following OGD. Overexpression of RIP1 also had deleterious effects 
following the OGD challenge. Taken together, our results highlight that cerebral 
ischemia activates transcriptional changes that lead to an increase in the endogenous 
RIP3 protein level which might contribute to the formation of the necrosome complex 
and to the subsequent component of necroptotic neuronal death that follows ischemic 
injury. 
 
 
Introduction 
The brain damage due to cerebral ischemia is one of the major causes of 
disability in the western world. Transient global cerebral ischemia that results from a 
lack of blood supply to the whole brain in consequence of cardiac arrest, leads to the 
selective and delayed death of certain populations of neurons. The hippocampus is one 
of the most severely affected areas in patients (Petito et al., 1987) and also in animal 
models of global ischemia (Kirino, 1982; Zukin et al., 2004). Global cerebral ischemic 
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insults can be simulated in vitro by performing oxygen-glucose deprivation (OGD) on 
primary neuronal cultures or slices, typically from the hippocampus or cortex (Goldberg 
and Choi, 1993; Martin et al., 1994; Calderone et al., 2003). 
Cerebral ischemic insults both in vivo and in vitro induce necrotic as well as 
apoptotic neuronal death (Gwag et al., 1995; Martinez-Sanchez et al., 2004; 
Malagelada et al., 2005). In recent years, however, a novel type of cell death, called 
necroptosis, has been shown to contribute to ischemic injury (Degterev et al., 2005; Xu 
et al., 2010; Meloni et al., 2011; Northington et al., 2011). This type of regulated 
necrotic cell death was described to occur as a consequence of death receptor (DR) 
signaling, in conditions where apoptosis is inhibited or downregulated (Fiers et al., 
1995; Vercammen et al., 1998; Van Herreweghe et al., 2010; Han et al., 2011). 
Although the necrotic component of cell death was so far considered to be unregulated 
and thus irreversible, a complete understanding of the mechanisms of regulated 
necrosis might provide new targets for the therapy of cerebral ischemia. 
Tumor necrosis factor receptor 1 (TNFR1) signaling is complex and might have 
distinct outcomes. Upon tumor necrosis factor α (TNFα) binding to TNFR1, the receptor 
becomes activated and recruits a complex of proteins (complex I) to its vicinity that 
comprises the receptor-interacting protein kinase 1 (RIP1) and the TNFR associated 
factor 2 (TRAF2). This leads to nuclear factor kappa B (NF-κB) activation followed by 
expression of anti-apoptotic proteins, such as cellular inhibitor of apoptosis proteins 
(cIAPs) (Micheau and Tschopp, 2003), among others. The NF-κB activation 
downstream TNFR1 signaling is regulated by the post-translational modifications of 
RIP1 and TRAF2. When RIP1 is deubiquitinated by cylindromatosis (CYLD) or cIAP 
proteins are inhibited, the proteins of complex I dissociate from the receptor allowing 
the association, in the cytoplasm, of the so-called complex II or death inducing 
signaling complex (DISC), that recruits proteins such as Fas-associated protein with 
death domain (FADD), procaspase-8 and RIP1 (Micheau and Tschopp, 2003). 
Caspase-8 then becomes active and initiates the extrinsic apoptotic pathway. In cells 
with high expression of RIP3, this kinase might enter complex II due to the interaction 
with RIP1. Caspase-8 acts as a negative regulator of necroptosis, by promoting 
cleavage of RIP1 and RIP3 in complex II (Feng et al., 2007; Cho et al., 2009). In 
conditions where apoptosis is inhibited, RIP1 and RIP3 are able to induce necroptosis, 
by forming the complex IIb, or necrosome (Vercammen et al., 1998; Holler et al., 2000). 
While the precise mechanism by which RIP1 and RIP3 induce necroptosis is not fully 
understood it is known that their kinase activity is important for this process (Cho et al., 
2009; He et al., 2009; Zhang et al., 2009) and recently it was shown that their 
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interaction is regulated by sirtuin2 (SIRT2)-dependent RIP1 deacetylation (Narayan et 
al., 2012). Nevertheless, the events that trigger the assembly of the necrosome in the 
context of cerebral ischemia are not yet known. 
In this work we examined the neuroprotective effect of the necroptosis inhibitor 
necrostatin-1 (Nec-1) on OGD-challenged hippocampal neurons and we investigated 
the molecular determinants underlying OGD-induced necroptosis in hippocampal 
neurons, namely the role of RIP3 in this process. We show that ischemic insults 
induced an upregulation of the RIP3 mRNA and protein levels, accompanied by a 
transient caspase-8 mRNA downregulation. The changes in RIP3 protein level 
correlated with increased hippocampal neuronal death following OGD. Importantly, we 
also observed an increased RIP3 protein level in the CA1 region of the hippocampus of 
rats submitted to global cerebral ischemia in vivo. These results contribute to the 
elucidation of the mechanism of cerebral ischemia-induced necroptosis and therefore 
may pave the way to novel therapeutic targets for cerebral ischemia. 
 
 
Materials & Methods 
Materials 
 The antibodies against RIP1 (#610458) and RIP3 (#ab62344) were purchased 
from BD Biosciences (Franklin Lakes, NJ) and Abcam (Cambridge, MA), respectively. 
The antibody against α-Spectrin (MAB1622) was from Millipore (Billerica, MA) and the 
antibody against β-tubulin was purchased from Sigma-Aldrich (St. Louis, MO). 
 The neutralizing antibody against TNFα (NBP1-43235) was purchased from 
Novus Biologicals (Cambridge, UK). The necroptosis inhibitor Nec-1 (#036SC-200142) 
and its inactive analog (SC-204815) were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA), and the broad caspase inhibitor N-benzyloxycarbonyl-Val-Ala-
Asp(O-Me)-fluoromethyl ketone (zVAD.fmk, ab120382) was from Abcam. The N-
methyl-D-aspartate receptor (NMDAR) antagonist (5S,10R)-(+)-5-methyl-10,11-
dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801, #0924) was 
purchased from Tocris Bioscience (Bristol, UK). 
 The plasmids pBOB-mRIP3, encoding mouse RIP3, pBOB-mRIP1, encoding 
mouse RIP1, pBOB (empty vector) and the short hairpin RNA (shRNA) plasmids pLV-
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H1-EF1a-puro-mRIP3-1465 (GCTCTCGTCTTCAACAACT) and pLV-H1-EF1a-puro-
LacZ (control shRNA: GCAGTTATCTGGAAGATCA) were generous gifts from Duan-
Wu Zhang and Jiahuai Han, Xiamen University, Xiamen, China. The plasmid pEGFP-
N1-hRIP3 (#41387), encoding human RIP3 was obtained from Addgene (Cambridge, 
MA), provided by Francis Chan, University of Massachusetts (Worcester, MA) (Cho et 
al., 2009). 
 
Cell Culture and Transfection  
Primary cultures of hippocampal neurons were prepared from embryonic day 18 
(E18) rats, as previously described (Santos and Duarte, 2008). Briefly, hippocampi 
were dissected and dissociated with trypsin (1.5 mg/ml) in Hank’s Balanced Salt 
Solution (HBSS). Neurons were cultured in multiwell (MW) plates with or without glass 
coverslips, coated with poly-D-lysine (PDL), at a density of 85,000 cells/cm2, in 
Neurobasal® medium (Gibco®, Life Technologies™, Paisley, UK) supplemented with 
2% NeuroCult™ SM1 Neuronal Supplement (StemCell™ Technologies, Grenoble, 
France), 0.5 mM glutamine, 0.125 µg/ml gentamicin and 25 µM glutamate. Neuronal 
cultures were maintained at 37ºC in a humidified incubator with 5% CO2 up to 15 days 
in vitro (DIV). At DIV 7, the cultures were fed with fresh supplemented neurobasal 
medium without glutamate. 
For overexpression studies, neurons cultured in 12MW plates were co-
transfected at DIV 7 using the calcium phosphate precipitation method (Dahm et al., 
2008). Briefly, precipitates containing 1.5 µg of GFP and 3 µg of RIP3, RIP1 or pBOB 
(empty vector) plasmids were prepared using the following solutions: TE (1 mM Tris-
HCl pH 7.3, 1 mM EDTA), 2x HEBS (12 mM Dextrose, 50 mM HEPES, 10 mM KCl, 
280 mM NaCl and 1.5 mM Na2HPO4•2H2O, pH 7.2) and CaCl2 (2.5M CaCl2 in 10 mM 
HEPES, pH 7.2), and allowed to develop for 30 min. The precipitates were added to 
the neurons, in the presence of 2 mM kynurenic acid (Sigma-Aldrich, St. Louis, MO), 
and incubated for 3h at 37ºC. After the transfection period, the cells were washed with 
Neurobasal medium containing 2 mM kynurenic acid (HCl was added to keep an acidic 
pH to dissolve the precipitates) and then placed in conditioned medium until DIV 15. 
For knock-down (KD) experiments, hippocampal cultures were prepared from 
E18 mice similarly to rat neuronal cultures, but papain was used for tissue dissociation 
(20 units/ml, 10 min, 37°C), instead of trypsin, as described (Ferreira et al., 2011). 
Hippocampal mouse neurons were maintained in supplemented Neurobasal Medium 
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(2% SM1, 0.5 mM Glutamine, 0.125 μg/ml gentamicin and 20 µg/ml insulin) at 37°C, in 
a humidified incubator with 5% CO2. At DIV 7, mouse neurons (cultured in 24MW 
plates) were co-transfected as described for rat cultures, using 0.75 µg of GFP and 1.5 
µg of the shRNAs for LacZ (control) or RIP3. For rescue experiments, 1.5 µg of hRIP3 
were used instead of the GFP plasmid. 
 
Oxygen-Glucose Deprivation (OGD) Challenge 
 At DIV 15, hippocampal neurons were challenged with an in vitro ischemic 
stimulus. For that purpose, neurons were placed in a glucose-free deoxygenated buffer 
medium (OGD medium – 10 mM HEPES, 116 mM NaCl, 5.4 mM KCl, 0.8 mM 
NaH2PO4, 25 mM sodium bicarbonate, 25 mM sucrose, 1.8 mM CaCl2, 0.04% phenol 
red, pH 7.3), inside an anaerobic chamber with 5% CO2 (OGD chamber, Thermo 
Forma 1029, Thermo Fisher Scientific, Waltham, MA), at 37ºC for 2h. Control neurons 
were placed in a similar buffer, containing 25 mM glucose, instead of sucrose (sham 
medium), and kept for 2h in a humidified incubator with 5% CO2/95% air, at 37ºC. After 
incubation, the neurons were placed in their conditioned medium and returned to the 
normoxic incubator for a period of recovery that lasted up to 24h. 
When indicated, chemical compounds such as receptor antagonists, Nec-1, 
zVAD.fmk or the TNFα neutralizing antibody were added to the medium 1h prior to 
stimulation and kept during the stimulation and post-stimulation periods, at the 
indicated concentrations. 
 
RNA extraction 
 Total RNA from DIV 15 hippocampal neurons was extracted with TRIzol® 
Reagent (Invitrogen, Madrid, Spain), following the manufacturers’ specifications. The 
total amount of RNA was quantified spectrophotometrically (Thermo Nanodrop 2000, 
Thermo Fisher Scientific, Wilmington, DE) and the RNA quality and integrity evaluated 
using the Experion automated gel electrophoresis system (BioRad, Hercules, CA). 
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qPCR 
 For cDNA synthesis, 1 µg of total RNA was used with the iScript™ cDNA 
Synthesis Kit (BioRad), according to the manufacturers’ instructions. For quantitative 
real-time PCR (qRT-PCR) 20 µl reactions were prepared with 2 µl of 1:10 diluted 
cDNA, 10 µl of 2x iQ™ SYBR® Green Supermix (BioRad) and specific primers at 250 
nM, as follows: β-Actin (Actb) forward – 5’-CGTCACCTACTCTAACCG-3’, reverse – 5’-
CTTGTGCTATCTGCTCATC-3’; Caspase-8 forward – 5’-GGAACCAACTATGA 
TGAAGAG-3’, reverse – 5’-GCAATCACTGAAGGACAC-3’; Glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) forward – 5’-  AACCTGCCAAGTATGATG-3’, 
reverse – 5’-GGAGTTGCTGTTGAAGTC-3’; Rip3 forward – 5’-TTCCAAGACTGTG 
AATCAA-3’, reverse 5’-CACTGCTTCTGTACTGAG-3’. 
 The fluorescent signal was measured after each elongation step of the PCR 
reaction in the iQ5 Multicolor Real-Time PCR Detection System (BioRad), and was 
used to determine the threshold cycle (Ct) as previously described (Manadas et al., 
2009). Melting curves were performed in order to detect non-specific amplification 
products, a non-template control was included in all assays, and for each set of primers 
a standard curve was performed to assess primer efficiency. Reactions were run in 
duplicate. The level of expression of each gene was analyzed at 7 and 24h of recovery 
following OGD and normalized to the level of expression of the gene in the 
corresponding control conditions. All Ct values were normalized relatively to two 
internal control genes, Actb and Gapdh, using the GenEx software (MultiD Analyses). 
 
Nuclear Morphology 
 Neuronal death was assessed by analysis of the nuclear morphology 24h 
following the OGD insult. For that purpose, neurons were stained with the nuclear dyes 
propidium iodide (PI – 2 µg/ml) and Hoechst 33342 (2 µg/ml) for 15 min at 37ºC, and 
immediately analyzed under fluorescence microscopy for the incorporation of PI and 
chromatin condensation. The cellular membranes are impermeable to PI, thus this dye 
only penetrates the cells upon membrane rupture. Hence, PI is considered as a 
necrotic marker, since membrane rupture is one of the main features of necrotic cell 
death. When using a primary culture system, we should take into account that some 
cells that activate apoptosis undergo secondary necrosis. For that reason, we could not 
attribute PI uptake solely to primary necrosis. On the other hand, Hoechst 33342 is cell 
permeable, thus we analyzed the nuclear morphology and extent of chromatin 
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condensation and pyknosis to classify cells as apoptotic. For the necrotic-like neuronal 
death, we considered cells that are positive for PI staining, but in the absence of 
pyknosis. At least 500 cells were counted in each coverslip. The results were 
expressed as the percentage of necrotic cell death (PI positive without pyknosis/total 
number of cells) or percentage of apoptotic-like cell death (apoptotic-like nuclei/total 
number of cells). When using transfected cells, GFP-positive neurons were detected 
using the green fluorescence filter and PI incorporation confirmed using the red 
fluorescence filter. The totality of transfected cells in each coverslip was counted. The 
results were expressed as the percentage of necrotic cell death (PI positive/total 
number of transfected cells). 
 
Lactate Dehydrogenase (LDH) Release Assay 
 At 24h of recovery after the OGD challenge, the LDH release to the extracellular 
medium was evaluated by a colorimetric assay using the CytoTox96 Non-Radioactive 
assay kit (Promega, Madison, WI), according to the manufacturer’s instructions. The 
percentage of LDH release was determined as the ratio between LDH activity in the 
extracellular medium and total LDH activity obtained after complete cell lysis with Triton 
X-100. All experiments were carried out in duplicate or triplicate, for each independent 
experiment, as previously described (Vieira et al., 2010). 
 
Protein extracts, SDS-PAGE and Western Blotting 
 Twenty four hours after OGD, cells were washed with ice-cold phosphate-
buffered saline (PBS) and 1x sample buffer (125 mM Tris, pH 6.8, 2% SDS, 100 mM 
DTT, 20% glycerol and 0.005% bromophenol blue diluted in 50 mM HEPES, 150 mM 
NaCl, 2 mM EGTA, 2 mM EDTA, 2 mM Na3VO4, 50 mM NaF, 1% Triton X-100, 10% 
glycerol, pH 7.4) was added. Cells were scraped, sonicated and denatured at 95ºC, for 
10 min. Fifty µl of each protein extract were separated by SDS-PAGE, using 10% 
polyacrilamide gels, and then transferred to a polyvinylidene fluoride (PVDF) 
membrane. The membranes were blocked with Tris-buffered saline-Tween20 (TBS-T) 
(20 mM Tris, 137 mM NaCl, pH 7.6, 0.1% Tween20) with 5% non-fat milk, for 1h at 
room temperature, and then incubated with the primary antibody in TBS-T 5% milk, for 
1h at room temperature. Alternatively, the incubation with the primary antibody was 
performed overnight at 4°C. After extensive washing, membranes were incubated with 
the secondary antibody conjugated with alkaline phosphatase for 1h at room 
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temperature. After additional washes, the membranes were developed using the 
enhanced chemifluorescence (ECF) substrate, and scanned on the Storm 860 Gel and 
Blot Imaging System (Amersham Biosciences, Buckinghamshire, UK). The density of 
the bands was analyzed with ImageQuant 5.0 software. For subsequent reprobing, the 
membranes were stripped of antibody with NaOH 0.2 M, blocked again and incubated 
with the appropriate antibodies. 
 
Transient Global Cerebral Ischemia in the Rat 
Experiments were carried out in accordance with the Guidelines of the 
European Union Council (86/609/EU), following Spanish regulations (RD 1201/2005, 
BOE 252/34367–91, 2005) for the use of laboratory animals, and were approved by the 
Scientific Committee of the University of León. All efforts were made to minimize 
animal suffering and to reduce the number of animals used. Global cerebral ischemia 
was performed as previously described (Montori et al., 2010), with slight modifications. 
Eight 3-month-old Sprague-Dawley male rats weighing 350–450 g were housed 
under standard temperature (22 ± 1ºC) in a 12h light/dark controlled environment with 
free access to food and water. The animals were divided randomly into ischemic and 
sham groups. Rats were placed in the anesthesia induction box supplied with 4% 
isoflurane (IsoFlo, Abbott Laboratories Ltd) at 3 L/min in 100% oxygen. Animals were 
maintained under anesthesia with a flux of 1.5–2.5% isoflurane at 800 mL/min in 100% 
oxygen, delivered through a face mask. Both common carotid arteries were exposed 
through a midline incision and transient global ischemia was induced by bilateral 
common carotid artery occlusion for 15 min with atraumatic aneurysm clips and a 
moderate hypotension (40–50 mm Hg). Hypotension was carried out by 
exsanguination. The femoral artery was exposed and catheterized thus allowing 
continuous recording of arterial blood pressure. Heparin was supplied to the animal at 
50 UI/kg through this catheter and 50 UI heparin were maintained in 3 ml saline in the 
syringe. Then, about 8 ml of blood were slowly extracted (1 ml/min) through the 
catheter and collected in the syringe until the desired hypotension was reached that 
was maintained introducing or extracting blood in the artery. Rectal temperature was 
controlled at 36 ± 1ºC during surgery with a feedback regulated heating pad. After 
ischemia, blood was returned to the animal at 1 ml/min until the animal arterial blood 
pressure recovered. The catheter was then removed and the animal was sutured. After 
regaining consciousness, animals were maintained in an air-conditioned room at 22 ± 
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1ºC during 48h. For sham-operated rats, all procedures were performed exactly as for 
ischemic animals with the exception that the carotid arteries were not clamped. 
Two days after the ischemic insult, the animals were decapitated and their 
brains were rapidly removed. The CA1, the CA3, the dentate gyrus (DG) and the 
cerebral cortex (Ctx) were obtained using a dissecting microscope, frozen in liquid 
nitrogen and stored at -80ºC until use. On the day of the experiment, tissue sections 
were weighted and 1.5 mg of tissue from each area of the hippocampus and 5 mg from 
the cortex were homogenized with 125 µl (for the hippocampus) or 250 µl (for the 
cortex) of 1x sample buffer [125 mM Tris, pH 6.8, 2% SDS, 100 mM DTT, 20% glycerol 
and 0.005% bromophenol blue diluted in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Triton, 1 mM EDTA, 1 mM NaF, 10% glycerol, 150 mM NaOH and supplemented with 
protease inhibitors 1 mM phenylmethanesulfonyl fluoride (PMSF) and 1 µg/ml CLAP 
(chymostatin, leupeptin, antipain and pepstatin)]. Brain extracts were then sonicated 
and denatured at 95ºC for 5 min, and 50 µl of each sample were applied on SDS-
PAGE. 
 
Statistical Analysis 
Results are presented as means ± S.E.M. of the indicated number of 
independent experiments. The normality of the data was assessed using the 
Kolmogorov-Smirnov test. Statistical significance was assessed by one-way analysis of 
variance (ANOVA) followed by the Bonferroni’s test. Alternatively, Student’s t-test was 
applied on log-transformed data (for qPCR analysis and in vivo western blot analysis). 
These statistical analyses were performed using the software package GraphPad 
Prism 5. 
 
 
Results 
OGD Induces a Component of Necroptotic Neuronal Death 
Emerging evidence suggests that necroptosis contributes to ischemic brain 
injury in vivo (Degterev et al., 2005; Xu et al., 2010; Northington et al., 2011). This 
evidence is mostly based on the neuroprotective effect of Nec-1, an inhibitor of 
necroptosis, against this type of insult. We investigated whether necroptotic neuronal 
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death occurs when hippocampal neurons are submitted to OGD, an in vitro model of 
global ischemia, more amenable to the molecular dissection of cell death mechanisms. 
The OGD challenge consists of combining the deprivation of both oxygen and glucose, 
thereby mimicking the lack of blood supply that occurs during ischemia. To study the 
putative contribution of necroptosis for the OGD-induced neuronal death, we incubated 
primary cultures of rat hippocampal neurons with Nec-1 or its inactive analog. Using 
different cell death assays we confirmed that Nec-1 had a neuroprotective effect 
against OGD-induced hippocampal neuronal death suggesting a component of 
necroptosis (Fig 3.1). In fact, using the nucleic acid dyes PI and Hoechst 33342, we 
observed that Nec-1 (20 µM) significantly reduced necrotic neuronal death from 12.4 ± 
1.0% to 8.9 ± 0.4% (Fig 3.1-A) without having an effect on the apoptotic-like neuronal 
death component (30.4 ± 6.2% cell death on the OGD condition and 32.7 ± 4.7% with 
Nec-1) (Fig 3.1-C). We performed this analysis by counting the number of PI positive 
nuclei that do not present pyknosis, which correspond to necrotic cells, while the 
apoptotic-like cells presented chromatin condensation with Hoechst staining. When we 
used the LDH assay, which is an indirect measure of membrane rupture, we also 
detected a neuroprotective effect of Nec-1 since we observed a reduction from 38.6 ± 
2.2% to 26.5 ± 2.1% of the LDH release (Fig 3.1-E). Moreover, we observed that 
zVAD.fmk (20 µM), a broad caspase inhibitor, affected the apoptotic component of cell 
death reducing the number of apoptotic-like nuclei from 30.4 ± 6.2% to 21.1 ± 2.9% 
(Fig 3.1-C), but had no significant neuroprotective effect when we analyzed necrotic 
neuronal death (12.4 ± 1.0% of necrotic neurons in OGD compared to 16.5 ± 1.2% for 
OGD in the presence of zVAD.fmk) (Fig 3.1-A). 
Recently, events of DR-independent necroptosis were described (Feoktistova et 
al., 2011; Tenev et al., 2011), so we tested whether a TNFα neutralizing antibody could 
influence cell death induced by OGD. We observed that by inhibiting TNFα signaling 
we were able to significantly protect neurons from OGD-induced death (LDH release 
was reduced from 24.2 ± 1.9% to 16.3 ± 1.4%) (Fig 3.1-F). This suggests that in 
neurons submitted to OGD, DR signaling may mediate the activation of necroptotic cell 
death. 
 
Necroptosis in OGD-challenged Neurons is Promoted by Up-regulation of RIP3 
 In recent years many efforts have been made to clarify the mechanisms 
underlying necroptosis (Chan and Baehrecke, 2012). However, in neurons, the 
mechanism by which necroptosis is activated is not known. In order to investigate the 
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mechanism underlying the necroptotic component of neuronal death induced by OGD 
we analyzed the mRNA levels of two known regulators of necroptosis: RIP3, a known 
specific necroptosis player upon adequate stimuli (Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009) (Fig 3.2-A) and caspase-8, which is a negative regulator of 
necroptosis (Oberst et al., 2011) (Fig 3.2-B). Interestingly, we found that RIP3 is 
significantly upregulated at 7 and 24h following OGD while caspase-8 is transiently 
downregulated 7h after OGD. These results suggest that a subset of neurons may 
downregulate apoptosis, while upregulating RIP3 expression, which may become 
afterwards more available for activation of necroptotic signaling. 
 To confirm that RIP3 mRNA levels translate to increased protein expression 
following OGD, we analyzed total RIP3 levels by western blotting. Indeed, at 24h after 
OGD we observed a significant increase in RIP3 protein expression, to about 1.5 fold 
of the control level (Fig 3.2-C, D), indicating that after OGD there is an increased 
availability of RIP3 that may facilitate its inclusion in the necrosome complex. 
Since NMDARs are generally considered to be responsible for much of the 
neurodegeneration resultant from ischemic insults due to excitotoxic events mediated 
by these receptors (Deupree et al., 1996; Gee et al., 2006), we investigated the effect 
of NMDAR inhibition on the induction of RIP3 following OGD. We observed that the 
increase in RIP3 protein levels observed 24h after OGD was completely blocked by 
treatment with MK-801 (Fig 3.2-C, D), suggesting that activation of NMDARs during an 
OGD challenge contributes to the induction of necroptotic neuronal death. Indeed, MK-
801 prevented hippocampal neuron death induced by OGD as assessed by the LDH 
release (data not shown). 
To determine whether RIP3 upregulation following OGD affects the 
susceptibility of hippocampal neurons to the ischemic insult, we studied the effect of 
RIP3 overexpression as well as the effect of RIP3 KD on hippocampal neuron survival 
(Fig 3.3). To do so, we co-transfected rat hippocampal neurons with GFP plus RIP3 or 
the empty vector pBOB (Fig 3.3-A, B), and analyzed the PI positive nuclei in neurons 
submitted to OGD under fluorescence microscopy, to assess necrotic cell death in 
transfected neurons. We observed that overexpression of RIP3 significantly potentiated 
the damaging effect of the OGD challenge (Fig 3.3-A). Interestingly, overexpression of 
RIP3 did not induce toxicity per se, which implies that RIP3-mediated necrosis is only 
activated upon specific insults. 
On the other hand, to confirm the contribution of RIP3 endogenous expression 
to cell death we performed KD experiments in mouse hippocampal neurons transfected 
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with GFP and a previously described shRNA targeting mRIP3 (Zhang et al., 2011) or a 
control shRNA against LacZ (Fig 3.3-C, E). We observed that RIP3 KD significantly 
protected hippocampal neurons against the OGD insult (Fig 3.3-C). The specificity of 
this effect was addressed through a rescue experiment, by co-transfecting neurons 
with the shRNAs plus a hRIP3 construct, which is not recognized by the mouse shRNA 
used in this work (Fig 3.3-D, E). The expression of hRIP3 rescues the toxic effect of the 
OGD challenge (Fig 3.3-D), thereby confirming the specificity of the protective effect of 
endogenous RIP3 KD. These results highlight that the up-regulation of RIP3 mRNA 
and protein following OGD has a detrimental effect, contributing to neuronal death by 
necrosis. 
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Figure 3.1. The OGD challenge induces necroptotic neuronal death. Mature cultures 
of hippocampal neurons (15 DIV) were challenged with OGD for 2h. Twenty four hours 
after the insult, cell viability was assessed. The necroptosis inhibitor Nec-1, its inactive 
control and the broad caspase inhibitor zVAD.fmk were added 1h prior to stimulation and 
kept during the stimulation and post-stimulation periods. (A) Analysis of PI staining of 
OGD challenged hippocampal neurons. The results were expressed as the percentage of 
necrotic neurons (PI positive cells without pyknosis - white arrowheads) relatively to the 
total number of cells. Bars represent the mean ± SEM of 9 independent experiments (n=4 
for zVAD.fmk conditions). (B) Representative images of data shown in A. Scale bar – 20 
µm. (C) Analysis of the nuclear morphology of hippocampal neurons, with Hoechst 33342 
staining. The results were expressed as the percentage of apoptotic-like cells relatively to 
the total number of cells. Bars represent the mean ± SEM of 9 independent experiments 
(n=7 for zVAD.fmk conditions). (D) Representative images of data shown in C. Scale bar 
– 20 µm. (E) The LDH activity was assayed as indicated in the manufacturer’s protocol. 
Bars represent the mean ± SEM of 12 independent experiments (n=6 for zVAD.fmk 
conditions). (F) A TNFα neutralizing antibody partially prevents the cell death induced by 
OGD, suggesting the activation of DRs in this system. The TNF antibody was added 1h 
prior to OGD (0.5 µg/ml) and kept for the remainder of the experiment. The LDH activity 
was assayed as indicated in the manufacturer’s protocol. Bars represent the mean ± SEM 
of 8 independent experiments (n=6 for Nec-1 conditions). *Significantly different from 
control (One way ANOVA followed by Bonferroni’s multiple comparison test: *p<0.05, 
**p<0.01, ***p<0.001, relatively to Control; #p<0.05, ##p<0.01, ###p<0.001, relatively to 
OGD and §p<0.05, §§p<0.01, relatively to inactive control). 
 
RIP1 Contributes to Necroptotic Neuronal Death Following OGD 
 A plethora of studies has established a determinant role for both RIP1 and RIP3 
in necroptotic signaling. In fact, they are thought to interact through their RIP homotypic 
interaction motif (RHIM) domains, forming a complex which is responsible for activation 
of cell death by necroptosis upon specific stimulation (Sun et al., 2002; Cho et al., 
2009; He et al., 2009; Zhang et al., 2009). To address whether RIP1 could also be 
induced in our model of ischemic injury, we analyzed the RIP1 protein content 24h after 
OGD, a time point for which we observed increased RIP3 expression (Fig 3.2). Indeed, 
24h after OGD, the amount of RIP1 is significantly increased (Fig 3.4-A, B). As 
observed for RIP3, the induction of RIP1 protein levels was correlated with the 
activation of neuronal death, since overexpression of RIP1 significantly contributed to 
necrotic cell death induced by the OGD insult, compared to the empty vector (Fig 3.4-
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C, D). Thus, both RIP1 and RIP3 contribute to necrotic cell death in hippocampal 
neurons challenged with OGD. 
 
Figure 3.2. OGD induces the expression of the necroptosis-related RIP3 protein. 
Mature cultures of hippocampal neurons (15 DIV) were challenged with OGD for 2h. (A, 
B) Seven and 24 hours after OGD, total RNA was extracted with TriZol. Real-time PCR 
analysis was performed using cDNA prepared from 1 µg of total RNA and the primers for 
RIP3 (n=4 independent experiments) (A) and Caspase-8 (7h: n=5; 24h: n=4 independent 
experiments) (B). The fold change in mRNA levels was normalized to GAPDH and β-
Actin. *Significantly different from control (*p<0.05, Student’s t-test on log-transformed 
data). (C) Total protein extracts were collected 24h after 2h of OGD and western blot 
analysis was performed for total RIP3. The NMDAR antagonist, MK-801 (10 µM) was 
added to the cells 15 min prior to OGD and kept during the stimulation and post-
stimulation periods. MK-801 abolishes the OGD-induced RIP3 up-regulation. (D) Bars 
represent the mean ± SEM of 4 independent experiments. *Significantly different from 
control [**p<0.01 (compared to control), #p<0.05 (compared to OGD), One-way ANOVA 
followed by Bonferroni’s multiple comparison test]. 
 
RIP3 is Upregulated Following Global Cerebral Ischemia in vivo 
 Although several brain ischemia paradigms have been suggested to have a 
component of necroptotic neuronal death, based on the neuroprotective effect of Nec-1 
(Degterev et al., 2005; Xu et al., 2010; Northington et al., 2011), to date, changes in the 
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protein levels of the necrosome components have not been reported. To investigate 
whether the changes in RIP1 and RIP3 observed in our in vitro model of ischemic injury 
reflect modifications that might occur in vivo, we submitted adult rats to transient global 
cerebral ischemia (Fig 3.5). We observed that RIP3 is indeed upregulated 48h after 
global ischemia, specifically in the CA1 region of the hippocampus, while it remained 
constant in the CA3 and DG areas, and in the cerebral cortex (Fig 3.5-A, B). RIP1, on 
the other hand, displayed a trend to a slight increase in the CA1, and DG areas of the 
hippocampus, although without statistical significance (Fig 3.5-A, C). We also observed 
that the upregulation of RIP3 in the CA1 area correlated with increased formation of α-
Spectrin break-down products (SBDPs) of 145 and 150 kDa, demonstrating the 
activation of calpains, which are proteases involved in cell death, namely in neuronal 
death induced by ischemic insults (Siman et al., 1989; Vosler et al., 2011). These 
results suggest that global ischemia induces the upregulation of necrosome 
components in CA1 hippocampal neurons, which is probably related to the activation of 
necroptotic neuronal death in this paradigm. 
 
 
Discussion 
Recently, necroptosis has been extensively studied as a novel type of 
programmed cell death and it has been implicated in a wide range of pathologies, 
including cerebral ischemia. Using an in vitro model of global cerebral ischemia, OGD, 
we showed that this challenge induces necroptotic neuronal death. Interestingly, we 
found that OGD upregulated both RIP1 and RIP3 protein levels, which we found to 
occur also in vivo, following a transient global cerebral ischemic insult, at least for the 
RIP3 protein. Furthermore, we were able to correlate the upregulation of endogenous 
RIP3 with an increase in necrosis of hippocampal neurons following OGD. 
Apoptosis is widely accepted as one of the major forms of programmed cell 
death, requiring the sequential activation of biochemical reactions, namely those 
leading to the formation of the apoptosome and the activation of caspases, as a result 
of the release of proapoptotic proteins from the mitochondria (reviewed in Taylor et al., 
2008; Andersen and Kornbluth, 2013). On the contrary, necrosis is generally thought of 
as an “accidental” type of cell death that occurs when the cell is submitted to an 
overwhelming stress that afterwards leads to the activation of an inflammatory 
response (Kanduc et al., 2002). This view of the necrotic cell death as a systematic 
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unregulated event has been challenged by studies showing that apoptotic inhibitors 
(such as broad caspase inhibitors like zVAD.fmk) do not always protect but instead 
they may sensitize the cells to a mechanism of programmed necrosis (Vercammen et 
al., 1998; Holler et al., 2000). Additionally, it was found that in caspase-8-/- mice, which 
die around E10.5, cells are sensitized to necrotic cell death, in response to DR activity 
(Oberst et al., 2011), uncovering a role of caspase-8 as a negative regulator of 
programmed necrosis or necroptosis. The role of DR signaling in activation of 
programmed cell death mechanisms, including necroptosis, has been extensively 
studied (reviewed in Dickens et al., 2012). 
 
Figure 3.3. The levels of the RIP3 protein influence the extent of OGD-induced 
neuronal death. (A-B) Primary cultures of rat hippocampal neurons were co-transfected 
at DIV 7 with the indicated constructs (3 µg) plus a GFP plasmid (1.5 µg), using the 
calcium phosphate protocol. At DIV 15 cells were challenged with OGD for 2h. Twenty 
four hours after stimulation cells were stained with the nuclear dyes Hoechst 33342 and 
PI and the number of PI positive transfected cells was counted. The results were 
expressed as the percentage of PI positive cells relatively to the total number of 
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transfected cells. (A) Overexpression of RIP3 significantly enhances OGD toxicity in 
hippocampal neurons. (B) Representative images of data shown in A. Scale bar – 20 µm; 
Insert – 10 µm. (C-E) Primary cultures of mouse hippocampal neurons were co-
transfected at DIV 7 with the indicated constructs (1.5 µg) plus a GFP plasmid (0.75 µg) 
or hRIP3 (1.5 µg), using the calcium phosphate protocol. At DIV 15 cells were challenged 
with OGD for 2h. Twenty four hours after stimulation cells were stained as in (A) and the 
number of PI positive transfected cells was counted. The results were expressed as the 
percentage of PI positive cells relatively to the total number of transfected cells. (C) 
Knock-down of RIP3 significantly protects neurons against OGD-induced death (n=5). (D) 
In OGD-challenged neurons, the neuroprotective effect of RIP3 KD is reversed by 
expression of hRIP3, which is not recognized by the mRIP3 shRNA. (E) Representative 
images of data shown in C and D. Scale bar – 20 µm; Insert – 10 µm. Bars represent the 
mean ± SEM of the indicated number of independent experiments. *Significantly different 
from control [One way ANOVA followed by Bonferronni’s multiple comparison test: 
*p<0.05, ***p<0.001 relative to control; #p<0.05, ##p<0.01, ###p<0.001 relative to OGD 
condition (A) or OGD-LacZ (C and D)]. 
 
In an effort to elucidate the involvement of necroptosis in pathologies with broad 
relevance, Nec-1 was identified as a specific inhibitor of necroptosis (Degterev et al., 
2005). More recently, Nec-1 was found to target the RIP1 kinase activity (Degterev et 
al., 2008). This inhibitor has been shown to be protective against a variety of cellular 
stresses, both in neurons (Li et al., 2008; Wang et al., 2012) as well as in non-neuronal 
cells (Upton et al., 2010; Narayan et al., 2012; Simenc and Lipnik-Stangelj, 2012). 
Moreover, this inhibitor of necroptosis was shown to be protective against focal 
ischemic injury in vivo (Degterev et al., 2005; Northington et al., 2011; Chavez-Valdez 
et al., 2012) and OGD in vitro (Xu et al., 2010; Meloni et al., 2011). Accordingly, we 
also observed a component of neuronal death that was inhibited by Nec-1 in our in vitro 
model of global cerebral ischemia. Additionally, we demonstrated that Nec-1 protected 
neurons from OGD-induced necrosis, without affecting the component of apoptotic-like 
cell death. Furthermore, the broad caspase inhibitor zVAD.fmk was only effective in 
reducing apoptotic-like neuronal death, whilst having no protective effect against 
necrotic neuronal death evaluated with PI staining. In this case, zVAD.fmk actually 
exacerbated the neuronal death induced by OGD, which is in accordance with previous 
reports showing that inhibition of caspases favors necroptotic cell death (Vercammen 
et al., 1998). We also observed that TNFα signaling contributes to hippocampal 
neuronal death induced by OGD, probably contributing to the activation of the extrinsic 
pathway of apoptosis as well as necroptosis. We were not able to detect a significant 
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effect of Nec-1 when neurons were co-treated with the TNFα neutralizing antibody and 
the necroptosis inhibitor since the TNFα neutralizing antibody provided a complete 
neuroprotection in our experimental conditions, suggesting that the induction of 
necroptosis in hippocampal neurons subjected to OGD might be mediated by TNFR1 
activation. 
 
Figure 3.4. RIP1 protein levels are induced following OGD. Mature cultures of 
hippocampal neurons (15 DIV) were challenged with OGD for 2h.  (A-B) Total protein 
extracts were collected 24h after 2h of OGD and western blot analysis was performed for 
total RIP1 (A). RIP1 is significantly up-regulated following OGD (B). Bars represent the 
mean ± SEM of the indicated number of independent experiments. *Significantly different 
from control (*p<0.05, ***p<0.001, Student’s t-test). (C-D) Primary cultures of rat 
hippocampal neurons were co-transfected at DIV 7 with the indicated constructs (3 µg) 
plus a GFP plasmid (1.5 µg), using the calcium phosphate protocol. At DIV 15 cells were 
challenged with OGD for 2h. Twenty four hours after stimulation cells were stained with 
the nuclear dyes Hoechst 33342 and PI and the number of PI positive transfected cells 
was counted. The results were expressed as the percentage of PI positive cells relatively 
to the total number of transfected cells. (C) Overexpression of RIP1 significantly 
enhances OGD toxicity in hippocampal neurons. (D) Representative images of data 
shown in C. Scale bar – 20 µm; insert – 10 µm. *Significantly different from control 
[***p<0.001 (relative to control); ###p<0.001 (relative to OGD-pBOB condition), One way 
ANOVA followed by Bonferronni’s multiple comparison test.] 
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The identification of a necroptotic cell death program in a subpopulation of 
hippocampal neurons submitted to OGD prompted us to investigate the mechanisms 
that might regulate necroptosis upon an ischemic stimulus, since the events underlying 
neuronal necroptotic death have not been elucidated so far. In non-neuronal systems, 
the interaction between the related proteins RIP1 and RIP3 as well as their kinase 
activity has been shown to be crucial for necroptotic cell death (Cho et al., 2009; He et 
al., 2009; Zhang et al., 2009; Li et al., 2012), while caspase-8 may act as a negative 
regulator possibly by promoting the cleavage of both RIP1 and RIP3 (Feng et al., 2007; 
Cho et al., 2009; Oberst et al., 2011). Our results indicate that in a subset of neurons 
OGD induces a transient down-regulation of caspase-8 mRNA while increasing RIP3 
mRNA levels. The transcriptional changes induced by OGD are paralleled by an 
increase in the endogenous RIP3 level. The endogenous RIP1 protein level is 
increased as well, suggesting these events may underlie the formation of the 
necrosome upon a toxic stimulus. Furthermore, we identified NMDAR signaling as an 
important regulator of RIP3 levels, which may explain the occurrence of necroptosis 
following NMDAR activation (Li et al., 2008). Importantly, we also observed increased 
levels of RIP3 in the CA1 region of the hippocampus of rats submitted to transient 
global cerebral ischemia in vivo. This region of the hippocampus is considered to be 
selectively vulnerable to this type of insult (Kirino, 1982; Zukin et al., 2004) and our 
results suggest that necroptosis contributes to the neurodegeneration that ensues in 
that area upon global cerebral ischemia. Moreover, our results demonstrate the 
relevance of the induction of endogenous RIP3 protein to the toxicity elicited by global 
cerebral ischemia, both in vitro and in vivo. This is, to our knowledge, the first report 
describing increased RIP3 expression following cerebral ischemic paradigms. 
To more accurately establish the role of the RIP3 and RIP1 proteins in the 
induction of necroptosis in hippocampal neurons submitted to OGD, we overexpressed 
both proteins in this system. Overexpression of either RIP1 or RIP3 resulted in the 
exacerbation of OGD-induced neuronal death. Importantly, we observed that the 
increase in the extent of cell death in transfected neurons occurred specifically upon 
OGD challenge since control neurons overexpressing RIP3 or RIP1 did not present 
significant changes in cell viability. This implies that regulated necrosis requires specific 
stimuli to be activated and that overexpression of RIP3 or RIP1 by themselves does not 
induce cell death. This is in accordance with a previous report, that demonstrated that 
overexpression of RIP3 and RIP1 specifically induces cell death only upon necroptotic 
stimulation (Zhang et al., 2009). 
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The determinant role of RIP3 in necroptosis has been demonstrated by 
complete abrogation of necrotic cell death in RIP3-depleted cells (Cho et al., 2009; He 
et al., 2009; Zhang et al., 2009). Similarly, we observed that RIP3 KD in hippocampal 
neurons abolished necrotic death induced by OGD (Fig 3). Importantly, we observed 
that by reintroducing RIP3 in KD neurons we rescued the necrotic component of cell 
death elicited by OGD. These results highlight the crucial impact of RIP3 expression 
levels on OGD-induced necrosis and support evidence showing an increase in necrotic 
cell death due to the expression of RIP3 in cells normally resistant to necroptotic stimuli 
(Zhang et al., 2009). 
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Figure 3.5. Global cerebral ischemia induces expression of the RIP3 protein. Adult 
rats were challenged with in vivo transient global cerebral ischemia (GCI) for 15 min. 
Forty-eight hours after GCI, the rats were sacrificed and the hippocampus and cortex Ctx 
were dissected. The hippocampus was further dissected to separate the CA1, CA3 and 
DG regions. (A) Total protein extracts were collected and western blot analysis was 
performed for RIP3, RIP1, SBDP (to demonstrate activation of cell death pathways), and 
β-tubulin. (B) GCI induced an upregulation of RIP3 in the CA1 region of the 
hippocampus. Bars represent the mean ± SEM of 3 independent experiments (n=4 for the 
Ctx). *Significantly different from control (*p<0.05, Student’s t-test on log-transformed 
data). (C) The RIP1 protein was not changed following GCI. Bars represent the mean ± 
SEM of 3 independent experiments (n=2 for the DG). 
 
Overall, our results support the view that ischemic insults induce a plethora of 
cell death mechanisms, including apoptosis and programmed necrosis (Meloni et al., 
2011). The understanding of the diverse death mechanisms that occur in ischemia may 
prove beneficial to the identification of novel molecular targets relevant to the 
development of new treatments for this pathology. Additionally, our results demonstrate 
the induction of both RIP1 and RIP3 proteins following OGD, as well as of RIP3 mRNA. 
The relevance of this upregulation of RIP3 is further demonstrated by an increase in 
RIP3 protein levels in the CA1 region of the hippocampus, following an in vivo global 
ischemic insult. Further studies concerning the mechanisms of necroptosis in neurons, 
namely the identification of putative RIP1/3 substrates, possibly neuron-specific, may 
provide important insights to clarify the mechanisms of cell death underlying global 
ischemic insults. 
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Activation of MAPK Signaling Following in vitro 
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Abstract 
 Global cerebral ischemia, that results from a lack of blood supply to the entire 
brain, is characterized by selective neurodegeneration of specific subsets of neurons, 
namely in the hippocampus. This type of insult can be mimicked in vitro by combined 
oxygen and glucose deprivation (OGD), in primary neuronal cultures or slices. Mitogen-
activated protein kinases (MAPKs) have been widely studied for their role in the 
response to cellular stress and were found to be involved in a variety of cell death 
paradigms, namely in neurons. In this work we addressed whether OGD induces the 
activation of the MAPKs c-Jun N-terminal kinase (JNK) and p38. We observed that 
indeed, we were able to detect increased activation of both kinases, at distinct time 
points after OGD. We observed increased p38 phosphorylation at 2h of recovery and 
higher levels of the classical JNK substrate c-Jun at 6h post-stimulation. Additionally, 
we also observed altered mRNA levels of the JNK and p38 pathways substrates Madd, 
Atf3 and Gadd45a and upstream kinases Ask2 and Tpl2. To confirm their role in 
neuronal death induced by OGD, we used the p38 inhibitor, SB203580 and the JNK 
cascade inhibitors, SP600125 and CEP11004 and observed that all these compounds 
conferred neuroprotection against OGD. Interestingly, we observed that the JNK 
signaling inhibitors were only neuroprotective when applied 4h after the end of the 
OGD challenge but not when present throughout the stimulation and post-stimulation 
periods. This effect suggests that JNK may have a dual role in the regulation of 
neuronal fate under OGD conditions. Overall our results highlight the role of MAPKs in 
the context of cerebral ischemia. Inhibition of these kinases may provide important 
benefits for the treatment of this type of insult. 
 
 
Introduction 
 Cerebral ischemia is one of the most prevalent neuropathologies worldwide 
(Flynn et al., 2008). Transient global ischemia results from a lack of blood supply to the 
entire brain, commonly due to a cardiac arrest. This blood deprivation induces the 
selective death of specific subsets of neurons in the brain, of which the CA1 region of 
the hippocampus is one of the most prominently affected (Zukin et al., 2004). This type 
of insult induces delayed neuronal death that occurs 24-72h following the insult, for 
which there are to date, no effective treatments. Currently, research in this area aims at 
reducing the amount of neurodegeneration that ensues as a consequence of ischemic 
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insults. Thus, there is great interest on the understanding of the toxic intracellular 
signaling pathways that are activated in these conditions, in order to identify new 
molecular targets useful for therapy. 
The mitogen-activated protein kinases (MAPKs) have a variety of functions in 
cells, including neurons, namely a crucial impact on the life and death balance. These 
signaling pathways have a typical three-tiered cascade, comprising a MAPK kinase 
kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAPK. Each sequential kinase is 
activated by phosphorylation and they exert their role in the cell by phosphorylating a 
variety of substrates, depending on the cellular context. There are three groups of 
mammalian MAPKs - extracellular signal-regulated kinase (ERK), p38 and c-Jun N-
terminal kinase (JNK) – and they have been all correlated to the response to cellular 
stress (Qi and Elion, 2005). However, while ERK1/2 is commonly associated with cell 
survival (Liu et al., 1998; Liu et al., 2013), the MAPKs p38 and JNK are thought to 
contribute to cell death, namely in neurons (Ham et al., 1995; Yang et al., 1997; 
Borsello et al., 2003; Cao et al., 2004; Semenova et al., 2007; Lee et al., 2013). In 
particular, both kinases have been correlated with neurodegeneration induced by 
ischemic insults, both in vitro (Behrens et al., 1999; Hirt et al., 2004) and in vivo (Ferrer 
et al., 1997; Sugino et al., 2000; Borsello et al., 2003; Kuan et al., 2003; Hirt et al., 
2004; Okuno et al., 2004). One of the preferential JNK substrates is the transcription 
factor c-Jun (Gupta et al., 1996). This transcription factor homodimerizes or 
heterodimerizes with other members of the Jun, activating transcription factor (ATF) 
and Fos families, assembling activator protein-1 (AP-1) transcription factor complexes, 
which mediate the transcription-dependent toxic effects of JNK activation (Ham et al., 
1995; Davis, 2000; Hess et al., 2004; Silva et al., 2005; Santos et al., 2006; Burke, 
2007). 
In this work, we aimed to study the activation of p38 and JNK in hippocampal 
neurons submitted to oxygen and glucose deprivation (OGD), an in vitro model of 
cerebral ischemia. We observed that both pathways are activated following OGD, but 
at different time points. Interestingly, our results suggest that JNK may be activated in a 
biphasic manner, since we observed that we were only able to confer neuroprotection 
with JNK inhibitors when the compounds were added at 4h of reoxygenation, but no 
neuroprotection was observed when the compounds were present during the 
stimulation and post-stimulation periods. This suggests that prior to a toxic activation 
that we detected at 6h of recovery, JNK may be involved in a prosurvival mechanism. 
This hypothesis supports previous observations concerning JNK activation mediated by 
tumor necrosis factor receptor 1 (TNFR1) signaling (Ventura et al., 2006) or induced by 
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cerebral ischemia injury (Hirt et al., 2004) and excitotoxic signaling (Vieira et al., 2010). 
Moreover, we show that this biphasic activation mediates differential effects on the 
neuronal fate following OGD. 
 
 
Materials & Methods 
Materials 
 The antibodies for phospho-c-Jun (Ser63) (#9261) and total p38 (#9212) were 
purchased from Cell Signaling Technology (Boston, MA). The antibodies for c-Jun/AP-
1 (sc-45-G) and p-p38 (Thr 180/Tyr 182-R) (sc-17852-R) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). 
The JNK pathway inhibitor CEP11004 was a generous gift from from Cephalon, 
Inc. (West Chester, PA) and SP600125 was purchased from Sigma-Aldrich (St. Louis, 
MO). The p38 inhibitor SB203580 was purchased from Calbiochem (Merck-Millipore, 
Billerica, MA). 
 
Cell Culture  
Primary cultures of hippocampal neurons were prepared from embryonic day 18 
(E18) rats, as previously described (Santos and Duarte, 2008). Briefly, hippocampi 
were dissected and dissociated with trypsin (1.5 mg/ml) in Hank’s Balanced Salt 
Solution (HBSS). Neurons were cultured in multiwell (MW) plates with or without glass 
coverslips, coated with poly-D-lysine (PDL), at a density of 85,000 cells/cm2, in 
Neurobasal® medium (Gibco®, Life Technologies™, Paisley, UK) supplemented with 
2% NeuroCult™ SM1 Neuronal Supplement (StemCell™ Technologies, Grenoble, 
France), 0.5 mM glutamine, 0.125 µg/ml gentamicin and 25 µM glutamate. Neuronal 
cultures were maintained at 37ºC in a humidified incubator with 5% CO2 up to 15 days 
in vitro (DIV). At DIV 7, the cultures were fed with fresh supplemented neurobasal 
medium without glutamate. 
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Oxygen-Glucose Deprivation (OGD) Challenge 
At DIV 15, hippocampal neurons were challenged with an in vitro ischemic stimulus. 
For that purpose, neurons were placed in a glucose-free deoxygenated buffer medium 
(OGD medium – 10 mM HEPES, 116 mM NaCl, 5.4 mM KCl, 0.8 mM NaH2PO4, 25 
mM sodium bicarbonate, 25 mM sucrose, 1.8 mM CaCl2, 0.04% phenol red, pH 7.3), 
inside an anaerobic chamber with 5% CO2 (OGD chamber, Thermo Forma 1029, 
Thermo Fisher Scientific, Waltham, MA), at 37ºC for 2h. Control neurons were placed 
in a similar buffer, containing 25 mM glucose, instead of sucrose (sham medium), and 
kept for 2h in an oxygenated incubator, at 37ºC. After incubation, the neurons were 
placed in their conditioned medium and returned to the normoxic incubator for a period 
of recovery that lasted up to 24h. 
When indicated, JNK or p38 inhibitors were added to the cell medium. 
SB203580 was pre-incubated for 1h and then kept during the stimulation and post-
stimulation periods. For inhibition of the JNK signaling pathway, CEP11004 and 
SP600125 were added 1h prior to stimulation and then kept during the stimulation and 
post-stimulation periods or, alternatively, the inhibitors were added 4h after the OGD 
insult and kept for the remainder of the post-stimulation period. 
 
RNA extraction 
 Total RNA from DIV 15 hippocampal neurons was extracted with TRIzol® 
Reagent (Invitrogen, Madrid, Spain), following the manufacturers’ specifications. The 
total amount of RNA was quantified spectrophotometrically (Thermo Nanodrop 2000, 
Thermo Fisher Scientific, Wilmington, DE) and the RNA quality and integrity evaluated 
using the Experion automated gel electrophoresis system (BioRad, Hercules, CA). 
 
qPCR 
 For cDNA synthesis, 1 µg of total RNA was used with the iScript™ cDNA 
Synthesis Kit (BioRad), according to the manufacturers’ instructions. For quantitative 
real-time PCR (qRT-PCR) 20 µl reactions were prepared with 2 µl of 1:10 diluted 
cDNA, 10 µl of 2x iQ™ SYBR® Green Supermix (BioRad) and specific primers at 250 
nM. Primer sequences are indicated in Table II. 
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Table II. Primers used for qPCR analysis. 
 
 The fluorescent signal was measured after each elongation step of the PCR 
reaction, in the iQ5 Multicolor Real-Time PCR Detection System (BioRad), and was 
used to determine the threshold cycle (Ct), as previously described (Manadas et al., 
2009). Melting curves were performed in order to detect non-specific amplification 
products, a non-template control was included in all assays, and for each set of primers 
a standard curve was performed to assess primer efficiency. Reactions were run in 
duplicate. The level of expression of each gene was analyzed at 7 and 24h of recovery 
following OGD and normalized to the level of expression of the gene in the 
corresponding control conditions. All Ct values were normalized to two internal control 
genes, ActB and Gapdh, using the GenEx software (MultiD Analyses). 
 
Nuclear morphology 
 Neuronal death was assessed by analysis of the nuclear morphology 24h 
following the OGD insult. For that purpose, neurons were stained with the nuclear dye 
Hoechst 33342 (2 µg/ml) for 15 min at RT and then mounted in fluorescent mounting 
medium. Neurons were analyzed under fluorescence microscopy for chromatin 
condensation and nuclear pyknosis, a feature of apoptotic-like cells. The results were 
expressed as the percentage of apoptotic-like cell death (apoptotic-like nuclei/total 
number of cells). At least 200 cells were counted in each coverslip. 
 
Lactate Dehydrogenase (LDH) release assay 
 At 24h of recovery after the OGD challenge, the LDH release to the extracellular 
medium was evaluated by a colorimetric assay using the CytoTox96 Non-Radioactive 
assay kit (Promega, Madison, WI), according to the manufacturer’s instructions. The 
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percentage of LDH release was determined as the ratio between LDH activity in the 
extracellular medium and total LDH activity obtained after complete cell lysis with Triton 
X-100. All experiments were carried out in duplicate or triplicate, for each independent 
experiment, as previously described (Vieira et al., 2010). 
 
Protein Extracts, SDS-PAGE and Western Blotting 
 Twenty four hours after OGD, cells were washed with ice-cold phosphate-
buffered saline (PBS) and lysis buffer [50 mM HEPES, 150 mM NaCl, 2 mM EGTA, 2 
mM EDTA, 2 mM Na3VO4, 50 mM NaF, 1% Triton X-100, 10% glycerol, pH 7.4 
supplemented with 1 mM phenylmethanesulphonylfluoride (PMSF) and 1 µg/ml of 
CLAP (cocktail containing chymostatin, leupeptin, antipain and pepstatin)] was added. 
Cell extracts were then sonicated and centrifuged for 20 min at 12000 x g, at 4ºC. 
Supernatants were recovered and the protein quantified by the BCA method. Samples 
were denatured at 95ºC, for 10 min and 80 µg of each protein extract were separated 
by SDS-PAGE, using 10% polyacrilamide gels, and then transferred to a polyvinylidene 
fluoride (PVDF) membrane. The membranes were blocked with Tris-buffered saline-
Tween20 (TBS-T) (20 mM Tris, 137 mM NaCl, pH 7.6, 0.1 % Tween20) with 5% non-
fat milk, for 1h at room temperature, and then incubated with the primary antibody in 
TBS-T 5% milk, for 1h at room temperature. Alternatively, the incubation with the 
primary antibody was performed overnight at 4°C. After extensive washing, 
membranes were incubated with the secondary antibody conjugated with alkaline 
phosphatase for 1h at room temperature. After additional washes, the membranes 
were developed using the enhanced chemifluorescence (ECF) substrate, and scanned 
on the Storm 860 Gel and Blot Imaging System (Amersham Biosciences, 
Buckinghamshire, UK). The density of the bands was analyzed with ImageQuant 5.0 
software. For subsequent reprobing, the membranes were stripped of antibody with 
NaOH 0.2 M, blocked again and incubated with the appropriate antibodies. 
 
Statistical Analysis 
Results are presented as means ± S.E.M. of the indicated number of 
experiments. Statistical significance was assessed by Student’s t-test or by one-way 
variance analysis (ANOVA) followed by the Dunnett’s test or the Bonferroni’s test. 
These statistical analyses were performed using the software package GraphPad 
Prism 5. 
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Results 
OGD Induces Up-regulation of the JNK signaling Pathway 
 The MAPK JNK has been shown to have a prominent role in the activation of 
cell death upon several stress insults (Eilers et al., 1998; Tournier et al., 2000; Cao et 
al., 2004; Hunot et al., 2004; Kukekov et al., 2006; Ventura et al., 2006; Wang et al., 
2013), including excitotoxicity (Yang et al., 1997; Borsello et al., 2003; Centeno et al., 
2007; Vieira et al., 2010) and cerebral ischemia (Ferrer et al., 1997; Kuan et al., 2003; 
Hirt et al., 2004; Okuno et al., 2004; Gao et al., 2005). Thus, we addressed whether our 
in vitro model of global ischemia, OGD, could induce the activation of the JNK signaling 
pathway. To address this question, we looked at changes on c-Jun phosphorylation, a 
classical JNK substrate, which is considered to be a measure of altered JNK activity. 
We tested different times of OGD and recovery and observed that c-Jun 
phosphorylation appeared to be up-regulated following 6h of reoxygenation after OGD 
(Fig 4.1-A). Since this was the only time point for which we observed an apparent 
increase in c-Jun phosphorylation we quantified the blots for 6h of recovery and 
confirmed that c-Jun was significantly up-regulated after 6h of recovery following 2h of 
OGD to 1.29 ± 0.09 times of the control (Fig 4.1-B). The phosphorylation of c-Jun is 
known to up-regulate its transcriptional activity, as c-Jun complexes with other 
members of the Jun and Fos families to form the AP-1 transcription factor (Bohmann et 
al., 1987; Santos et al., 2006), and to regulate transcription of genes related to cell 
death (Herdegen and Waetzig, 2001; Hess et al., 2004). To confirm that the increase in 
p-c-Jun observed following OGD correlates with an increased transcriptional activity of 
this protein, we analyzed changes in the mRNA level of some of the genes it may 
regulate, namely the Atf3, which is known to be induced by c-Jun/AP-1 (Liang et al., 
1996; Mei et al., 2008) (Fig 4.1-C), the growth arrest and DNA damage 45a (Gadd45a, 
Fig 4.1-D), also known to be up-regulated by JNK activity (Yin et al., 2004), and the 
MAP-kinase activating death domain (Madd, Fig 4.1-E), which is down-regulated upon 
activation of JNK (Del Villar and Miller, 2004). As observed by qRT-PCR analysis, both 
the Atf3 and Gadd45a genes had a higher expression 7h and 24h after OGD, 
respectively, while Madd expression was decreased at both time points. These results 
suggest that c-Jun might be indeed activating gene transcription following OGD. 
Since JNK activity may be initiated by a variety of MAPKKKs, depending on the 
specific stimulus (Davis, 2000), we also analyzed the changes induced by OGD in the 
expression of a few MAPKKKs, by qRT-PCR. We observed that both apoptosis signal-
regulating kinase 2 (Ask2) (Fig 4.2-A) and tumor progression locus 2 (Tpl2) (Fig 4.2-B) 
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had a higher expression, especially at 24h after OGD. On the contrary, we did not 
observe changes in the mRNA levels of TAO kinase 3 (Taok3) (Fig 4.2-C). These 
results suggest that ASK2 and TPL2 may be involved in hippocampal neuronal death 
induced by OGD. 
 
Figure 4.1. OGD induces changes in JNK pathway targets. (A) Mature cultures of 
hippocampal neurons (15 DIV) were challenged with OGD for different periods. At the 
end of the insult, protein extracts were immediately prepared or, alternatively, The 
cultures were transferred to the conditioned medium and returned to the air/CO2 
incubator for a period of reoxygenation that lasted up to 24h and total protein extracts 
were prepared. Eighty µg of total protein were used for immunoblot analysis with an anti-
phospho-c-Jun antibody. The membranes were reprobed with an anti-total c-Jun 
antibody. The figure is representative of 2 (30 min OGD and 2h OGD + 24h recovery), 1 
(1h OGD, 2h OGD and 2h OGD + 2h of recovery) or 5 (2h OGD + 6h recovery) assays 
performed with extracts from independent experiments. (B) Quantification of the ratio 
between phospho-c-Jun and total levels of c-Jun at 6h of recovery, normalized to the 
control. Bars represent the mean ± SEM of the indicated number of experiments 
(*p<0,05, Student’s t test). (C-E) Seven and 24 hours after OGD, total RNA was extracted 
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with TriZol. Real-time PCR analysis was performed using cDNA prepared from 1 µg of 
total RNA and the primers for ATF3 (C), GADD45a (D) and MADD (E). Fold change in 
mRNA levels was normalized to GAPDH and β-Actin. Bars represent the mean ± SEM of 
5 independent experiments. *Significantly different from control (*p<0.05, Student’s t-test 
on log-transformed data). 
 
JNK Inhibition Protects Against Neuronal Death 
To confirm that the increase of JNK activity in our system is indeed correlated 
with neuronal death, we used two JNK cascade inhibitors – CEP11004 [a Mixed-
lineage kinase (MLK) inhibitor] and SP600125 (a specific JNK inhibitor). Surprisingly, 
we observed that if we inhibited JNK signaling throughout the entire experiment 
(including both the OGD insult as well as the 24h of recovery), we could not detect any 
neuroprotection against the OGD challenge. However, if we added the compounds to 
the cells 4h after the end of OGD, we were able to significantly reverse the majority of 
cell death elicited by this challenge [from about 39.7 ± 4.7% to 18.2 ± 1.9% of cell 
death for CEP1104 and from about 38.6 ± 5.1% to 21.6 ± 2.5% of cell death for 
SP600125 (Fig 4.3)]. These results suggest that OGD may elicit two distinct phases of 
JNK activity, with different contributions to hippocampal neurons cell fate. This is in line 
with our previous work (Vieira et al., 2010), where we reported a biphasic JNK 
activation induced by excitotoxicity, a deleterious phenomenon also present in cerebral 
ischemia. We propose that the initial activation of JNK (prior to 4h of reoxygenation) 
may have a prosurvival effect, while the second phase of JNK activation results in 
increased c-Jun phosphorylation within 6h of recovery and contributes to neuronal 
death. Additionally, the neuroprotective effect afforded by CEP11004 suggests that 
MLK3 may be one of the MAPKKKs to induce JNK activation in this context.~ 
 
OGD Elicits Activation of the p38 MAPK 
 Another MAPK, p38, has been extensively studied for its role in induction of 
neuronal death following ischemia (Behrens et al., 1999; Sugino et al., 2000; Li et al., 
2013). Thus, we addressed the question of whether this pathway is also activated in 
hippocampal neurons following OGD. We tested several times of OGD and recovery 
and observed a significant increase in p-p38 levels following OGD, to about 1.4 times 
of the control (Fig 4.4-A, B), at 2h of recovery following 2h of OGD. We did not detect 
increased c-Jun phosphorylation at this time point (Fig 4.1-A). We were also able to 
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correlate p38 activation with neuronal death since we observed that SB203580, a 
specific p38 inhibitor, afforded significant neuroprotection against the OGD challenge 
(Fig 4.4-C, D). The inhibitor SB203580 was able to reduce the cell death induced by 
OGD from about 31.6 ± 2.2% to 21.0 ± 2.7% on the LDH assay and from about 41.2 ± 
3.7% to 28.7 ± 0.6% on the nuclear morphology analysis. Interestingly, p38 inhibition is 
protective if performed previously to OGD and through the recovery period, suggesting 
p38 activation by ischemic stimulus has mainly a deleterious role while JNK might have 
an initial prosurvival action and a later prodeath activity. Thus, the roles of these two 
MAPKs are not redundant, with p38 influencing only hippocampal neuronal death, 
whilst JNK may have dual roles in neuronal fate. 
 
Figure 4.2. OGD up-regulates MAPKKKs of the JNK signaling pathway. Mature 
cultures of hippocampal neurons (15 DIV) were challenged with OGD for 2h. The cultures 
were then transferred to the conditioned medium and returned to the air/CO2 incubator. 
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Seven and 24 hours after OGD, total RNA was extracted with TriZol. Real-time PCR 
analysis was performed using cDNA prepared from 1 µg of total RNA and the primers for 
ASK2 (A), TPL2 (B) and TAOK3 (C). Fold change in mRNA levels was normalized to 
GAPDH and β-Actin. Bars represent the mean ± SEM of 5 independent experiments. 
*Significantly different from control (*p<0.05, **p<0.001, Student’s t test on log-
transformed data). 
 
 
Discussion 
The MAP kinases are hallmark signaling pathways in stress response, namely 
in cerebral ischemia insults. We tested whether these kinases, specifically p38 and 
JNK, were activated by an in vitro model of cerebral global ischemia, OGD. We 
observed that OGD induced an increase in the phosphorylation of p38 and of the 
classical JNK substrate, c-Jun. We also detected changes in the mRNA levels of c-Jun 
target genes and other JNK substrates as well as in a few MAPKKKs. Notably, we also 
report significant neuroprotection afforded by a p38 inhibitor. Interestingly, we were 
also able to protect neurons from OGD-induce damage but only when we applied the 
inhibitors of JNK signaling 4h after the insult. This result suggests that JNK may have a 
dual effect, contributing both to neuron survival as well as demise. Overall our results 
highlight the importance of these signaling pathways in the neuronal response to in 
vitro ischemia. 
The MAPK signaling, mostly through p38 and JNK MAPKs, has been 
extensively studied in recent years for its role in cell fate upon a plethora of stress 
insults, including cerebral ischemia (Ferrer et al., 1997; Behrens et al., 1999; Sugino et 
al., 2000; Harper and LoGrasso, 2001; Borsello et al., 2003; Kuan et al., 2003; Hirt et 
al., 2004; Okuno et al., 2004). These kinases have a typical three-tiered signaling 
cascade regulated by phosphorylation. Upon induction of a specific stimulus, a 
MAPKKK is activated, usually by autophosphorylation, giving rise to the 
phosphorylation of a more specific MAPKK. This protein then phosphorylates a specific 
MAPK that may target a wide variety of substrates (Weston and Davis, 2007). JNK has 
been correlated with a plethora of apoptotic cell death paradigms, both in neurons 
(Ham et al., 1995; Yang et al., 1997; Coffey et al., 2002; Borsello et al., 2003; Cao et 
al., 2004; Centeno et al., 2007) and in non-neuronal cells (Tournier et al., 2000; Bonny 
et al., 2001; Lei and Davis, 2003). Although all JNK isoforms can induce cell death 
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(Bjorkblom et al., 2008), JNK3, a brain specific isoform has been demonstrated to be 
essential for the neurodegeneration that ensues following excitotoxic and ischemic 
insults (Yang et al., 1997; Kuan et al., 2003). On the other hand, the p38 MAPK also 
mediates relevant signaling pathways of neuronal death (Kawasaki et al., 1997; 
Behrens et al., 1999; Sugino et al., 2000; Cao et al., 2004; Segura Torres et al., 2006; 
Semenova et al., 2007; Lee et al., 2013). Nevertheless, JNK and p38 are argued to 
mediate distinct apoptotic paradigms (Cao et al., 2004). In this work we observed that 
both kinases are activated following OGD, in hippocampal neurons. Notably, the peak 
of activation of each kinase was distinct. However, we report a concomitant role of both 
kinases upon in vitro ischemia, as previously reported for in vivo insults (Ozawa et al., 
1999). This may imply a redundant mechanism, to ensure neuronal death upon 
extensive cellular damage. 
 
Figure 4.3. JNK has dual effects on neuronal fate following the OGD challenge. 
Mature cultures of hippocampal neurons (15 DIV) were challenged with OGD for 2h. 
Twenty four hours after OGD, cell viability was assessed. The JNK pathway inhibitors 
CEP11004 (A) and SP600125 (B) were added 1h prior to stimulation and kept during the 
stimulation and post-stimulation periods or, alternatively, were added 4h after the OGD 
insult and kept for the remainder of the reoxygenation period. The LDH activity was 
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assayed as indicated in the manufacturer’s protocol. Bars represent the mean ± SEM of 
10 independent experiments (    n=4;     n=7). *Significantly different from control 
(*p<0.05, **p<0.01, ***p<0.001, One way ANOVA followed by Bonferroni’s multiple 
comparison test). 
 
The MAPK signaling, mostly through p38 and JNK MAPKs, has been 
extensively studied in recent years for its role in cell fate upon a plethora of stress 
insults, including cerebral ischemia (Ferrer et al., 1997; Behrens et al., 1999; Sugino et 
al., 2000; Harper and LoGrasso, 2001; Borsello et al., 2003; Kuan et al., 2003; Hirt et 
al., 2004; Okuno et al., 2004). These kinases have a typical three-tiered signaling 
cascade regulated by phosphorylation. Upon induction of a specific stimulus, a 
MAPKKK is activated, usually by autophosphorylation, giving rise to the 
phosphorylation of a more specific MAPKK. This protein then phosphorylates a specific 
MAPK that may target a wide variety of substrates (Weston and Davis, 2007). JNK has 
been correlated with a plethora of apoptotic cell death paradigms, both in neurons 
(Ham et al., 1995; Yang et al., 1997; Coffey et al., 2002; Borsello et al., 2003; Cao et 
al., 2004; Centeno et al., 2007) and in non-neuronal cells (Tournier et al., 2000; Bonny 
et al., 2001; Lei and Davis, 2003). Although all JNK isoforms can induce cell death 
(Bjorkblom et al., 2008), JNK3, a brain specific isoform has been demonstrated to be 
essential for the neurodegeneration that ensues following excitotoxic and ischemic 
insults (Yang et al., 1997; Kuan et al., 2003). On the other hand, the p38 MAPK also 
mediates relevant signaling pathways of neuronal death (Kawasaki et al., 1997; 
Behrens et al., 1999; Sugino et al., 2000; Cao et al., 2004; Segura Torres et al., 2006; 
Semenova et al., 2007; Lee et al., 2013). Nevertheless, JNK and p38 are argued to 
mediate distinct apoptotic paradigms (Cao et al., 2004). In this work we observed that 
both kinases are activated following OGD, in hippocampal neurons. Notably, the peak 
of activation of each kinase was distinct. However, we report a concomitant role of both 
kinases upon in vitro ischemia, as previously reported for in vivo insults (Ozawa et al., 
1999). This may imply a redundant mechanism, to ensure neuronal death upon 
extensive cellular damage. 
Interestingly, we observed that, whilst inhibition of p38 during the OGD 
challenge and the whole recovery period is neuroprotective, JNK signaling seems to be 
more complex since neuroprotection was achieved only when the JNK inhibitor was 
added 4h after the stimulus. Indeed, JNK inhibition continuously during OGD and the 
recovery period abrogated any possible neuroprotective effect. A similar effect was 
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reported by Hirt et al. (2004) in organotypic hippocampal slices submitted to OGD. 
These authors observed that applying D-JNKI-1 at 3h or 9h after OGD had no 
protective effect, but administration 6h after the insult was neuroprotective (Hirt et al., 
2004). Thus, our results suggest the occurrence of a dual role of JNK, with two distinct 
phases of activity. Accordingly, JNK has been suggested to have a role both in 
neuronal survival as well as neuronal death (Waetzig et al., 2006; Weston and Davis, 
2007), depending on its cellular localization (Coffey et al., 2000; Bjorkblom et al., 
2008). Accordingly, in our OGD model, the cytoplasmic pool of JNK may be activated 
in an initial phase during the insult or early after the end of OGD, contributing to 
neuronal survival while the activation of the nuclear JNK pool, contributing to neuronal 
death, may only occur at later time points. In fact, there are evidences that some cell 
death paradigms induce a biphasic JNK activation (Vieira et al., 2010) with distinct 
impact on cellular fate (Ventura et al., 2006; Kenchappa et al., 2010), as suggested in 
our study. 
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Figure 4.4. OGD induces p38 activation. (A) Mature cultures of hippocampal neurons 
(15 DIV) were challenged with OGD for 15 min or 2h. The cultures challenged with 2h of 
OGD were then transferred to the conditioned medium and returned to the air/CO2 
incubator for a period of time that lasted up to 24h. At the indicated times, total cell 
extracts were prepared. Eighty µg of total protein were used for immunoblot analysis with 
an anti-phospho-p38 antibody. The membranes were reprobed with an anti-pan-p38 
antibody. The figure is representative of 2 (15min, 4h and 24h) or 5 (2h of recovery) 
assays performed with extracts from independent experiments. (B) Quantification of the 
ratio between phospho-p38 and total levels of p38, normalized to the control. Bars 
represent the mean ± SEM of the indicated number of experiments (p<0,05). (C) The 
LDH activity was assayed at 24h post-stimulation as indicated in the manufacturer’s 
protocol. Bars represent the mean ± SEM of 7 independent experiments. (D) Analysis of 
the nuclear morphology of hippocampal neurons. The results were expressed as the 
percentage of apoptotic cells relatively to the total number of cells. Bars represent the 
mean ± SEM of 7 independent experiments. *Significantly different from control (*p<0.05, 
**p<0.01, One way ANOVA followed by Bonferroni’s multiple comparison test). 
 
We also investigated changes in the expression of putative MAPKKKs that 
might be responsible for activation of the JNK and p38 signaling pathways, to better 
clarify the specific cascade that contributes to neuronal death. ASK2 is a MAPKKK that 
forms heteromeric complexes with the related protein ASK1, leading to stress-induced 
JNK activation (Wang et al., 1998; Takeda et al., 2007). To date there are no 
evidences for a role of ASK2 in ischemia-induced neuronal death, but our results 
suggest a significant expression of the Ask2 gene. TPL2 is a common MAPKKK to p38, 
JNK and ERK (Salmeron et al., 1996; Chiariello et al., 2000), but seems to be more 
correlated with physiological functions of these kinases (Hagemann et al., 1999). In 
fact, TPL2 seems to have a prosurvival function, by targeting Bim for degradation upon 
phosphorylation by ERK (Banerjee et al., 2008). Although we observed the 
upregulation of the mRNA of both ASK2 and TPL2, it remains to be clarified whether 
this translates into increased protein level and kinase activation. On the other hand, the 
neuroprotective effect of CEP11004 suggests that MLKs may be responsible for the 
activation of JNK in our ischemic paradigm, which correlates with evidence in the 
literature for a role of this MAPKKK in neurons (Xu et al., 2001; Tian et al., 2003; Zhu et 
al., 2012). 
The classical effector of the transcription-dependent cell death mediated by 
JNK, the transcription factor c-Jun, activates the transcription of deleterious genes, 
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such as caspase-3 (Song et al., 2011) and Dp5 (Ma et al., 2007; Towers et al., 2009). 
Additionally to an increase in c-Jun phosphorylation, we observed an increase of Atf3 
gene expression, which has been shown to have ATF and AP-1 binding sites and to be 
regulated by the transcription factor c-Jun (Liang et al., 1996), which keeps in view with 
the idea of an increase of c-Jun activity upon the OGD challenge. Moreover, JNK has 
also been shown to up-regulate the mRNA and protein expression of GADD45α (Yin et 
al., 2004), which was also observed in our system for the mRNA, thus suggesting JNK 
activation following OGD. In fact, gadd45a mRNA has been shown to be altered 
following excitotoxic stimulation and cerebral ischemia (Hou et al., 1997; Zhu et al., 
1997; Laabich et al., 2001). We also observed a decrease in MADD mRNA following 
the OGD challenge, which agrees with the decrease observed for the MADD protein as 
a consequence of NMDA excitotoxicity (Centeno et al., 2007) or in Alzheimer’s disease 
(AD) (Del Villar and Miller, 2004). Both in neurons insulted with Aβ1-42 or in AD 
transgenic mice, MADD mRNA and protein levels are decreased and this effect is 
correlated with neuronal death. MADD interacts, in physiological conditions, with 
TNFR1 and JNK3 and the decrease in its protein levels is speculated to be a 
mechanism that allows TRADD interaction with TNFR1 and subsequent neuronal 
apoptosis (Del Villar and Miller, 2004). This protein is a known JNK substrate that 
translocates to the nucleus upon ischemic insults (Zhang et al., 1998). 
 
Overall, our results demonstrate that both JNK and p38 are activated following 
the OGD insult. While p38 activation seems to contribute to neuronal death, the 
activation of JNK seems to have dual effects. This hypothesis is supported by the lack 
of neuroprotection observed when JNK inhibitors are present throughout the 
stimulation, implying that an initial activation of JNK may contribute to neuronal survival 
probably through the phosphorylation of endogenous substrates other than the nuclear 
pool of c-Jun. The activation of c-Jun within 6h of recovery with concurrent 
neuroprotection afforded by the JNK inhibitors when applied during the post-stimulation 
period suggests that after an initial period JNK activity is pro-survival, hence the duality 
of JNK function within the scope of cell fate upon ischemic stimulation. 
 
 
 
  
 
 
 
Chapter V 
General Conclusions and Future Directions 
 
 
Chapter V 
116 
 
   
Conclusions 
117 
 
Conclusions 
 Cerebral ischemia is a major cause of disability and morbidity in the world 
(Flynn et al., 2008). Global cerebral ischemia, resultant from a lack of blood supply to 
the entire brain, induces selective neurodegeneration of the CA1 region of the 
hippocampus. Research efforts aim at the understanding of the molecular mechanisms 
underlying the neurodegeneration associated with cerebral ischemia. However, to date, 
effective treatments to global cerebral ischemia are lacking and the mechanisms 
underlying this pathology are still not completely understood. Thus, the goal of this 
work was the identification of the molecular mechanisms that induce 
neurodegeneration of hippocampal neurons following global ischemia using an in vitro 
model, OGD. For that purpose, we studied the neuronal demise induced by OGD by 
addressing different steps of the death process. 
First, we studied the mechanism of excitotoxicity mediated by NMDARs, in 
particular the role of the GluN2B subunit in this process. We observed that OGD 
induces a component of excitotoxic neuronal death that is prevented by antagonism of 
NMDARs with the general inhibitor MK-801 and with ifenprodil, an antagonist of 
GluN2B-containing NMDARs. The determinant role of this subunit was further 
evidenced by the absence of toxicity in GluN2B-/- neurons that was rescued upon 
reintroduction of the subunit in these neurons. Although these receptors have long 
been recognized as important contributors to neuronal toxicity, the cause for the 
distinct effects of the GluN2A and GluN2B subunits remains elusive. While GluN2A is 
proposed by several reports to have a role in neuronal survival, GluN2B is most 
commonly correlated with neuronal death upon excitotoxic insults. One of the 
suggested regulators of the function of GluN2 subunits to neuronal response to 
excitotoxic challenges is the C-terminal domain, which is the most distinct region 
between the two subunits. To address this question we introduced a GluN2B subunit 
with the C-terminal domain swapped for that of GluN2A and observed that this subunit 
did not have the ability to rescue the toxicity induced by OGD. This effect corroborates 
a recent report that adopted a similar strategy to uncover the distinct roles of the GluN2 
subunit in a context of excitotoxicity (Martel et al., 2012). In this work, we used a more 
physiological model, OGD that resembles more closely the effects of in vivo ischemia, 
thus demonstrating the crucial role of the C-terminus of the GluN2B subunit to ischemic 
damage. To further characterize the C-terminal domain of the GluN2B subunit, we 
treated WT neurons with a cell-permeable peptide that targets the interaction of the C-
terminal domain of GluN2B with PSD95. This peptide significantly reduced the 
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neuronal death induced by OGD. This peptide has already been shown to have a 
neuroprotective effect against in vivo ischemia models (Aarts et al., 2002). Notably, we 
achieved a similar effect by expressing a GluN2B subunit with a mutation in the PDZ 
binding site in GluN2B-/- neurons, which is the domain responsible for this interaction. 
Interestingly, our findings demonstrate that other domains besides the PDZ binding site 
are important for GluN2B toxicity. We observed that subunits with mutations in the 
CaMKII-and the AP2-binding domains fail to evoke the toxicity of the WT GluN2B 
subunit. Ultimately, our results support the view that the GluN2B subunit has a 
determinant role in induction of neuronal death induced by ischemic insults. The 
selectivity of this subunit seems to reside on its C-terminal domain, which is highly 
divergent from that of the GluN2A subunit namely in respect to the established 
interactions with intracellular proteins. 
Next, we studied a novel type of cell death, called necroptosis, in a context of 
OGD. Although some studies point to the occurrence of a component of necroptosis in 
the neurodegeneration induced by cerebral ischemia (Degterev et al., 2005; Xu et al., 
2010; Northington et al., 2011), this evidence is mostly based on the neuroprotective 
effect of Nec-1, a necroptotic inhibitor. Thus, the specific molecular mechanism of 
necroptosis in neurons is yet to be clarified. We observed that Nec-1 was 
neuroprotective in our system, suggesting that OGD induces a component of 
necroptotic neuronal death. This mechanism relies on DR signaling and is activated in 
conditions where caspase-8, a negative regulator of necroptosis, is down-regulated or 
inhibited (Weinlich et al., 2011). When these conditions are gathered, RIP3 is recruited 
to a complex containing RIP1 and together they assemble the necrosome. We 
observed that, in hippocampal neurons submitted to OGD, the mRNA levels of 
caspase-8 are transiently decreased and concomitantly, RIP3 mRNA levels are 
induced. Furthermore, we observed that both necrosome proteins, RIP1 and RIP3 are 
upregulated 24h following OGD. This suggests that OGD may induce necroptosis by 
upregulating the proteins responsible for this cell death mechanism. We confirmed the 
toxic role of RIP3 induction in neurons by KD of the endogenous RIP3. This resulted in 
significant neuroprotection against the OGD challenge. Notably, we were able to 
rescue the damaging effect of OGD by expressing the human protein that is resistant to 
mouse shRNA against RIP3. Furthermore, we observed that overexpression of both 
RIP1 and RIP3 exacerbated the necrotic component of neuronal death induced by 
OGD. Our findings demonstrate the paramount role of RIP3 induction to the neuronal 
death initiated by OGD. These results gain relevance by the fact that RIP3 is also 
induced in the CA1 area of rats submitted to in vivo transient global ischemia. This 
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region of the hippocampus is considered to be selectively vulnerable to global ischemic 
insults and our results suggest that necroptosis might be one of the programmed cell 
death mechanisms that contribute to neurodegeneration in this area. 
 Finally, we studied the activation of death effector signaling pathways, in 
particular MAPKs. These proteins are widely associated with stress responses and are 
involved in several paradigms of cell death, including cerebral ischemia. In this work we 
addressed the activation of p38 and JNK and found that both pathways are activated. 
Accordingly, we observed changes in the mRNA levels of Atf3, Madd and Gadd45a, 
known substrates of JNK whose transcription may be mediated by c-Jun. Additionally, 
we observed changes in the mRNA levels of Ask2 and Tpl2, which are MAPKKKs that 
may activate both JNK and p38 signaling pathways. Interestingly, whilst p38 activation 
appears to have a deleterious effect, JNK is suggested to have a dual effect in 
neuronal fate. We observed that inhibition of JNK was only neuroprotective if the 
compounds were added 4h after OGD, but not before. This implies that JNK may have 
an initial prosurvival role and a second phase of activation may be responsible for its 
role in neurodegeneration. Our previous work demonstrated a biphasic activation of 
JNK following excitotoxic stimulation of AMPARs (Vieira et al., 2010), and other studies 
support the notion of a dual role of JNK in response to certain stimuli (Hirt et al., 2004; 
Ventura et al., 2006). These results demonstrate that MAPKs are activated following in 
vitro ischemia, contributing to neuronal demise. 
 
 Overall, the work presented here demonstrates that ischemic insults activate a 
plethora of intracellular mechanisms that contribute to neuronal death. The multitude of 
effects that characterize this type of insult is evidenced by the fact that diverse sources 
of Ca2+ contribute to excitotoxic mechanisms (Arundine and Tymianski, 2003) and also 
that distinct mechanisms of cell death may occur, including apoptosis and necroptosis. 
Also, several effector pathways, including MAPKs and beyond, are activated 
culminating in neuronal demise. These facts highlight the importance of a broad 
understanding of the diverse mechanisms that are induced by ischemic insults and the 
value of the development of therapeutical strategies combining the inhibition of several 
deleterious intracellular mechanisms. Finally, this work demonstrates the avail of OGD 
as an in vitro ischemic model, since it can reproduce many of the molecular events 
underlying cerebral ischemia. 
 In the future, it will be important to validate some of the present findings in vivo 
and to further study some of the mechanisms implicated in neuronal death. For 
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example, regarding the NMDARs and the contribution of the GluN2B subunit, we 
describe three distinct domains in the C-terminus of this subunit that ablate neuronal 
death induced by OGD when mutated. Further work should be performed in order to 
better characterize the C-terminal domain of GluN2B and for a better understanding of 
the signaling pathways associated with these domains. Regarding the types of cell 
death that are activated following OGD, a combined action that prevents both 
apoptosis and necroptosis may prove beneficial and for that, a better understanding of 
the neuronal mechanisms of necroptosis is necessary, namely regarding the events 
downstream of the necrosome. This work focused on the understanding of the 
molecular mechanisms underlying in vitro ischemia, with the ultimate goal of preventing 
the neurodegeneration that ensues. Thus, in the future, these findings may contribute 
to the development of novel therapeutic strategies to cerebral ischemia. 
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